<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">67555</article-id><article-id pub-id-type="doi">10.7554/eLife.67555</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Two <italic>de novo</italic> GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-232003"><name><surname>Kellner</surname><given-names>Shai</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232013"><name><surname>Abbasi</surname><given-names>Abeer</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241866"><name><surname>Carmi</surname><given-names>Ido</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232005"><name><surname>Heinrich</surname><given-names>Ronit</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232006"><name><surname>Garin-Shkolnik</surname><given-names>Tali</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232007"><name><surname>Hershkovitz</surname><given-names>Tova</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241863"><name><surname>Giladi</surname><given-names>Moshe</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-241864"><name><surname>Haitin</surname><given-names>Yoni</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-232008"><name><surname>Johannesen</surname><given-names>Katrine M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-136282"><name><surname>Steensbjerre Møller</surname><given-names>Rikke</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-226656"><name><surname>Berlin</surname><given-names>Shai</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5153-4876</contrib-id><email>shai.berlin@technion.ac.il</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Department of Neuroscience, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology</institution><addr-line><named-content content-type="city">Haifa</named-content></addr-line><country>Israel</country></aff><aff id="aff2"><label>2</label><institution>Clalit health services</institution><addr-line><named-content content-type="city">Tel Aviv</named-content></addr-line><country>Israel</country></aff><aff id="aff3"><label>3</label><institution>Genetics Institute, Rambam medical center</institution><addr-line><named-content content-type="city">Haifa</named-content></addr-line><country>Israel</country></aff><aff id="aff4"><label>4</label><institution>Department of Physiology and Pharmacology, Sackler Faculty of Medicine, Tel Aviv University</institution><addr-line><named-content content-type="city">Tel Aviv</named-content></addr-line><country>Israel</country></aff><aff id="aff5"><label>5</label><institution>Department of Epilepsy Genetics and Personalized Treatment, the Danish Epilepsy Centre</institution><addr-line><named-content content-type="city">Dianalund</named-content></addr-line><country>Denmark</country></aff><aff id="aff6"><label>6</label><institution>Institute for Regional Health Services, University of Southern Denmark</institution><addr-line><named-content content-type="city">Odense</named-content></addr-line><country>Denmark</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chao</surname><given-names>Moses V</given-names></name><role>Reviewing Editor</role><aff><institution>New York University Langone Medical Center</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Zoghbi</surname><given-names>Huda Y</given-names></name><role>Senior Editor</role><aff><institution>Texas Children's Hospital</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>02</day><month>07</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e67555</elocation-id><history><date date-type="received" iso-8601-date="2021-02-15"><day>15</day><month>02</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-06-27"><day>27</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Kellner et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Kellner et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-67555-v2.pdf"/><abstract><p>The N-methyl-D-aspartate receptors (NMDARs; GluNRS) are glutamate receptors, commonly located at excitatory synapses. Mutations affecting receptor function often lead to devastating neurodevelopmental disorders. We have identified two toddlers with different heterozygous missense mutations of the same, and highly conserved, glycine residue located in the ligand-binding-domain of <italic>GRIN2B</italic>: G689C and G689S. Structure simulations suggest severely impaired glutamate binding, which we confirm by functional analysis. Both variants show three orders of magnitude reductions in glutamate EC<sub>50</sub>, with G689S exhibiting the largest reductions observed for <italic>GRIN2B</italic> (~2000-fold). Moreover, variants multimerize with, and upregulate, GluN2B<italic>wt</italic>-subunits, thus engendering a strong dominant-negative effect on mixed channels. In neurons, overexpression of the variants instigates suppression of synaptic GluNRs. Lastly, while exploring spermine potentiation as a potential treatment, we discovered that the variants fail to respond due to G689’s novel role in proton-sensing. Together, we describe two unique variants with extreme effects on channel function. We employ protein-stability measures to explain why current (and future) LBD mutations in GluN2B primarily instigate Loss-of-Function.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>GRIN</kwd><kwd>encephalopathy</kwd><kwd>ligand binding domain</kwd><kwd>de novo mutation</kwd><kwd>loss of function</kwd><kwd>neurons</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd><italic>Xenopus</italic></kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003977</institution-id><institution>Israel Science Foundation</institution></institution-wrap></funding-source><award-id>1096/17</award-id><principal-award-recipient><name><surname>Berlin</surname><given-names>Shai</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006259</institution-id><institution>Teva Pharmaceutical Industries</institution></institution-wrap></funding-source><award-id>PR783187</award-id><principal-award-recipient><name><surname>Kellner</surname><given-names>Shai</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Two novel mutations in the GRIN2B gene reduce glutamate affinity by &gt;1000-fold, reduce the receptors proton-sensitivity, and exert a dominant-negative effect over receptors in neurons.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>N-methyl-D-aspartate receptors (NMDARs or GluNRs) are excitatory glutamate receptors found throughout the brain, playing critical roles in neuronal development, synaptogenesis, plasticity, and in most processes of learning and memory (<xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Lau and Zukin, 2007</xref>). The heterotetrametric receptor is assembled from seven different <italic>GRIN</italic> genes (<italic>Glutamate Receptor, Ionotropic, NMDA-kind</italic>) (<xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>; <xref ref-type="bibr" rid="bib28">Hansen et al., 2018</xref>), commonly by two glycine-binding GluN1-subunits (encoded by <italic>GRIN1</italic> gene) combined with two glutamate- (<italic>GRIN2A-D</italic>) or glycine-binding (<italic>GRIN3A-B</italic>) subunits. GluN1 subunits are an obligatory subunit of all channel types and are therefore found throughout the brain and during all stages of life, whereas GluN2B- and GluN2D-subunits are particularly abundant during embryonic stages (<xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>; <xref ref-type="bibr" rid="bib28">Hansen et al., 2018</xref>; <xref ref-type="bibr" rid="bib85">Xu and Luo, 2018</xref>). Conversely, GluN2A and GluN2C-subunits increase after birth, and GluN2A further replaces GluN2B during maturation of excitatory synapses (<xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Lau and Zukin, 2007</xref>). This variety of subunits gives rise to a large combinatorial diversity of channel subtypes in neurons (<xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>; <xref ref-type="bibr" rid="bib38">Lau and Zukin, 2007</xref>) (but also glia [<xref ref-type="bibr" rid="bib76">Verkhratsky and Kirchhoff, 2007</xref>]) with each channel-type displaying unique biophysical and pharmacological properties, and differential patterns (and timing) of expression (<xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>; <xref ref-type="bibr" rid="bib28">Hansen et al., 2018</xref>). Hence, owing to their essential roles in the brain, dysfunctional GluNRs are highly associated with a myriad of diseases of the brain (<xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib88">Yuan et al., 2015</xref>).</p><p>Since 2010, thousands of different <italic>GRIN</italic> variants have been discovered in pediatric patients (<xref ref-type="bibr" rid="bib85">Xu and Luo, 2018</xref>; <xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>), with the majority of mutations predominantly concentrated within the <italic>GRIN2A</italic> and −<italic>2B</italic> genes (46% and 38%, respectively) (<xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">García-Recio et al., 2021</xref>). To date, a small fraction of mutations have been functionally characterized, notably &lt;15% reported for <italic>GRIN2B</italic> (<xref ref-type="bibr" rid="bib85">Xu and Luo, 2018</xref>; <xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Tang et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>) (see full list of mutation in <xref ref-type="supplementary-material" rid="supp1">Supplementary files 1</xref> and <xref ref-type="supplementary-material" rid="supp2">2</xref>). Pathogenic variants in <italic>GRIN</italic> genes cause severe encephalopathies, with complex and overlapping clinical pictures involving intellectual disabilities (ID), neurodevelopmental delays (DD), autism spectrum disorders (ASD), movement and language disorders, schizophrenia, seizures, epilepsy and more (<xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib88">Yuan et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>). Currently, there are no specific treatments for different <italic>GRIN</italic>-diseases, rather patients receive supportive care and/or are specifically treated for the different co-morbidities of the disease (e.g. anti-seizure medication). Nevertheless, in the case of Gain-of-Function (GoF) mutations, there are several exploratory treatments with non-specific GluNR-blockers as primary candidates, notably the FDA-approved drug memantine (<xref ref-type="bibr" rid="bib58">Pierson et al., 2014</xref>; <xref ref-type="bibr" rid="bib70">Strehlow et al., 2019</xref>; <xref ref-type="bibr" rid="bib1">Amador et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Lipton, 2006</xref>). Loss-of-Function (LoF) mutations are harder to treat, as there are few channel openers, and even fewer subunit-selective (e.g. <xref ref-type="bibr" rid="bib73">Tang et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Mony et al., 2009</xref>; <xref ref-type="bibr" rid="bib15">Costa et al., 2010</xref>; <xref ref-type="bibr" rid="bib57">Perszyk et al., 2018</xref>; <xref ref-type="bibr" rid="bib79">Warikoo et al., 2018</xref>). Moreover, none are FDA-approved (<xref ref-type="bibr" rid="bib82">Wilkinson and Sanacora, 2019</xref>; <xref ref-type="bibr" rid="bib67">Silva et al., 2019</xref>). A recent report suggests an alternative approach consisting of the use of L-serine for enhancing channel activity (<xref ref-type="bibr" rid="bib68">Soto et al., 2019</xref>). L-serine is converted to D-serine; the co-agonist of the GluN1 subunit (<xref ref-type="bibr" rid="bib51">Neame et al., 2019</xref>). This supplementation was shown to improve the condition of children with a mild <italic>GRIN2B</italic> LoF mutation (&lt;sevenfold reduction in glutamate affinity) (<xref ref-type="bibr" rid="bib68">Soto et al., 2019</xref>) and is currently under clinical trials (<xref ref-type="bibr" rid="bib16">de Déu, 2020</xref>). However, it is worth noting that before treatments can be suggested (even if experimental), it is essential to understand the effects of the mutations on channel function (e.g. GoF <italic>vs</italic> LoF) because of the potential to worsen symptoms and provoke devastating effects (i.e. excessive channel activation, unwarranted cellular excitability, cytotoxicity, or neurodegeneration [<xref ref-type="bibr" rid="bib29">Hardingham et al., 2002</xref>; <xref ref-type="bibr" rid="bib87">Yan et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Choi, 1987</xref>; <xref ref-type="bibr" rid="bib43">Lipton and Rosenberg, 1994</xref>]) if, for example, an ‘opener’ is provided to treat a GoF mutation. These highlight the importance in curating and functionally characterizing each mutation before treatment(s) can be formulated (<xref ref-type="bibr" rid="bib24">García-Recio et al., 2021</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>clinical proband of patients suffering from De novo GRIN2B mutations.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Mutation</th><th valign="top"><italic>GRIN2B</italic> <break/>p.Gly689Ser</th><th valign="top"><italic>GRIN2B</italic> <break/>p.Gly689Cys</th></tr></thead><tbody><tr><td valign="top">Genotype <break/>(type)</td><td valign="top">c.2065G&gt;A, De Novo, heterozygous <break/>(WES; performed at ~1 year of age)</td><td valign="top">c.2065G&gt;T, De Novo, heterozygous <break/>(WES; performed at 8 months of age)</td></tr><tr><td valign="top">CMA</td><td valign="top">N/A</td><td valign="top">Normal</td></tr><tr><td valign="top">Age</td><td valign="top">6</td><td valign="top">3.5</td></tr><tr><td valign="top">EEG</td><td valign="top">Initial EEG (before 1 y): epileptiform discharges <break/>1.5- year -old: diffuse mix of beta activity, sometimes sharp waves centrally in the midline; sleep: recurrent trains of sharp waves / polyspikes and slow waves with a very high amplitude, as well as trains of fast activity (20 Hz) occipito-post-temporal, sometimes with a diffuse spread (correlated with myoclonic seizures) <break/>Latest EEG: May 2019: Spikes / Sharp-waves in the left temporo/central region</td><td valign="top">Normal with no epileptic behavior</td></tr><tr><td valign="top">Seizures</td><td valign="top">Myoclonic seizures + epileptic spasms</td><td valign="top">No epileptic activity</td></tr><tr><td valign="top">MRI</td><td valign="top">Normal (at 1 year of age)</td><td valign="top">Asymmetry in left ventricle (up to 11 mm; prenatally) <break/>Normal (at 1.5 year of age)</td></tr><tr><td valign="top">DD</td><td valign="top">Severe, crawl for short distance</td><td valign="top">Severe, can crawl, walk with aid</td></tr><tr><td valign="top">ID</td><td valign="top">Severe – nonverbal</td><td valign="top">Severe - speaks 10 words, understands simple commands</td></tr><tr><td valign="top">Strabismus</td><td valign="top">No</td><td valign="top">Yes</td></tr><tr><td valign="top">Gastrointestinal symptoms</td><td valign="top">N/A</td><td valign="top">Constipation <break/>(until two years old), reflux</td></tr><tr><td valign="top">Additional observations</td><td valign="top">Dyskinetic movements, hypertonia</td><td valign="top">Dyskinetic movements (resolved at age of 2), hypotonia, hyperflexible, no dysmorphism</td></tr><tr><td valign="top">Current medication</td><td valign="top">Piracetam and serine <break/>Previously treated with CBD and valproic acid</td><td valign="top">N/A</td></tr><tr><td valign="top">VUS</td><td valign="top">SLC6A8, CACNA1A</td><td valign="top">N/A</td></tr><tr><td valign="top">Collaboration</td><td valign="top">Danish Epilepsy Centre</td><td valign="top">The Genetics institute -Rambam</td></tr></tbody></table><table-wrap-foot><fn><p>CMA – chromosomal microarray analysis; DD -developmental delay; ID – intellectual disability; VUS - Variant of uncertain significance; N/A – not available.</p></fn></table-wrap-foot></table-wrap><p>Here, we provide functional characterization of two <italic>de novo</italic> GRIN2B mutations, occurring at the same residue (p.G689) in two pediatric patients; an Israeli patient with a G689C mutation and a Danish patient with G689S. The two patients have been diagnosed with a severe <italic>GRIN2B</italic>-encephalopathy, both showing similar—but also diverging—clinical symptoms (<xref ref-type="table" rid="table1">Table 1</xref>). We surveyed the literature and found that the G689C is a novel mutation, whereas the G689S variant has been noted in two previous patients though, to the best of our knowledge, characterization of the G689S-variant has not been reported (<xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>; <xref ref-type="bibr" rid="bib12">Bosch et al., 2016</xref>).</p><p>We simulated the structures of the LBD with G689C or G689S and find the two variants to destabilize the glutamate-binding pocket; suggesting them to prompt LoF. Indeed, scrutiny of channel function showed that both variants show very strong reductions in glutamate potency, with G689S presenting a more drastic shift in EC<sub>50</sub> (G689C- ~1000-fold and G689S- ~2000-fold reduction). We also find that while G689C express poorly at membranes of cells (and therefore yields lower current amplitudes), G689S does not. The latter stands in contrast to the common notion that reduced glutamate potency correlates with reduced surface levels of the receptors (<xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>; <xref ref-type="bibr" rid="bib64">She et al., 2012</xref>). Yet, despite differences in expression levels of the variants, both enhance the expression of GluN2B<italic>wt-</italic>subunits and exert a very strong dominant-negative effect on receptor function. In primary neurons, these features translate into reduced synaptic NMDAR-dependent currents. We go on to explore channel potentiators (e.g. spermine), however, find that both variants fail to respond under physiological conditions. Scrutiny of the reasons behind this observation led us to discover that G689 is an essential residue in the elusive proton-sensor of the GluN2B subunit. Together, we describe two exceptional mutations in two patients exhibiting a diverging clinical picture. We demonstrate the two first cases showing LBD-mutations that exert a <italic>bona-fide</italic> dominant negative effect in oocytes and primary cultured neurons. Lastly, we estimate the effect of more than 5200 mutations on the stability of the LBD and these data help to explain why most LBD mutations instigate Loss-of-Function and further suggest that substitutions to glycine or serine are the most damaging to the LBD.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Two different variants occurring at the same residue in the ligand-binding domain of GluN2B are associated with neurodevelopmental disorders</title><p>We have identified a toddler with a previously unknown, <italic>de novo</italic>, heterozygous missense mutation in the <italic>GRIN2B</italic> gene. The mutation consists of a single base-pair substitution in the gene (c.2065G&gt;T), thereby changing a highly conserved glycine into a cysteine residue at position 689 (G689C, <xref ref-type="fig" rid="fig1">Figure 1a</xref>). This residue is located deep within the ligand-binding-domain (LBD) of the receptor (<xref ref-type="fig" rid="fig1">Figure 1b</xref>), adjacent to <italic>all</italic> residues directly involved in agonist-binding (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a</xref>; <xref ref-type="bibr" rid="bib75">Traynelis et al., 2010</xref>). We found another pediatric patient in Denmark carrying an analogous mutation, specifically G689S. We combed the literature and found that although the G689S mutation has been previously reported, it has not been characterized (<xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>; <xref ref-type="bibr" rid="bib12">Bosch et al., 2016</xref>). Of note, the incidence of two different variants affecting the same residue within <italic>GRIN2B</italic> is relatively low (&lt;15%, Extended data 1), for instance the N615K and N615I variants (<xref ref-type="bibr" rid="bib85">Xu and Luo, 2018</xref>; <xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Fedele et al., 2018</xref>; <xref ref-type="bibr" rid="bib2">Amin et al., 2018</xref>). Both <italic>GRIN2B</italic>-G689x (x; cysteine or serine)-patients exhibit a similar clinical picture of severe DD, ID, and dyskinetic movements. However, the toddler with the G689S variant also presents myoclonic seizures and spasms (<xref ref-type="table" rid="table1">Table 1</xref>), even though seizures are more associated with mutations in <italic>GRIN2A</italic> (<xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>). Thus, despite the overlapping clinical picture, the differences between the conditions of the patients—even if slight—suggest that the variants should differently affect receptor function.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>De novo</italic> mutations occurring at a highly conserved glycine residue in the human GluN2B subunit.</title><p>(<bold>a</bold>) Sequence alignment, showing strong homology and conservation of Glycine residue at position 689 (black arrowhead) among different GluN2 subunits (<bold>A–D</bold>) and different species. (<bold>b</bold>) Crystal structure of GluN1a-2B (PDB 4PE5 [<xref ref-type="bibr" rid="bib34">Karakas and Furukawa, 2014</xref>]). Left image- light and dark gray depicts GluN1a and GluN2B subunits respectively; GluN2B LBD is highlighted in pink. Inset- Space filling of the GluN2B’s LBD showing the deep location of Gly689 residue (blue), positioned adjacent to the bound glutamate ligand (orange). (<bold>c</bold>) Prediction of <italic>de novo</italic> mutations occurring at p.689; left image- p.Gly689 (dark blue); center image- p.Gly689Cys (cyan) and right- p.Gly689Ser (red). Note that the side chains of the mutations point toward the glutamate ligand. This apposition required structural shifting of the glutamate ligand to prevent clashes with the original position, as shown in (<bold>d</bold>). (<bold>d</bold>) Simulation of the shift (1.2 Å) in the position of the glutamate ligand, resulting from mutagenesis of G689. Original position (as in PDB 4PE5) is shown in dark blue (representing the presence of the original G689). Cyan and red glutamates correspond to the newly positioned glutamate ligands obtained by the simulations when G689 was replaced by C or S, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>G689 lies adjacent to essential residues involved in glutamate binding.</title><p>(<bold>a</bold>) GluN2B LBD crystal structure (PDB 4PE5, magenta) showing residues (red) involved in binding of glutamate (orange). (<bold>b</bold>) Mutagenesis of G689 to C or S results in disruption of the glutamate-binding pocket. Stick representation of glutamate (orange) and its interacting residues in their original positions (purple) when residue G689 is intact (dark blue). Mutagenesis of G689 to C or S (see <xref ref-type="fig" rid="fig1">Figure 1c</xref>) results in shifts in the positions of the interacting residues, shown in cyan or red, respectively.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>G689C and G689S mutations block possible water exit tunnels.</title><p>(<bold>a</bold>) GluN2B LBD crystal structure (<bold>a</bold>, PDB 4PE5) showing a large hole adjacent to the buried ligand (orange); depicting possible water entry/exit routes in the closed conformation. (<bold>b</bold>) The holes are completely sealed by the simulated G689C mutation (cyan-orange mesh, middle image) or G689S (red-orange mesh, bottom image) compared to native G689 residue (blue, top image).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>GluN2B LBD unbound cysteine residues.</title><p>Naturally occurring cysteine residues (red) in the GluN2B LBD (light gray) are distant from the G689 (blue) residue. Glutamate shown in orange.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Mutations of G689 yield destabilized LBD.</title><p>(<bold>a</bold>) ΔΔG estimation for all possible substitutions of the G689 residue (19 substitutions). The sorted values (high to low- red to blue, respectively) show no correlation between residue’s features (polarity, hydrophobicity, and volume) and ΔΔG values, but show that both variants rank quite negatively (with similar ΔΔG values).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig1-figsupp4-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title>Variants exhibit a destabilized LBD and glutamate-binding pocket</title><p>To try to understand the effect of the mutations before functional assessments, we initially simulated the structures of the LBD of GluN2B by replacing G689 by a cysteine or a serine residue in the reported GluN1a/GluN2B structure (PDB 4PE5 [<xref ref-type="bibr" rid="bib34">Karakas and Furukawa, 2014</xref>]). Briefly, we isolated the LBD of one of the GluN2B monomers from the tetrameric structure, introduced the mutations, followed by protein preparation and energy minimization (see Materials and methods). Although the general structure of the LBD appears to remain intact, the simulations predict the side chains of the two mutations to point toward the ligand and, thereby, to occupy a larger volume in the glutamate binding pocket, as opposed to the original glycine which points away (<xref ref-type="fig" rid="fig1">Figure 1c</xref>, cysteine-cyan, serine-red). This apposition required shifting of the bound glutamate (by ~1 Å) to prevent clashes with the original position (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). This is accompanied by similar shifts in all residues involved in binding and coordination of glutamate (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref>). Together, these strongly suggest destabilization of the glutamate-binding pocket by steric interference (<xref ref-type="fig" rid="fig1">Figure 1d</xref>). The simulations also show that the side chains of the variants completely block water-accessible entry sites found in the glutamate-bound and closed state of the LBD (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), and these are implicated in modulating deactivation kinetics (<xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>; <xref ref-type="bibr" rid="bib80">Wells et al., 2018</xref>). Lastly, the cysteine in the G689C variant remains sufficiently distant from other naturally occurring cysteines in the LBD and should therefore remain unbound (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>). Nevertheless, the latter does not preclude the possibility that the cysteine may interact with additional cysteines during translation and folding of the subunit, in which case should negatively impact the variant’s expression levels (<xref ref-type="bibr" rid="bib23">Feige et al., 2018</xref>). If correct, then the G689S variant should have less of an effect on expression levels of mutant channels. Further analysis of protein stability (ΔΔG; by employing Mutation Cutoff Scanning Matrix [<xref ref-type="bibr" rid="bib59">Pires et al., 2014</xref>]) shows that, whereas all possible mutations of the G689 residue yield a negative ΔΔG, both mutations are among the substitutions that mostly impact the stability of the LBD (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref> and see below). Together, the simulations and assessment of protein stability suggest that both variants interfere with glutamate-binding and likely instigate LoF. Our simulations also point toward minor effects on deactivations kinetics and potential impact on expression levels of G689C.</p></sec><sec id="s2-3"><title>The G689C and G689S variants show drastically reduced glutamate potency</title><p>We turned to functionally characterize the effects of the mutations on glutamate potency (EC<sub>50</sub>). Therefore, we co-expressed the human GluN1A-<italic>wt</italic> (hGluN1a) subunit with three different human GluN2B variants, namely hGluN2B<italic>wt</italic>, 2B-G689C, or 2B-G689S, in <italic>Xenopus</italic> oocytes and assessed receptor function by two-electrode voltage clamp (TEVC). Briefly, oocytes were held at −60 mV and perfused with Mg<sup>2+</sup>-free (to avoid voltage-dependent block [<xref ref-type="bibr" rid="bib28">Hansen et al., 2018</xref>]) and Ca<sup>2+</sup>-free solutions (to avoid Ca<sup>2+</sup>-activated chloride currents in oocytes [<xref ref-type="bibr" rid="bib49">Mony et al., 2011</xref>; <xref ref-type="bibr" rid="bib9">Berlin et al., 2016</xref>]), with incrementing concentrations of glutamate (as in <xref ref-type="bibr" rid="bib9">Berlin et al., 2016</xref>, see Materials and methods). We initially conducted experiments using glutamate concentrations suitable for the hGluN2B<italic>wt</italic> receptors (e.g. <xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>) and find the <italic>wt</italic>-receptors to respond to very low glutamate concentrations (here, 0.2 μM), with micromolar glutamate potency (EC<sub>50</sub> = 1.4 ± 0.04 µM, n = 43; <xref ref-type="fig" rid="fig2">Figure 2a</xref> and <xref ref-type="table" rid="table2">Table 2</xref>; <xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>; <xref ref-type="bibr" rid="bib75">Traynelis et al., 2010</xref>). Under these conditions, however, we could barely detect glutamate-dependent currents from oocytes injected with the hGluN2B-G689C mutant, and even less so in oocytes expressing the G689S variant (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a and b</xref>, respectively). Glutamate-dependent currents appeared only at ~mM concentrations (<xref ref-type="fig" rid="fig2">Figure 2b,c</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a,b</xref>; 2 mM). Importantly, glutamate-currents were not observed in uninjected oocytes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c</xref>), unless when glutamate concentrations exceeded 10 mM (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c,d</xref>). We therefore did not apply glutamate concentrations past 10 mM when assessing glutamate efficacy of the variants. On a side note, we find others to use 10 mM glutamate as an upper limit when performing glutamate dose-responses, although the authors do not provide the rationale for this choice (<xref ref-type="bibr" rid="bib40">Lemke, 2016</xref>). Regardless, under these conditions, whereas the hGluN2B-<italic>wt</italic> channels were fully saturated (<xref ref-type="fig" rid="fig2">Figure 2b</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1e</xref>), the variants display &gt;1000-fold reduction in EC<sub>50</sub>, with G689S presenting a more severe phenotype (glutamate EC<sub>50</sub>: hGluN2B-G689C = 1.54 ± 0.14 mM [1100-fold], n=31; hGluN2B-G689S = 2.56 ± 0.14 mM [1814-fold], n=23; <xref ref-type="fig" rid="fig2">Figure 2a,b</xref>, <xref ref-type="table" rid="table2">Table 2</xref>). To the best of our knowledge, this is the largest reduction in affinity observed for GluN2B-mutants (<xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>; <xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>). Thus, our observations confirm the predicted LoF and complement previous studies showing that most LBD mutations lead to LoF (<xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>; <xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>) (see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>). We also observed that hGluN2B-G689C-containing channels—but not GluN2B-G689S—exhibit significantly smaller currents (I<sub>max</sub>~40%) than those of hGluN2B<italic>wt</italic>-containing receptors (<xref ref-type="fig" rid="fig2">Figure 2c</xref>) and lower glycine affinity (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a,b</xref>). However, neither present alteration in Mg<sup>+2</sup>-sensitivity (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2c,d</xref>, summarized in <xref ref-type="table" rid="table2">Table 2</xref>). Together, the G689C and G689S variants induce a severe LoF, although to different extents. These dissimilarities could reflect the differences observed between the clinical phenotypes (<xref ref-type="table" rid="table1">Tables 1</xref> and <xref ref-type="table" rid="table2">2</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>GluN2B LBD mutations drastically reduce glutamate potency.</title><p>(<bold>a</bold>) Representative glutamate-dependent currents recorded from <italic>Xenopus</italic> oocytes co-expressing hGluN1a with GluN2B-<italic>wt</italic> (blue); GluN2B-G689C (cyan) or GluN2B-G689S (red). Glutamate concentrations are marked next to current steps (note the differences in units, namely μM and mM); summarized in (<bold>b</bold>). (<bold>c</bold>) Summary of the normalized maximal current (I<sub>max</sub>) of the different GluN2B-subunits, showing the significantly smaller currents of G689C, but not G689S, mutant. For (<bold>b</bold>), <italic>wt</italic>- 43 cells; G689C- 31 cells; G689S- 23 cells, collected form two to three independent experiments; (<bold>c</bold>), <italic>wt</italic>- 22 cells; G689C- 30 cells; G689S- 21 cells, collected form one to two independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Assessment of the effect of low to very high glutamate concentrations on uninjected oocytes and G689C/S-injected oocytes.</title><p>(<bold>a and b</bold>) Representative traces of oocytes co-expressing hGluN1a and GluN2B-G689C (cyan, <bold>a</bold>) or -G689S (red, <bold>b</bold>) in response to low glutamate concentrations (indicated next to trace), from two to three independent experiments, n = 32 and 11, respectively. (<bold>c</bold>) Responses of uninjected oocytes to low and very high glutamate concentrations. Uninjected oocytes start responding to glutamate concentrations surpassing 10 mM, although osmolarity was maintained in all groups. (<bold>d</bold>) Summary of the effects of different glutamate concentrations on uninjected oocytes. Pie chart represents the fraction of oocytes (from N=2, n = 19 oocytes) that began responding only at the concentration indicated: 10.5% of all oocytes did not show any non-specific response even to 100 mM glutamate (no inward current, cyan). A similar fraction of oocytes (10.5%) showed non-specific inward current already at 1 mM (gray) and 10.5% started to respond only at 10 mM (orange). 63% of oocytes began responding when reaching 50 mM glutamate (yellow) and only 5.2% showed non-specific responses only when reaching 100 mM glutamate. (<bold>e</bold>) hGluN1a-GluN2B-<italic>wt</italic> are saturated at 100 μM glutamate. Plot shows normal dose responses curve (dashed blue, taken from <xref ref-type="fig" rid="fig2">Figure 2</xref>) and the small contribution (&lt;15%) to the total current by excess glutamate &gt;100 μM glutamate (blue closed circles) for N = 3, n = 26 oocytes.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Variants’ effect on Glycine and Mg<sup>2+</sup>-sensitivity.</title><p>(<bold>a, c</bold>) Representative traces showing responses of the variants to glycine (<bold>a</bold>) or Mg<sup>2+</sup> (<bold>c</bold>) of oocytes co-expressing hGluN1a and hGluN2B-G689C (cyan) or -G689S (red). (<bold>b, d</bold>) Summary of dose-response curves for glycine (<bold>b</bold>) and Mg<sup>2+</sup> (<bold>d</bold>) are shown for GluN2B-<italic>wt</italic> (dark blue), G689C (cyan) and G689S (red). Glycine EC<sub>50</sub> and Mg<sup>2+</sup> IC<sub>50</sub> values are listed in <xref ref-type="table" rid="table2">Table 2</xref>. For (<bold>b</bold>) n = <italic>wt</italic>- 33 cells; G689C- 35 cells; G689S- 15 cells; for (<bold>d</bold>) n = <italic>wt</italic>- 33 cells; G689C- 17 cells; G689S- 23 cells, from one to three independent experiments. **, p&lt; 0.01.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig2-figsupp2-v2.tif"/></fig></fig-group><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Summary of pharmacological profiling for hGluN2B-G689C and hGlun2B-G689S.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top">Variant</th><th valign="top">Glutamate EC<sub>50</sub> (n)</th><th valign="top">I<sub>max</sub> Norm. to <italic>wt</italic> (n)</th><th valign="top">Glycine EC<sub>50</sub> <break/>(n)</th><th valign="top">Mg<sup>+2</sup> IC<sub>50</sub> (−60 mV) <break/>(n)</th><th valign="top">10–90% inhibition rate <break/>(n)</th><th valign="top">τ<sub>off</sub> <break/>(n)</th><th valign="top">Proton IC<sub>50</sub> <break/>(n)</th></tr></thead><tbody><tr><td valign="top">hGluN2B-<italic>wt</italic></td><td valign="top">1.4 ± 0.04 µM; (43) <break/>0.8 ± 0.01 µM; (6, HEK293T cells)</td><td valign="top">1 ± 0.08; (22)</td><td valign="top">0.23 ± 0.03 µM; (33)</td><td valign="top">31 ± 3.7 µM; (33)</td><td valign="top">8554 ± 827 ms; <break/>(24)</td><td valign="top">4590 ± 603 ms; <break/>(24)</td><td valign="top">7.26 ± 0.02; <break/>(15)</td></tr><tr><td valign="top">hGluN2B- G689C</td><td valign="top">1.54 ± 0.14* mM; (31)</td><td valign="top">0.41 ± 0.06*; (30)</td><td valign="top">0.4 ± 0.05** µM; (33)</td><td valign="top">34.5 ± 3.8 µM; (17)</td><td valign="top">9604 ± 547 ms; <break/>(29)</td><td valign="top">4950 ± 456 ms; <break/>(29)</td><td valign="top">7.04 ± 0.01*; (19)</td></tr><tr><td valign="top">hGluN2B- G689S</td><td valign="top">2.56 ± 0.40* mM; (23) <break/>2.2 ± 0.39 mM *; (20, HEK293T cells)</td><td valign="top">0.82 ± 0.08; (21)</td><td valign="top">0.31 ± 0.03 µM; (15)</td><td valign="top">40 ± 2.1 µM; (23)</td><td valign="top">18904 ± 1375* ms; <break/>(26)</td><td valign="top">7907 ± 658* ms; <break/>(26)</td><td valign="top">6.96 ± 0.03*; (21)</td></tr></tbody></table></table-wrap></sec><sec id="s2-4"><title>GluN2B variants show reduced surface expression in HEK293 cells</title><p>The reduced current-amplitudes of G689C-containing channels suggests differences in expression levels of the receptors. We therefore addressed expression levels by β-lactamase activity. Briefly, we tagged the extracellular amino termini of the various hGluN2B-subunits with β-lactamase and incubated transfected cells with the cell-impermeable β-lactamase substrate (nitrocefin) and measured expression by extracting the slopes from continuous absorption measurements obtained by a plate reader (see Materials and methods and [<xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>]). The results obtained from multiple independent experiments show that the 2B-G689C variant expresses the least at membrane of mammalian cells (HEK293T cells), at levels corresponding to ~45% of GluN2Bwt-containing receptors (<xref ref-type="fig" rid="fig3">Figure 3a,b</xref>), without any apparent differences in channel open probability (P<sub>o</sub>) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a–c</xref>). The 2B-G689S-variant, on the other hand, expressed as well as <italic>wt</italic>-receptors, in spite of the small reduction in P<sub>o</sub> (<xref ref-type="fig" rid="fig3">Figure 3b</xref>, red and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1a–c</xref>, red). These results provide the reason behind the lower current amplitudes obtain for 2B-G689C (~40%) (see <xref ref-type="fig" rid="fig2">Figure 2c</xref>).</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>The G689C variant is poorly expressed at membranes of cells, but both variants enhance expression of GluN2B<italic>wt</italic>.</title><p>(<bold>a</bold>) Representative plot of nitrocefin absorbance (O.D) over time (min) in HEK293T cells expressing GluN2B-β-lac (gray), hGluN1a-GluN2B-<italic>wt</italic>-β-lac (blue), hGluN1a-GluN2B-G689C-β-lac (cyan), hGluN1a-GluN2B-G689S-β-lac (red). Background signal (backgd.; gray) was collected from cells expressing GluN2B<italic>wt-</italic>β-lac only (<italic>wt</italic>-β, 1 μg DNA) without GluN1a (thereby not transported to membrane). (<bold>b</bold>) Summary of expression of the various channel types from three to five independent experiments. Colors are as depicted in (<bold>a</bold>). Results show that G689C expresses at ~44% compared to the expression of 2B-<italic>wt</italic> or G689S subunits. (<bold>c</bold>) Summary of the expression of GluN2B<italic>wt</italic>-β-lac (<italic>wt</italic>-β, 1 μg DNA), co-transfected with 1 μg GluN1a, when also co-transfected with increasing DNA amounts (0.1, 0.5, and 1 μg) of the G689C (cyan) or G689S variants (N = two independent experiments). *, p&lt;0.05; **, p&lt;0.01; ***, p&lt;0.001; n.s. non-significant. Statistics show comparison to the <italic>wt</italic>-β group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>hGluN2B-G689S, but not hGluN2B-G689C, shows reduced apparent open probability (P<sub>o</sub>).</title><p>(<bold>a</bold>) Representative deactivation traces of oocytes co-expressing hGluN1a with hGluN2B<italic>wt</italic> (black), hGluN2B-G689C (cyan) or hGluN2B-G689S (red). Following opening of channels by 3 mM glutamate, oocytes were washed with glutamate and 1 μM MK-801 (activity-dependent blocker; indicated by black bar above traces). (<bold>b, c</bold>) Summary of deactivation kinetics. t<sub>10-90%</sub> inhibition (<bold>b</bold>) and τ<sub>off</sub> (<bold>c</bold>) (see Materials and methods) are shown (bars are color coded as representative currents). (<bold>d</bold>) Summary of the the expression of GluN2B<italic>wt</italic>-β-lac (<italic>wt</italic>-β, 1 μg DNA) in HEK293T cells, co-transfected with 1 μg GluN1a, when also co-transfected with increasing DNA amounts (0.1, 0.5, and 1 μg) of Kv4.2 (N = two independent experiments). *, p&lt;0.05; **, p&lt;0.01; ***, p&lt;0.001; n.s. non-significant. Statistics show comparison to the GluN2<italic>wt</italic>-β group.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig3-figsupp1-v2.tif"/></fig></fig-group><p>Owing to the heterozygosity nature of the disease, we next wondered whether the mutant subunits could also affect the expression of GluNB<italic>wt</italic>-subunits or mimic cases of haploinsufficiency, in which case there would simply be less channels (here less responsive channels) at the membrane (<xref ref-type="bibr" rid="bib24">García-Recio et al., 2021</xref>). We have therefore co-expressed constant amounts of GluN1a and GluN2B<italic>wt</italic>-β-lac with incrementing concentrations of the 2B-G689C or 2B-G689S variant (spanning an order of magnitude, see Materials and methods). Surprisingly, both variants significantly improved the surface expression of receptors expressing the GluN2B<italic>wt</italic>-β-lac subunit (<xref ref-type="fig" rid="fig3">Figure 3c</xref>). These increases were not seen when co-expressing another control plasmid encoding for a non-NMDAR-related channel subunit (Kv4.2) (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1d</xref>). In fact, incrementing DNA amounts of Kv4.2 reduced the surface levels of the GluN2B<italic>wt</italic>-β-lac subunit, likely by competing for translation, as shown earlier for other channels and proteins (<xref ref-type="bibr" rid="bib10">Berlin et al., 2020</xref>). Thus, increases in surface levels of GluN2B<italic>wt</italic>-β-lac (and also of the mandatory GluN1a-subunit) suggests that the variants multimerize with the GluN2B<italic>wt</italic>-subunits to form tri-heteromeric channels (‘mixed channels’) with a 2:1:1 stoichiometry, namely two copies of GluN1a-<italic>wt</italic> coupled with one copy of GluN1B<italic>wt</italic> and another copy of the GluN2B-mutant.</p></sec><sec id="s2-5"><title>The two variant exert a dominant-negative effect over GluN2B-wt in <italic>Xenopus</italic> oocytes</title><p>We were next interested in examining the functional outcome of the collection of data showing that G689C-containing channels—but not G689S—express poorly at membranes of mammalian cells (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>), along the observations that both variants increase the membrane levels of the GluN2B<italic>wt</italic>-receptors (<xref ref-type="fig" rid="fig3">Figure 3</xref>). To do so, we co-expressed hGluN1a with different mixtures of hGluN2B-<italic>wt</italic> and hGluN2B-G689C or -G689S mRNAs in <italic>Xenopus</italic> oocytes (i.e. mRNA titrations [<xref ref-type="bibr" rid="bib10">Berlin et al., 2020</xref>; <xref ref-type="bibr" rid="bib8">Berlin et al., 2011</xref>; <xref ref-type="bibr" rid="bib86">Yakubovich et al., 2015</xref>; <xref ref-type="bibr" rid="bib56">Peleg et al., 2002</xref>; <xref ref-type="bibr" rid="bib35">Katz et al., 2021</xref>]) and assessed glutamate dose-responses (see Materials and methods). When large mRNA amounts of hGluN2B-<italic>wt</italic> were co-expressed with very low amounts of hGluN2B-G689C (mRNA ratio: ~16:1, denoted wildtype-high; <italic>wt</italic><sub>H</sub>), we recorded large currents that readily responded to glutamate (<xref ref-type="fig" rid="fig4">Figure 4a,b</xref>; <italic>wt</italic><sub>H</sub>). These features are indicative of the predominant expression of the hGlu2B<italic>wt</italic>-containing receptors. However, the dose-response curve for this group could not be fitted for a single population, rather was best fitted bimodally (Materials and methods and <xref ref-type="bibr" rid="bib6">Ben-Chaim et al., 2003</xref>). This strongly suggested <italic>two</italic> receptor populations with differing affinities for glutamate, namely high and low (<xref ref-type="fig" rid="fig4">Figure 4c</xref>; <italic>wt</italic><sub>H</sub>). We tested several different adjustments to the fits to ensure that we did not over-represent the data for the G689C group (see Materials and methods, <xref ref-type="disp-formula" rid="equ2 equ3">Equations 2 and 3</xref>) and, indeed, obtained several different low and high apparent KDs (KD<sup>L</sup> and KD<sup>H</sup>). In the <italic>wt</italic><sub>H</sub> group co-expressing 2B-G689C, no matter the fitting procedure, the different KD<sup>H</sup> obtained by the various fits (0.44 or 0.21 μM, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref> and <xref ref-type="table" rid="table3">Table 3</xref>) were on par with those obtained for the single <italic>wt</italic> population (<italic>wt</italic>- EC<sub>50 </sub>= 1.4 μM, see <xref ref-type="fig" rid="fig2">Figure 2</xref>); however, KD<sup>L</sup> did not match the EC<sub>50</sub> obtained solely for G689C receptors (1.54 mM vs. 0.37 or 0.15 mM, <xref ref-type="table" rid="table3">Table 3</xref>). We also fitted the same curves after these have been normalized to the responses obtained by 100 μM glutamate (assuming saturation of all <italic>wt</italic> receptors). This handling left KD<sup>H</sup> constant (as above), but only slightly increased KD<sup>L</sup> (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1a</xref>, blue traces and <xref ref-type="table" rid="table3">Table 3</xref>). Thus, the data demonstrate that expression of GluN2B<italic>wt</italic> mRNA with very low amounts of GluN2B-G689C yields two receptor-populations: one closely resembling full <italic>wt</italic> receptors (i.e. GluN1a-<italic>wt</italic> and GluN2B<italic>wt</italic>), and another population of mixed-channels exhibiting three orders of magnitude lower EC<sub>50</sub> than <italic>wt</italic> receptors (from 0.44 μM to 0.37 mM). We proceeded to examine <italic>wt</italic><sub>E</sub> (<italic>E</italic>qual amounts of mRNA between <italic>wt</italic> and variant) and <italic>wt</italic><sub>L</sub> (<italic>L</italic>ow amounts of <italic>wt</italic> mRNA), co-expressed with G689C. We first note that both groups yield similar I<sub>max</sub> as the <italic>wt</italic><sub>H</sub> group (<xref ref-type="fig" rid="fig4">Figure 4a</xref>, summarized in b). This is particularly surprising for the <italic>wt</italic><sub>L</sub> group containing 16-fold more mRNA of the G689C variant than GluN2B<italic>wt</italic>. In this instance, we expected the currents to be dominated by G689C-containing channels and thereby of lower expression and current-amplitudes (see <xref ref-type="fig" rid="fig2">Figure 2</xref>). Interestingly, these results are consistent with our expression assays showing that G689C does not interfere, rather promotes the expression of GluN2B<italic>wt</italic>-containing receptors (see <xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1d</xref>). Scrutiny of the glutamate dose-response curves for <italic>wt</italic><sub>E</sub> and <italic>wt</italic><sub>L</sub> showed pronouncedly right-shifted curves (<xref ref-type="fig" rid="fig4">Figure 4c</xref>, purple and turquoise curves). We find that, although all curves were best fitted by bimodally as <italic>wt</italic><sub>H</sub>, the proportion of the KD<sup>H</sup> part of the curve was dramatically decreased, expectedly showing that the contribution of the affinity of GluN2B<italic>wt</italic> subunits is diminished (relative responses to 100 μM glutamate: 60% for <italic>wt</italic><sub>H</sub>; 16% for <italic>wt</italic><sub>E</sub>; 5% for wt<sub>L</sub>). Second, the KD<sup>L</sup> values were also reduced dramatically, both in proportion (increase) and in values corresponding better to those obtained for when 2B-G689C channels were assessed alone (<xref ref-type="table" rid="table2">Tables 2</xref> and <xref ref-type="table" rid="table3">3</xref>). Together, these observations demonstrate that the GluN2B<italic>wt</italic> subunits are readily expressed in all three groups. These are attested by: (1) the size of current, (2) by the high-affinity population in dose-response curves and further supported (3) by expression assays. However, even at low expression levels of G689C variant (<italic>wt</italic><sub>H</sub>, <italic>wt</italic><sub>E</sub>), the apparent affinities for glutamate are persistently diminished. Similar results were obtained when GluN2B-G689S was co-expressed with GluN2B<italic>wt</italic> (<xref ref-type="fig" rid="fig4">Figure 4d–f</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref> and <xref ref-type="table" rid="table3">Table 3</xref>). Collectively, our functional results complement our expression assays and suggest that both variants readily co-assemble with the <italic>wt</italic>-subunits to form tri-heteromeric channels at membrane of cells, without affecting current size and expression of the channels. This effect is unique as similar reports suggest that mixed channels should yield reduced currents (e.g. <xref ref-type="bibr" rid="bib40">Lemke, 2016</xref>; <xref ref-type="bibr" rid="bib21">Endele et al., 2010</xref>). Importantly, both variants strongly reduce the glutamate affinities of the tri-heteromeric channels (approaching the affinities of the variants when these are expressed alone); demonstrating their strong dominant negative effect.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>GluN2B LBD variants exert a dominant-negative effect over GluN2B-<italic>wt</italic> subunit in <italic>Xenopus</italic> oocytes.</title><p>(<bold>a</bold> and <bold>d</bold>) Representative traces from oocytes co-expressing hGluN1a, hGluN2B-<italic>wt</italic> and GluN2B-G689C (<bold>a</bold>) or G689S (<bold>d</bold>) at different mRNA ratios in response to incrementing glutamate concentrations (indicated next to trace, in μM unless mentioned otherwise). Oocytes in which we co-injected mRNA of GluN2B<italic>wt</italic> 16-fold over mRNA of variant belong to wildtype-High group (<italic>wt</italic><sub>H</sub>). Oocytes co-injected with equal mRNA amounts belong to <italic>wt</italic>-Equal group (<italic>wt</italic><sub>E</sub>) and, inversely, oocytes co-injected with 16-fold more mRNA of variant over GluN2B<italic>wt</italic>, belong to the <italic>wt</italic>-Low group (<italic>wt</italic><sub>L</sub>). (<bold>b</bold> and <bold>e</bold>) Summary of the normalized maximal current (I<sub>max</sub>) obtained by 5 mM glutamate and 100 μM glycine for the different treatments (<italic>wt</italic><sub>H</sub>, <italic>wt</italic><sub>E</sub> and <italic>wt</italic><sub>L</sub>) when G689C (<bold>b</bold>) or G689S (<bold>e</bold>) were co-injected with the GluN2B<italic>wt</italic>-subunit. N = 1–2 experiments, n = 10–19 oocytes. (<bold>c and f</bold>) Glutamate dose-response curves for the three different treatments with G689C (<bold>c</bold>), namely <italic>wt</italic><sub>H</sub>, <italic>wt</italic><sub>E</sub> and <italic>wt</italic><sub>L</sub> groups fitted by different bimodal curves in blue-, purple-, and cyan-shades, respectively (values are shown in <xref ref-type="table" rid="table3">Table 3</xref>) and for G689S (<bold>f</bold>) by light blue-, pink- and cyan shades, respectively. Dashed plots (blue and cyan in <bold>c</bold>; blue and pink in <bold>f</bold>) show dose-response curves for di-heteromeric channels, hGlun1a-hGluN2B-<italic>wt</italic> and hGlun1a-hGluN2B-G689C or G689S, respectively (as shown in <xref ref-type="fig" rid="fig2">Figure 2b</xref>). For (<bold>c</bold>), <italic>wt<sub>H</sub></italic>- 18 cells; <italic>wt<sub>E</sub></italic> - 26 cells; <italic>wt<sub>L</sub></italic>- 19 cells, collected form two to three independent experiments; (<bold>f</bold>), <italic>wt<sub>H</sub></italic>- 14 cells; <italic>wt<sub>E</sub></italic> - 11 cells; <italic>wt<sub>L</sub></italic>- 12 cells, collected form one to two independent experiments.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Re-normalization of dose-response curves to 100 μM glutamate persistently shows dominant-negative effect of variants at wt<sub>H</sub> group.</title><p>(<bold>a, b</bold>) Glutamate dose-response curves for <italic>wt</italic><sub>H</sub>, <italic>wt</italic><sub>E</sub>, and <italic>wt</italic><sub>L</sub> for hGluN1a+hGluN2B<italic>wt</italic> co-expressed with varying doses of hGluN2B-G689C (<bold>a</bold>) or -G689S (<bold>b</bold>); fitted by bimodal curves after values have been normalized to 100 μM glutamate (instead of 10 mM as in <xref ref-type="fig" rid="fig4">Figure 4</xref>). Dashed traces show the standard dose-response curve for the di-heteromeric hGlun1a co-expressed with hGluN2B<italic>wt</italic> (dark blue in <bold>a</bold> and <bold>b</bold>), G689C (dashed cyan, <bold>a</bold>) or -G689S (dashed pink, <bold>b</bold>) (taken from <xref ref-type="fig" rid="fig2">Figure 2</xref>). Fit types are indicated below graphs.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig4-figsupp1-v2.tif"/></fig></fig-group><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Glutamate dose-response fitted parameters.</title></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top"/><th valign="top">EC<sub>50</sub> <break/>Two site saturation (<xref ref-type="disp-formula" rid="equ2">Equation 2</xref>) <break/>KD<sup>H</sup> (top row), KD<sup>L</sup> (bottom row)</th><th colspan="2" valign="top">EC<sub>50</sub> <break/>Two site saturation (<xref ref-type="disp-formula" rid="equ3">Equation 3</xref>) <break/>KD<sup>H</sup> (top row), KD<sup>L</sup> (bottom row)</th><th valign="top">N</th></tr></thead><tbody><tr><td valign="top"><italic>wt</italic><sub>H</sub> (16:1 <named-content content-type="author-callout-style-a1">G689C</named-content>)</td><td valign="top">440 nM ± 57 nm <break/>366.5 μM ± 74.4 μM</td><td colspan="2" valign="top">212 nM ± 32 nM <break/>148 μM ± 37 μM</td><td valign="top">18</td></tr><tr><td valign="top"><italic>wt</italic><sub>H</sub> (16:1 <named-content content-type="author-callout-style-a1">G689C</named-content>) – normalized to 100 μm glutamate</td><td valign="top">430 nM ± 76 nm <break/>370 μM ± 93.3 μM</td><td colspan="2" valign="top">212 nM ± 25 nM <break/>154 μM ± 27 μM</td><td valign="top">18</td></tr><tr><td valign="top"><italic>wt</italic><sub>E</sub> (1:1 <named-content content-type="author-callout-style-a1">G689C</named-content>)</td><td valign="top">1.725 μM ± 1.541 μM <break/>2.128 mM ± 728 μM</td><td colspan="2" valign="top">812 nM ± 818 nM <break/>778 μM ± 320 μM</td><td valign="top">26</td></tr><tr><td valign="top"><italic>wt</italic><sub>L</sub>(1:16 <named-content content-type="author-callout-style-a1">G689C</named-content>)</td><td valign="top">646 μM ± 3.716 mM <break/>5.492 mM ± 33.48 mM</td><td colspan="2" valign="top">65 μM ± 79 uM <break/>1.426 mM ± 648 uM</td><td valign="top">19</td></tr><tr><td valign="top"><italic>wt</italic><sub>H</sub> (16:1 <named-content content-type="author-callout-style-a3">G689S</named-content>)</td><td valign="top">11.85 μM ± 154 nM <break/>3.460 mM ± 1.233 mM</td><td colspan="2" valign="top">490 nM ± 90 nM <break/>1.127 mM ± 487 μM</td><td valign="top">14</td></tr><tr><td valign="top"><italic>wt</italic><sub>H</sub> (16:1 <named-content content-type="author-callout-style-a3">G689S</named-content>) – normalized to 100 μm glutamate</td><td valign="top">1.15 nM ± 164 nm <break/>3.39 mM ± 1.25 mM</td><td colspan="2" valign="top">481 nM ± 94 nM <break/>1.12 mM ± 491 μM</td><td valign="top">14</td></tr><tr><td valign="top"><italic>wt</italic><sub>E</sub> (1:1 <named-content content-type="author-callout-style-a3">G689S</named-content>)</td><td valign="top">3.503 μM ± 5.162 μM <break/>2.460 mM ± 1.081 mM</td><td colspan="2" valign="top">3.792 μM ± 3.946 μM <break/>1.208 mM ± 406 μM</td><td valign="top">11</td></tr><tr><td valign="top"><italic>wt</italic><sub>L</sub>(1:16 <named-content content-type="author-callout-style-a3">G689S</named-content>)</td><td valign="top">13.34 mM ± 4.68 nM <break/>13.34 mM ± 2.53 nM</td><td colspan="2" valign="top">1.593 mM ± 78.62 mM <break/>6.261 mM ± 1498 mM</td><td valign="top">11</td></tr></tbody></table></table-wrap><p>Dominant negative effects in <italic>GRINs</italic> is quite uncommon. In support, we find only a handful (three) of reports that explicitly note a dominant-negative effect for mixed channels for three <italic>GRIN</italic> variants (<italic>GRIN1</italic> <xref ref-type="bibr" rid="bib40">Lemke, 2016</xref>, <italic>GRIN2A</italic> (<xref ref-type="bibr" rid="bib21">Endele et al., 2010</xref>) and GRIN2B [<xref ref-type="bibr" rid="bib41">Li et al., 2019</xref>]). In two reports (<xref ref-type="bibr" rid="bib40">Lemke, 2016</xref>; <xref ref-type="bibr" rid="bib21">Endele et al., 2010</xref>), the authors interpret reduced current amplitudes (~50%) as an indication for dominant negative effect, whereas the third report indicates that a single copy of GluN2B‐N616K produces a dominant reduction in Mg<sup>2+</sup>-block similar to channels including two copies of the variant (<xref ref-type="bibr" rid="bib41">Li et al., 2019</xref>). However, most reports examining other <italic>GRIN</italic> mutations do not describe dominance. For instance, a recent report examining eight different <italic>GRIN</italic> variants (M2-pore mutations) shows that mixed-channels exhibit very mild reduction in Mg<sup>2+</sup> IC<sub>50</sub>, with values corresponding to values of the <italic>wt</italic> channels (<xref ref-type="bibr" rid="bib41">Li et al., 2019</xref>). Another report examining mixed-channels containing GluN2A<italic>wt</italic> and 2A-P552R (<xref ref-type="bibr" rid="bib53">Ogden et al., 2017</xref>) shows that, whereas 2A-P552R significantly alters stability of the pore when it is found in two copies per channel, it fails to do so when mixed with GluN2A<italic>wt</italic>. Very similar observations are reported for mixed channels bearing 2B<italic>wt</italic> and the GluN2B-E413G variant in which the EC<sub>50</sub> is not dominated by the low-affinity subunit (<xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>) (and see Discussion). Thus, while a dominant negative effect is somewhat intuitive—as all LBDs of NMDARs need to be liganded for full channel opening in which case the <italic>weakest</italic> subunit would be the limiting factor (<xref ref-type="bibr" rid="bib9">Berlin et al., 2016</xref>; <xref ref-type="bibr" rid="bib81">Wilding et al., 2014</xref>; <xref ref-type="bibr" rid="bib37">Kussius and Popescu, 2009</xref>)— it is not commonly reported for <italic>GRIN</italic> mutations, especially not for LBD mutations in <italic>GRIN2B</italic>.</p><p>Together, our observations suggest a dual effect by the variants. First, mutant receptors bearing two copies of the variants are (likely) completely non-functional physiologically. This can be potentially related to cases of haploinsufficiency (with 50% the amount of the protein [<xref ref-type="bibr" rid="bib24">García-Recio et al., 2021</xref>; <xref ref-type="bibr" rid="bib63">Santos-Gómez et al., 2021</xref>; <xref ref-type="bibr" rid="bib66">Shin et al., 2020</xref>]); however, the normal expression of the G689S variant challenges this categorization. Third, the variants instigate a strong dominant-negative effect over glutamate potency when combined with 2B<italic>wt</italic> subunits (see Discussion).</p></sec><sec id="s2-6"><title>Spermine weakly potentiates GluN2B-G689C currents in <italic>Xenopus</italic> oocytes</title><p>With the intent to rescue (i.e. increase) current amplitudes, we turned our attention toward spermine— a naturally-occurring and highly specific GluN2B-subunit potentiator (<xref ref-type="bibr" rid="bib48">Mony et al., 2009</xref>; <xref ref-type="bibr" rid="bib49">Mony et al., 2011</xref>). We firstly assessed the effect of spermine (starting at its reported EC<sub>50</sub>: 200 μM [<xref ref-type="bibr" rid="bib49">Mony et al., 2011</xref>]) at physiological pH, specifically 7.3. Under these conditions, GluN2B<italic>wt</italic>-containing receptors underwent strong potentiation (~70%) by 200 μM spermine (hGluN2B-<italic>wt </italic>= 172% ± 7.8, n=14), and this potentiation gradually decreased the higher spermine was applied, consistent with the inhibitory effect of the reagent (<xref ref-type="fig" rid="fig5">Figure 5a</xref>, dark blue trace and b) (<xref ref-type="bibr" rid="bib49">Mony et al., 2011</xref>; <xref ref-type="bibr" rid="bib74">Traynelis et al., 1995</xref>). Surprisingly, spermine was much less effective over the variants under all concentrations tested, with G689S channels showing the least propensity to undergo potentiation (at 200 μM spermine- hGluN2B-G689C = 123% ± 4.0, n=16; G689S = 102.6% ± 3.5, n=15) (<xref ref-type="fig" rid="fig5">Figure 5a</xref>). In fact, spermine inhibited 2B-G689S channels at 500 μM, as well as 2B-G689C channels but at higher concentrations (1 mM). Notably, this effect was not observed for 2B<italic>wt</italic>-receptors (<xref ref-type="fig" rid="fig5">Figure 5b</xref>). To examine whether the weak potentiation, and further inhibition, of the variants by spermine resulted from changes in spermine’s binding site (even though the binding domain is thought to be located at the interface of the amino terminal domains of GluN1a and −2B subunits—very distant from he G689 residue [<xref ref-type="bibr" rid="bib49">Mony et al., 2011</xref>]), we turned to assess spermine’s effect at lower pH (pH 6.3), at which its effect is maximized (<xref ref-type="bibr" rid="bib49">Mony et al., 2011</xref>; <xref ref-type="bibr" rid="bib74">Traynelis et al., 1995</xref>). Indeed, GluN2B<italic>wt</italic>-containing receptors showed significantly larger potentiation by spermine, for instance ~25-fold at 200 μM of spermine (<xref ref-type="fig" rid="fig5">Figure 5c</xref>, dark blue trace, d; compare with <xref ref-type="fig" rid="fig5">Figure 5b</xref> 200 μM). Under these conditions, spermine did potentiate the currents of mutant channels in a dose-dependent manner (<xref ref-type="fig" rid="fig5">Figure 5c,d</xref>). These indicate that the binding domain of spermine remained intact. To further address this issue we employed arcaine-sulfate (a competitive antagonist of the polyamine site [<xref ref-type="bibr" rid="bib25">Gomes et al., 2014</xref>; <xref ref-type="bibr" rid="bib3">Araneda et al., 1999</xref>; <xref ref-type="bibr" rid="bib62">Reynolds, 1990</xref>]). We applied arcaine at 200 μM (~3.5-fold above its IC<sub>50</sub>[<xref ref-type="bibr" rid="bib20">Donevan et al., 1992</xref>]) during the activation of the channels by saturating glutamate and glycine concentrations (Materials and methods). This treatment yielded equipotent inhibition (~90%) of all channel types (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a,b</xref>). Then, application of incrementing concentrations of spermine led to increases in current amplitudes of all channel types, showing spermine’s expected capacity to displace arcaine (e.g., <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a</xref>). However, potentiation remained largest for GluN2B<italic>wt</italic>-containing channels (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1c</xref>). This observation supports our above results and demonstrates that the common binding site for arcaine-sulfate and spermine has not been altered by the mutations. However, it fails to explain the poor potentiation of the variants by spermine (<xref ref-type="fig" rid="fig5">Figure 5d</xref> and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1c</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Spermine weakly potentiates variants <italic>in Xenopus oocytes.</italic></title><p>(<bold>a and c</bold>) Representative traces from oocytes co-expressing hGluN1a and hGluN2B-<italic>wt</italic> (blue) or GluN2B-G689C (cyan) or G689S (red), in response to increases in spermine concentrations (indicated next to trace in μM) after receptors activation (indicated by black line by 5 mM glutamate) at pH=7.3 (<bold>a</bold>) or pH 6.3 (<bold>c</bold>). At pH = 7.3, G689S failed to respond to spermine under all conditions and, instead, was inhibited by the drug. (<bold>b and d</bold>) Summary of spermine potentiation at pH=7.3 (<bold>b</bold>) or pH = 6.3 (<bold>d</bold>). Black arrowhead (<bold>c</bold>) shows the strongly diminished basal glutamate-current at pH=6.3; I<sub>basal</sub>. In <bold>c</bold>, note that the variants (cyan and red) exhibit a larger I<sub>basal</sub> than oocytes expressing hGluN1a and hGluN2B-<italic>wt</italic> (blue), though it did not reach significance. This resulted from the application of 5 mM glutamate that saturates currents of hGluN1a and hGluN2B-<italic>wt</italic> (blue), but not of the variants. From two to three independent experiments, (<bold>b</bold>) n = 4–16 oocytes; (<bold>d</bold>) n = 14–20 cells. *, p&lt;0.05; ***, p&lt;0.001. Statistics show comparison to the corresponding GluN2B<italic>wt</italic> group (blue).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>LBD mutations do not affect spermine binding site.</title><p>(<bold>a</bold>) Representative traces from oocytes co-expressing hGluN1a and hGluN2B-<italic>wt</italic> (blue) or GluN2B-G689C (cyan) or G689S (red) in response to block by arcaine (200 μM), after receptors have been activated by saturating glycine (100 μM) and glutamate (5 mM) at pH 6.5. Then, application of incrementing concentrations of spermine (concentration indicated next to plot; in μM) are added in the presence of arcaine, showing increases of the current despite antagonist. Arrowhead indicates I<sub>basal </sub>at pH 6.5, prior block by arcaine. (<bold>b</bold>) Summary of arcaine-dependent antagonism of the current. (<bold>c</bold>) Summary of spermine potentiation at pH=6.5 in the presence of 200 μM arcaine. (<bold>d</bold>) Summary of I<sub>basal</sub> at pH=6.5, showing that 2B<italic>wt</italic> receptors exhibit smallest I<sub>basal</sub>. *, p&lt;0.05 when compared to control group (in <bold>d</bold>). *** indicates p&lt; 0.001 when compared to control group exposed to the same spermine concentration. n.s., not significant. hGluN2B-<italic>wt</italic>, n=9; hGluN2B-G689C, n=10; hGluN2B-G689S, n=9.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Spermine potentiation is correlated with proton sensitivity of the variants.</title><p>(<bold>a</bold>) Representative currents of GluN2Bwt (blue), G689C (cyan), and G689S (red) showing responses to 5 mM glutamate (top black bar) and incrementing concentrations of spermine (μM, noted next to trace) at pH = 6.3, followed by glutamate responses at pH 7.3; summarized in (<bold>b</bold>). (<bold>c</bold>) Summary of the ratio of currents obtained at pH 7.3 and pH = 6.3 (I<sub>7.3/6.3</sub>). (<bold>d</bold>) relationship between I<sub>7.3</sub>/I<sub>6.3</sub> ratio and spermine potentiation (linear fit). *, p&lt;0.05; **, p&lt;0.01; ***, p&lt;0.001; n.s. non-significant. Statistics show comparison to the GluN2<italic>wt</italic>-β group. Fits were assessed by Spearman correlation.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig5-figsupp2-v2.tif"/></fig></fig-group><p>To address the latter, we re-examined our recordings and noted that, whereas all currents were significantly smaller at pH 6.5 (expectedly owing to GluN2B’s pH-dependence [<xref ref-type="bibr" rid="bib48">Mony et al., 2009</xref>; <xref ref-type="bibr" rid="bib74">Traynelis et al., 1995</xref>; <xref ref-type="bibr" rid="bib46">Low et al., 2003</xref>; <xref ref-type="bibr" rid="bib33">Jang et al., 2004</xref>; <xref ref-type="bibr" rid="bib4">Banke et al., 2005</xref>; <xref ref-type="bibr" rid="bib83">Williams, 2009</xref>]), those of −2B<italic>wt</italic> receptors were consistently the smallest (<xref ref-type="fig" rid="fig5">Figure 5c</xref>, arrowheads and <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1a</xref>, arrowheads; summary in d). To ensure these differences did not stem from potential differences in expression (or even mRNA quality), we repeated the experiment with additional measurements of the total currents of each oocyte at pH = 7.3 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2a</xref>). We observed that −2B<italic>wt</italic> receptors exhibit both smallest and largest currents at pH = 6.3 and pH = 7.3, respectively (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>, blue; summarized in b); better reflected by the pH-dependent current-ratio (I<sub>7.3</sub>/I<sub>6.3</sub>; <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2c</xref>, blue). The variants, on the other hand, displayed larger currents at low pH (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2a,b</xref>, cyan, red), but smaller at pH 7.3 (G689C showing ~45% of maximal current as shown above; <xref ref-type="fig" rid="fig2">Figure 2</xref>), thereby smaller pH-dependent current ratios (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2c</xref>). These results demonstrate that the activity of the variants is much less pH-dependent than GluN2B<italic>wt</italic>-containing receptors and provides an explanation why spermine fails to potentiate the channels (proton-inhibition is coupled to spermine potentiation for GluN2B-containing receptors [<xref ref-type="bibr" rid="bib28">Hansen et al., 2018</xref>; <xref ref-type="bibr" rid="bib48">Mony et al., 2009</xref>; <xref ref-type="bibr" rid="bib49">Mony et al., 2011</xref>; <xref ref-type="bibr" rid="bib74">Traynelis et al., 1995</xref>; <xref ref-type="bibr" rid="bib46">Low et al., 2003</xref>; <xref ref-type="bibr" rid="bib4">Banke et al., 2005</xref>]). Indeed, we find a positive correlation between pH-sensitivity (I<sub>7.3</sub>/I<sub>6.3</sub>) and spermine-potentiation for all channel types (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2d</xref>). Together, this analysis shows that the variants do bind and respond to spermine (by a similar mechanism as 2B<italic>wt</italic>-containing receptors), but the lower magnitudes of potentiation suggest that the variants have reduced proton-sensitivity.</p></sec><sec id="s2-7"><title>GluN2B-G689C and G689S-receptors are resistant to proton inhibition</title><p>Proton-sensing in GluN2-subunits is thought to be contributed by a ‘proton-senor’ residing somewhere along the linkers connecting S2 and the transmembrane domains, though its exact location remains debated (and likely involves multiple regions in the subunit) (<xref ref-type="bibr" rid="bib48">Mony et al., 2009</xref>; <xref ref-type="bibr" rid="bib46">Low et al., 2003</xref>). Interestingly, several of the proposed locations are adjacent to the G689 residue. We conducted pH dose-response curves for all three channels and found that, as hypothesized (above), mutant channels exhibit a significant rightward shift (i.e. reduction) in pH-sensitivity (<xref ref-type="fig" rid="fig6">Figure 6a,b</xref>), and behind the reason why they fail to respond to spermine. These results also point toward the fact that the G689 residue is part of the GluN2B’s proton-sensing domain. Although highly unlikely that the G689 residue directly binds protons (glycine is weakly titratable ), our results are in-line with reports showing the involvement of other small non-titratable amino acids (e.g. alanine and valine [<xref ref-type="bibr" rid="bib46">Low et al., 2003</xref>]) in proton sensing (<xref ref-type="bibr" rid="bib48">Mony et al., 2009</xref>). Thus, G689 is a new residue involved in proton sensing by the GluN2B subunit; accounting for the strongly reduced pH-sensitivity of the variants, larger currents at acidic pH and the reason for their reduced spermine sensitivity.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>GluN2B variants show reduced proton-sensitivity.</title><p>(<bold>a</bold>) Representative traces from oocytes co-expressing hGluN1a and hGluN2B-<italic>wt</italic> (blue) or GluN2B-G689C (cyan) or G689S (red), in response to decreases in pH (indicated next to trace in 8.3–6), summarized in (<bold>b</bold>). * (cyan- G689C and red, G689S) indicate p&lt; 0.05 compared to IC<sub>50</sub> of <italic>wt</italic> (see <xref ref-type="table" rid="table2">Table 2</xref>). From N=two independent experiments, n = 15–21 cells.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig6-v2.tif"/></fig></sec><sec id="s2-8"><title>D-serine does not potentiate GluN2B-currents</title><p>With the failure of spermine to potentiate the mutant channels, we proceeded to test another suggested channel potentiator, D-serine (<xref ref-type="bibr" rid="bib68">Soto et al., 2019</xref>). Briefly, Soto et al. showed the augmentation of glutamate currents (of GluN2B<italic>wt</italic>-containing receptors and a GluN2B-mutant with a ~7-fold reduction in EC<sub>50</sub>) by direct application of D-serine, or by <italic>in vivo</italic> supplementation of L-serine (which converts to D-serine [<xref ref-type="bibr" rid="bib51">Neame et al., 2019</xref>]). To test whether this could be a potential treatment in our cases, we first tested the potentiation nature of D-serine. We applied 5 mM glutamate (to maximally open the channels) along three different glycine concentrations (over three orders of magnitude). To each ligand combination, we added a constant concentration of D-serine (100 μM; shown to exert the greatest potentiating effect <xref ref-type="bibr" rid="bib68">Soto et al., 2019</xref>; <xref ref-type="fig" rid="fig7">Figure 7</xref>). At low glycine concentrations (1 μM), the addition of D-serine increased the maximal current of the 2B<italic>wt</italic> receptors by ~35%, as well as the currents of the variants, and even to a larger extent (~60%)(<xref ref-type="fig" rid="fig7">Figure 7a,b</xref>). However, D-serine poorly augmented the currents when glycine was added at 10 μM and showed no augmentation in the presence of 100 μM (saturating) glycine (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). These observations strongly suggests that D-serine is not a <italic>bona fide</italic> potentiator, rather increase in current amplitudes results from saturating the GluN1a subunit (see glycine dose-responses, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2a,b</xref> and Discussion). Next, we assessed the effect of D-serine, albeit at physiologically relevant sub-saturating glutamate and, more importantly, glycine concentrations (<xref ref-type="bibr" rid="bib90">Zhang et al., 2018</xref>). In the case of G689C, application of D-serine (on top of 1 μM glycine) yielded a ~2-fold increase in the glutamate current, however this current represents &lt;15% of the total current that can be obtained by fully opened receptors (i.e. at 5 mM glutamate) (<xref ref-type="fig" rid="fig7">Figure 7c,d</xref>; cyan-filled bars). Notably, G689S channels did not respond to physiological concentrations of glutamate/glycine and thus did not show any responses to D-serine (<xref ref-type="fig" rid="fig7">Figure 7c, d</xref>; red-filled bars). Thus, the effect of D-serine over these severe LoF mutations is negligible, and completely absent in the case of G689S. We therefore do not recommend the use of L-serine as a treatment for these, and potentially other variants, exhibiting extreme LoF, as the benefits (i.e. subtle increases in current of the variants) may not exceed the potential side-effects that may ensue by the non-specific activation of <italic>all</italic> other GluNRs in the brain by D-serine.</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>D-serine does not potentiate GluNRs.</title><p>(<bold>a</bold>) Representative traces from oocytes co-expressing hGluN1a and hGluN2B-<italic>wt</italic> (blue) or GluN2B-G689C (cyan) or G689S (red) in response to 100 μM D-serine (green bar above traces) after receptors have been activated by 5 mM glutamate along 1 (orange), 10 (light blue), or 100 μM (light green) glycine. <bold>b</bold> Summary of changes in amplitude after application of 100 μM (color coded as in <bold>a</bold>). <bold>c</bold> Representative traces and assessment of the effect of application of 100 μM D-serine (as shown in a), but when channels are activated by physiologically relevant glutamate (10 μM) and glycine (1 μM) concentrations. Total current of channels (and proof of expression) was obtained by application of 5 mM glutamate before end of recording. D-serine further activates, albeit weakly, G689C (cyan), but has no effect over 2B-G689S receptors (red); summarized in (<bold>d</bold>) and inset (zoom in on region of plot). In (d), black outline of bars represents currents obtained by 1 μM glycine. Green outline represents the currents obtained by 1 μM glycine and D-serine. *** indicates p&lt; 0.001 compared to other glycine concentrations for the same variant. n.s., not significant. hGluN2B-<italic>wt</italic>, n=10; hGluN2B-G689C, n=11; hGluN2B-G689S, n=12. For (<bold>d</bold>), n = 8 (G689C), n=7 (G689S).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig7-v2.tif"/></fig></sec><sec id="s2-9"><title>Major reduction in glutamate potency reconstituted in mammalian cells and dominant-negative effect in neurons</title><p>We next turned to assess glutamate potency in mammalian cells, specifically HEK293T cells. As in oocytes, we co-expressed hGluN1a with the different GluN2B-subtypes and performed dose-response curves using patch clamp (Materials methods). We obtained similar EC<sub>50</sub> values for GluN2B<italic>wt</italic> and 2B-G689S-containing receptors, on par with values obtained in oocytes (~2 mM; <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref>). GluN2B-G689C failed to express at sufficient levels for precise current measurements. Here, too, we did not exceed 10 mM as application of higher concentrations of glutamate tended to yield non-specific responses (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1a</xref>, black trace). Thus, these observations are consistent with our expression assays (see <xref ref-type="fig" rid="fig3">Figure 3</xref>) and TEVC measurements (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="table" rid="table2">Table 2</xref>). Additionally, these results also highlight the advantage in using oocytes for biophysical characterization of <italic>GRIN</italic> mutations, in particular mutations that reduce membrane expression levels.</p><p>We next overexpressed the variants (without over-expression of GluN1) in cultured rat primary hippocampal neurons, in which we examined synaptic activity by patch clamp (<xref ref-type="fig" rid="fig8">Figure 8a</xref>). Each neuron was initially recorded under conditions isolating α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs; GluARs)-dependent miniature EPSCs (minis<sub>AMPAR</sub>), followed by recording of GluNR (NMDAR)-dependent minis (minis<sub>NMDAR</sub>)(see Materials and methods). Neurons overexpressing the variants did not show any differences in morphology, membrane resistance, capacitance, and resting potential (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2a,b</xref>). However, overexpression caused a strong reduction in synaptic GluNR-events (<xref ref-type="fig" rid="fig8">Figure 8b</xref>). More specifically, neurons overexpressing the variants showed a strong reduction in the frequency of mini<sub>NMDAR</sub>, but with unaffected frequencies of mini<sub>AMPAR</sub> (<xref ref-type="fig" rid="fig8">Figure 8b</xref>, asterisks); yielding a ~50% reduction in the mini<sub>NMDAR/AMPAR</sub> ratio compared to control group (<xref ref-type="fig" rid="fig8">Figure 8c,d</xref>). Interestingly, solely the overexpression of G689S induced a significant reduction in the amplitude of mini<sub>NMDAR</sub> along an increase in the amplitude of mini<sub>AMPAR</sub> (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2c</xref>). Overexpression of G689C caused a small, albeit significant, increase in mini<sub>NMDAR</sub>’s amplitude (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2c</xref>, right panel). Importantly, mini<sub>NMDARs</sub> from neurons overexpressing the variants displayed faster deactivation kinetics than control (<xref ref-type="fig" rid="fig8">Figure 8d</xref>). These demonstrate that overexpression of the variants in hippocampal neurons prompts a pronounced effect on synaptic GluNRs. The reduction in the frequency of mini<sub>NMDAR</sub>—in combination with the unaffected frequency of mini<sub>AMPAR</sub>— rules-out loss of excitatory synapses (as may be instigated by other variants, for example GluN2B-S1413L [<xref ref-type="bibr" rid="bib45">Liu et al., 2017</xref>]). Moreover, the mirroring changes in the amplitudes of both mini-types, following G689S-overexpression, is highly reminiscent of synaptic scaling induced by the strong decrease in responsive GluNRs at the synapse (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2c</xref>), during which persistent block of GluNRs causes increases in synaptic GluARs (<xref ref-type="bibr" rid="bib71">Sutton et al., 2006</xref>). Lastly, the reductions in τ<sub>off</sub> due to overexpression of the variants strongly suggests that the remaining current is contributed by the faster deactivating GluN2A-subunits (<xref ref-type="fig" rid="fig8">Figure 8d</xref>; <xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>). Notably, these effects are consistent with our dominant-negative observations (see <xref ref-type="fig" rid="fig4">Figure 4</xref>) and results obtained from animal model bearing a GluN2B LoF mutation (<xref ref-type="bibr" rid="bib66">Shin et al., 2020</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>GluN2B variants modulate synaptic glutamatergic activity.</title><p>(<bold>a</bold>) Representative micrograph showing a transfected neurons (expressing GluN2B and YFP) and a recording pipette (dashed white line). (<bold>b</bold>) Representative recordings of miniature EPSCs from neurons overexpressing GluN2B<italic>wt</italic> (top), GluN2B-G689C (middle) or GluN2B-G689S (bottom) subunits. Left- recordings of mini<sub>AMPAR</sub>; right- mini<sub>NMDAR</sub> (highlighted by asterisks). (<bold>c</bold>) Frequencies of mini<sub>AMPAR</sub> and mini<sub>NMDAR</sub> for each cell, summarized in (<bold>d</bold>). (<bold>d</bold>) Ratio of NMDAR to AMPAR minis’ frequency. (<bold>e</bold>) mini<sub>NMDAR</sub> show reduced decay kinetics. Traces are averaged miniature EPSCs from events as shown in (<bold>b</bold>), fitted with a mono-exponential fit (red), summarized in plot (τ<sub>off</sub>). n.s., not significant. *, p&lt;0.05 compared to control group, 2B<italic>wt</italic>. hGluN2B-<italic>wt</italic>, n=5; hGluN2B-G689C, n=5; hGluN2B-G689S, n=6. Fit (red)- exponential.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>GluN2B-G689S shows reduced glutamate potency in mammalian cells.</title><p>(<bold>a</bold>) Representative glutamate-dependent currents recorded from HEK293T cells, transfected with hGluN1a with GluN2B-<italic>wt</italic> (blue, top trace) or with GluN2B-G689S (red), and non-transfected cells (black, bottom trace). Note that non-transfected cells exhibit non-specific responses to glutamate only at &gt;10 mM glutamate. (<bold>b</bold>) Dose-response curves, color coded as in (<bold>a</bold>). GluN2B<italic>wt</italic>, n=6; hGluN2B-G689S, n=20.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig8-figsupp1-v2.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>GluN2B variants modulate miniature EPSCs' amplitudes.</title><p>(<bold>a</bold>) Representative micrographs showing comparable morphology of neurons overexpressing GluN2B<italic>wt</italic>, G689C, or G689S. (<bold>b</bold>) Summary of membrane resistance (left), capacitance (middle) and resting potential (right) of neurons presented in <xref ref-type="fig" rid="fig8">Figure 8</xref>. (<bold>c</bold>) Cumulative distribution for amplitude of mini<sub>AMPAR</sub> (left) and mini<sub>NMDAR</sub> (right). *, p&lt;0.05 compared to control group (number of events are noted in plots).</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-67555-fig8-figsupp2-v2.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Here, we describe, and characterize, two <italic>de novo</italic> heterozygous <italic>GRIN2B</italic> loss-of-function (LoF) variants—G689C and G689S—in two pediatric patients (<xref ref-type="fig" rid="fig1">Figure 1a</xref>). Both patients display severe DD, ID, dyskinetic movements, and speech impairment (<xref ref-type="table" rid="table1">Table 1</xref>); four very well-documented phenotypes observed in <italic>GRIN2B</italic> patients (<xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>). We also find that the G689S-patient exhibits epileptic seizures, consistent with the two previously documented G689S-patients (<xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>). Interestingly, the G689C-patient does not show seizures, but the clinical likelihood of this young patient to develop epileptic seizures remains relatively high (<xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>; <xref ref-type="bibr" rid="bib18">Devinsky et al., 2018</xref>). Along with the known comorbidities of <italic>GRIN2B</italic> patients, here we report several phenotypes that deviate from reported symptoms. The G689S patient displays hypertonia, rather than hypotonia (<xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>; <xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>), as is also displayed by the G689C patient. Moreover, while movement disorders are common in <italic>GRIN</italic> patients, the G689C patient (but not the G689S patient) is also reported to exhibit hypermobility/hyperflexibility. The reason for this divergence between these two synonymous mutations is poorly understood (as both mutations are highly analogous and instigate similar LoF). However, it is highly common for <italic>GRIN</italic>-patients with similar (or even identical) mutations to show diversifying symptoms (<xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">García-Recio et al., 2021</xref>; <xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>; <xref ref-type="bibr" rid="bib70">Strehlow et al., 2019</xref>; <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) or, inversely, for patients with different mutations (even in different <italic>GRINs</italic>) to display overlapping symptoms (<xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>). These phenotypes are likely to involve additional genetic and environmental factors. In the case of the G689S patient, we do find (by whole-exome sequencing; WES) two additional variants of unknown/uncertain significance (VUS), specifically the <italic>SLC6A8</italic> (creatine Transporter) and <italic>CACNA1A</italic> (voltage-gated calcium Channel) genes. However, whether these are directly involved or implicated in the disease remains unknown. Nonetheless, no VUS, pathogenic variants, nor aberrations in the Chromosomal Microarray Analysis (CMA) were detected in screens of the G689C patient (<xref ref-type="table" rid="table1">Table 1</xref>). Resultantly, we and others suggest that patients' symptoms cannot serve as primary diagnostic measures for <italic>GRIN</italic>-related encephalopathies (e.g. [<xref ref-type="bibr" rid="bib89">Zehavi et al., 2017</xref>]). Indeed, no formal diagnostic criteria for <italic>GRIN2B</italic>-related neurodevelopmental disorder have been established (<xref ref-type="bibr" rid="bib61">Platzer and Lemke, 1993</xref>; revised 2021).</p><p>An additional puzzling observation shows that the severity of phenotypes does not correlate with the magnitude of the effect of the mutation on channel function (<xref ref-type="bibr" rid="bib73">Tang et al., 2020</xref>). In fact, despite the critical LoF effect of the mutations described here, the clinical phenotypes resemble many other <italic>GRIN2B</italic> LoF mutations (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>; <xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>; <xref ref-type="bibr" rid="bib5">Bell et al., 2018</xref>). For instance, GluN2B-E413G inflicts a much smaller reduction in glutamate potency (EC<sub>50</sub> = 79 ± 5.3 μM), though manifests with severe phenotypes as described here for the two variants. This dissonance is reflected in a recent <italic>GRIN2B</italic> study (consisting of a cohort of 86 patients), in which they found no clear association between: (1) effect of mutation (GoF or LoF), (2) extent of effect (e.g. shift in EC<sub>50</sub>), and (3) localization of the mutations in the subunit, with the clinical outcomes (<xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>). The only significant correlation obtained was between variant class (i.e. missense or truncation mutation) and intellectual outcome (mild to moderate moderate vs severe ID); with truncation carriers <italic>tending</italic> to present mild/moderate intellectual disability. However, it is not really unexpected for these symptoms to appear in <italic>GRIN2B</italic> cases, owing to the subunit’s very early (embryonic) expression pattern (<xref ref-type="bibr" rid="bib55">Paoletti et al., 2013</xref>; <xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>; <xref ref-type="bibr" rid="bib50">Myers et al., 2019</xref>). In contrast, analysis of a larger cohort of <italic>GRIN2A</italic> patients (n = 248) finds only <italic>two</italic> distinct phenotypes that could be associated with the location and effect (gain or loss—but not size of effect) of the mutations (<xref ref-type="bibr" rid="bib70">Strehlow et al., 2019</xref>). More precisely, the authors show that: (1) mutations in TMDs and connecting linkers yield GoF (although to very different extents) and these may be associated with broad developmental and epileptic encephalopathy phenotypes. (2) Mutations in the two large extracellular domains (ATD, LBD) typically instigate LoF and are better related with speech abnormalities and seizures, with mild to no ID (<xref ref-type="bibr" rid="bib70">Strehlow et al., 2019</xref>). These observations highlight the need for larger cohorts in order to establish better correlations (if any).</p><p>Despite these associations, it remains challenging to infer how, and to what extent, a mutation may affect receptor function or its expression solely based on clinical symptoms or even based on the location of the mutation within the protein (<xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>). In our case, <italic>in silico</italic> scrutiny of the G689 residue shows it to reside at the lower lobe of the LBD of the GluN2B subunit (S2 domain)—at the base of the glutamate entry tunnel—virtually lining the glutamate binding pocket (<xref ref-type="fig" rid="fig1">Figure 1b</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). When the location of the residue is combined with structure simulations of the variants (<xref ref-type="fig" rid="fig1">Figure 1c,d</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1b</xref> and <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>), estimation of protein stability (ΔΔG; <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>), and considering that most GluN2B mutations in LBD reduce glutamate potency (<xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and <xref ref-type="supplementary-material" rid="supp2">2</xref>; <xref ref-type="bibr" rid="bib84">XiangWei et al., 2018</xref>; <xref ref-type="bibr" rid="bib73">Tang et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Platzer et al., 2017</xref>; <xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>; <xref ref-type="bibr" rid="bib77">Vyklicky et al., 2018</xref>), it was safe to assume that the variants would yield LoF. However, these could not have predicted the extent of the effect, explicitly &gt;1000-fold and ~2000-fold by G689C and G689S, respectively (<xref ref-type="fig" rid="fig2">Figure 2</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref>). Potential reasons why we could not anticipate these large shifts are likely because they represent two very extreme cases (only second to another potent <italic>GRIN2A</italic> mutation D731N; ~6000-fold reduction [<xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>]) and because of the very few characterized LBD-mutations in <italic>GRIN2B</italic> (~20 mutations, See <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> and <xref ref-type="supplementary-material" rid="supp2">2</xref>). With these limitations in mind, we decided to explore the functional outcome of any possible mutation within the LBD (consisting of ~280 a.a.); yielding a collection of 5282 substitutions. This large number made it impractical for us to employ structure simulations, thereby motivating us to proceed with ΔΔG estimations (<xref ref-type="bibr" rid="bib59">Pires et al., 2014</xref>). We calculated ΔΔG for 5282 substitutions within the LBD of GluN2B (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>, closed circles) and immediately note that most of the substitutions yield a negative outcome on protein stability (ΔΔG &lt; −0.5; <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3a</xref>, red region). Substitutions with a stabilizing nature appeared in a much smaller fraction of cases (~20%) (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3a, b</xref> -blue). We explored the relationship between characterized LBD mutations with our ΔΔG estimates, however there are too few characterized mutations (18 mutations) to address this (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3c</xref>). However, we can observe that LoF mutations correlate better with more negative ΔΔG, whereas GoF mutations are associated with less negative ΔΔG (albeit this is based on two out of three characterized mutations) (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3c</xref>). To examine whether there are locations within the LBD that might be more vulnerable for mutagenesis, we estimated each residue’s relative contribution to the stability of the LBD (by averaging the ΔΔG of 19 substitutions for each residue, see Materials and methods) and plotted these on the structure. Unfortunately, we do not observe negative hot-spots nor did the 18 characterized mutations show a pattern in the LBD (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3d</xref>). However, the data does suggest that stabilizing mutations are likely to locate on the outer layers of the LBD (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3e</xref>, blue and dashed blue circle). Indeed, these estimations encompassed all three GoF mutations. Interestingly, and perhaps with the most predictive nature, this analysis emphasizes that mutations resulting in a glycine or a serine—no matter the residue they replace in the LBD—are likely to be the most damaging (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3f</xref>). This is highly reasonable as these amino acids are very small (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>), especially glycine, and their incorporation <italic>in-lieu</italic> of other (larger) residues should be very destabilizing. Interestingly, the same may apply inversely, namely removal of glycine and its substitution by other (larger) residue should be highly disfavorable for receptor function. In support, glycine residues are suggested to serve as essential hinges in <italic>GRIN2B</italic> and their mutagenesis causes severe channel dysfunction (<xref ref-type="bibr" rid="bib2">Amin et al., 2018</xref>), including the two cases described here.</p><p>Another elusive feature for prediction is expression of variants, especially when the mutations do not lead to truncation (<xref ref-type="bibr" rid="bib24">García-Recio et al., 2021</xref>). It has been previously shown that high glutamate affinity is associated with proper surface trafficking (<xref ref-type="bibr" rid="bib64">She et al., 2012</xref>; <xref ref-type="bibr" rid="bib31">Horak et al., 2014</xref>; <xref ref-type="bibr" rid="bib78">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib36">Kenny et al., 2009</xref>). Thus, it can be assumed that since most LBD mutations yield reduction in EC<sub>50</sub>, most should also show reduced expression levels. This assumption correctly predicts the effect of the G689C mutation (<xref ref-type="fig" rid="fig3">Figure 3a,b</xref>), but completely fails to explain the robust expression of the G689S variant with an even larger reduction in EC<sub>50</sub> (<xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1</xref> and <xref ref-type="fig" rid="fig8s2">2</xref>). This assumption (<xref ref-type="bibr" rid="bib64">She et al., 2012</xref>; <xref ref-type="bibr" rid="bib77">Vyklicky et al., 2018</xref>) further neglects to explain how both low-affinity variants enhance the expression of the <italic>wt</italic> subunit (<xref ref-type="fig" rid="fig3">Figures 3c</xref> and <xref ref-type="fig" rid="fig4">4</xref> and <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>). Thus, our results describe two novel cases in which intracellular glutamate-binding is not essential for proper trafficking of GluN2B<italic>-</italic>subunits to the membrane and cautions the use of glutamate affinity for predicting expression levels and/or functional effect. Together, the functional outcome of our observations suggests that during normal synaptic transmission, tri-heteromeric receptors assembled from GluN2B<italic>wt</italic> and mutant variants, are non-responsive to normal neurotransmission (<xref ref-type="fig" rid="fig4">Figures 4</xref> and <xref ref-type="fig" rid="fig8">8</xref>; <xref ref-type="bibr" rid="bib44">Lisman et al., 2007</xref>). In fact, regular neurotransmission does not typically saturate <italic>wildtype</italic> receptors (<xref ref-type="bibr" rid="bib32">Ishikawa et al., 2002</xref>; <xref ref-type="bibr" rid="bib52">Nimchinsky et al., 2004</xref>). Thus, we suggest that the severe clinical phenotypes observed for both variants arise from a complex combination of: (1) severe LoF of channel consisting of two copies of the variants, (2) poor trafficking to membrane, (3) co-assembly and exertion of dominant-negative effect over native GluN2B<italic>wt</italic>-containing receptors.</p><p>With the intention to provide a potential treatment, we examined whether spermine would potentiate the currents of the variants. Of note, we focused on spermine as it is highly GluN2B-selective (<xref ref-type="bibr" rid="bib49">Mony et al., 2011</xref>), unlike other potentiators (e.g. tobramycin, pregnenolone-sulfate; PS or D-serine) that can exert non-specific effects on other GluN-subunits or even other glutamate-receptors (<xref ref-type="bibr" rid="bib73">Tang et al., 2020</xref>; <xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>; <xref ref-type="bibr" rid="bib69">Stoll et al., 2007</xref>; <xref ref-type="bibr" rid="bib47">Masuko et al., 1999</xref>). Secondly, spermine can cross the blood-brain-barrier to certain extents (BBB [<xref ref-type="bibr" rid="bib65">Shin et al., 1985</xref>; <xref ref-type="bibr" rid="bib19">Diler et al., 2002</xref>]), and could potentially be administered orally or intraperitoneally (e.g. <xref ref-type="bibr" rid="bib54">Okumura et al., 2016</xref>; <xref ref-type="bibr" rid="bib26">Guerra et al., 2016</xref>). Third, it is inexpensive. Importantly, previous reports showed that spermine acted on LoF GluN2B variants in a similar fashion as they do on GluN2B<italic>wt</italic>-subunits (<xref ref-type="bibr" rid="bib72">Swanger et al., 2016</xref>). However, and strikingly, we found that G689C- and G689S-containing channels poorly respond to the reagent under physiological conditions; with the G689S-mutant even undergoing strong inhibition by spermine (<xref ref-type="fig" rid="fig5">Figure 5a,b</xref>). We go on to demonstrate that reduced spermine-sensitivity stems from the variants’ reduced pH-sensitivity (<xref ref-type="fig" rid="fig6">Figure 6</xref> and <xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>) (but not disrupted binding domain; <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>). This suggests that the G689 residue is directly involved in proton-sensing in the GluN2B subunit (<xref ref-type="bibr" rid="bib46">Low et al., 2003</xref>; <xref ref-type="bibr" rid="bib4">Banke et al., 2005</xref>; <xref ref-type="bibr" rid="bib17">DeCoursey, 2018</xref>). This feature adds another layer of complexity to the growing list of effects exerted by these unique mutations. These observations suggest that though spermine (or potentially other GluN2B-positive allosteric modulators [<xref ref-type="bibr" rid="bib48">Mony et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Burnell et al., 2019</xref>; <xref ref-type="bibr" rid="bib91">Zhu and Paoletti, 2015</xref>]) may be useful in other cases of GluN2B-LoF mutations, it is not suitable for treating G689C- or G698S-induced deficiencies at the synapse.</p><p>We similarly tested another suggested potentiator, namely L- (but <italic>de facto</italic> D)-serine (<xref ref-type="bibr" rid="bib68">Soto et al., 2019</xref>). D-serine was suggested to act as potentiator owing to its ability to increase currents of a mild LoF <italic>GRIN2B</italic> variant (showing ~seven-fold reduction in EC<sub>50</sub>). We applied 100 μM D-serine onto receptors activated by sub- or saturating glycine concentrations (<xref ref-type="fig" rid="fig7">Figure 7</xref>), but D-serine enhanced the currents of the variants solely when glycine concentrations were sub-saturating (see glycine EC<sub>50</sub>, <xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Thus, it appears that D-serine does not act as a classic potentiator (i.e. [<xref ref-type="bibr" rid="bib73">Tang et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Mony et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Burnell et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">Hackos et al., 2016</xref>]). Instead, it is an equipotent ligand for the GluN1a subunit and the observed increases in currents (up to 60%) are obtained by saturation of GluN1 (glycine or D-serine; EC<sub>50</sub>: ~0.7 [<xref ref-type="bibr" rid="bib75">Traynelis et al., 2010</xref>]). Regardless the exact definition of the mechanism by which D-serine augments the currents, under physiological conditions increase in the extracellular D-serine concentration would likely lead to further opening of the channels, as resting glycine (and D-serine) extracellular concentrations may be sub-saturating; 1–5 μM (<xref ref-type="bibr" rid="bib90">Zhang et al., 2018</xref>; <xref ref-type="bibr" rid="bib30">Hashimoto et al., 1995</xref>; <xref ref-type="bibr" rid="bib39">Lazarewicz et al., 1992</xref>). However, and even in cases where GluN1a subunits are not fully saturated by glycine, the G689C or G689S mutations require very high (mM) glutamate concentrations for opening and, therefore, increase in D-serine (via L-serine supplementation) is ineffective (<xref ref-type="fig" rid="fig7">Figure 7c,d</xref>). We therefore do not recommend the use of L-serine in this, or other extreme LoF mutations, as L-serine may acts on the obligatory GluN1-subunit found in <italic>all</italic> receptor combinations and possibly induce side effects.</p><p>In summary, we have systematically characterized two unique mutations occurring at the same residue of the <italic>GRIN2B</italic> gene in two patients. The variants exert a strong dominant-negative effect over <italic>wt</italic>-subunits, leading to reduced potency of mixed channels and reduced synaptic GluNR-currents (and compensation by AMPARs [<xref ref-type="bibr" rid="bib71">Sutton et al., 2006</xref>]). To make things worse, the variants are resistant to protons, thereby limiting the use of spermine. We provide an assessment of the stability of the LBD for all possible mutations within the LBD. These exemplify the vulnerability of the LBD to mutagenesis, particularly for insertion (but also deletions) of glycine and serine. Together, our study complements ongoing efforts invested in characterizing <italic>GRIN</italic> variants (appearing faster than can be functionally tested, <xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>), provide insights concerning the structure-function relationship of GluN2B and underscore the need for new, more potent, GluN2B-specific channel openers.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title><italic>Xenopus</italic> oocytes extraction</title><p>All Experiments were approved by the Technion Institutional Animal Care and Use Committee (permit SB, no. IL-129-09-17). <italic>Xenopus laevis</italic> oocytes were harvested, prepared, and injected with mRNA as previously described (<xref ref-type="bibr" rid="bib10">Berlin et al., 2020</xref>). Briefly, oocytes were obtained from anesthetized (by 0.4% tricaine solution) female frogs. Oocytes were extracted from ovaries, defolliculated by collagenase treatment in ND96 Ca<sup>+2</sup>-free solution (in mM: 96 NaCl, 2 KCL, 1 MgCl2, 5 HEPES, pH 7.4) for about 45 min at RT. Cells were washed with ND96 Ca<sup>+2</sup> -free and transferred to enriched ND96 (NDE) consisting of ND96 supplemented with 1.8 mM CaCl<sub>2</sub>, 2.5 mM sodium pyruvate, 100 μg/ml streptomycin and 62.75 μg/ml penicillin. Stage V oocytes were manually isolated, incubated overnight at 18°C and injected with mRNA the next day.</p></sec><sec id="s4-2"><title>Mammalian cell culture and transfection</title><p>HEK293T cells were maintained in DMEM (containing 10% FBS and 1% L-glutamine) in 100 mm Corning cell culture dishes. Cells were purchased from the American Tissue Culture Collection (ATCC) and are regularly tested for mycoplasma. A day prior transfection, medium was replaced by 2 mL of fresh medium and cell were suspended (by gentle pipetting). Suspended cells were then transferred (~250 μl) onto a 35 mm cell culture dish containing 2 ml medium. Cells were grown to 70–90% confluency (~overnight). The following day, cells were transfected with ViaFect Transfection Reagent (Promega) by DNA mixtures: 400 μl serum free DMEM+ 1 µg DNA of hGluN1a-<italic>wt</italic> + 1 µg hGluN2B variant + 2 µg EGFP; at 3:1 ratio of transfection (µl reagent: µg DNA, here 12 µl reagent/4 µg total DNA). Reaction mix was allowed to settle at room temperature for 20 min, prior addition to cells. Following 4–8 hr, old medium (containing ViaFect reaction mix) was replaced by 2 mL of fresh DMEM-containing 10% FBS and 1% L-glutamine. Then, cells were resuspended and transferred into a new 24 well plate, containing poly-D-lysine (PDL)-coated coverslips (12 mm), and grown overnight with broad GluNR blockers, explicitly 2 µM MK-801 (Alomone labs, Cat. #M-230) and 200 µM AP5 (Alomone labs, Cat. #D-145).</p></sec><sec id="s4-3"><title>Dissociation, culturing, maintenance, and transfection of primary neurons</title><p>Primary cultures of hippocampal neurons were done as previously reported (<xref ref-type="bibr" rid="bib11">Berlin and Isacoff, 2018</xref>). Briefly, hippocampi were extracted from rat neonates (P0), dissociated and transferred to 24-well plates containing PDL-covered glass coverslips containing MEM (Gibco)-based growth medium and kept in an incubator (37°C and 5% CO<sub>2</sub>). After 5 days in vitro (DIV), the neuronal culture medium was supplemented with 4 μM cytosine arabinoside (ARA-C) for suppression of glial cell proliferation. At 7–9 days in vitro (DIV), neurons were transfected by the calcium-phosphate method with 0.3 μg DNA eYFP and 1 μg DNA of GluN1a and GluN2B<italic>wt</italic> or 2B-G689C or 2B-G689S. Neurons were then grown for 3–4 more days prior to recordings.</p></sec><sec id="s4-4"><title>Molecular biology and in vitro mRNA preparation</title><p>Human GluN1a-<italic>wt</italic> (hGluN1a), human GluN2B-<italic>wt</italic> (hGluN2B<italic>wt</italic>) and human GluN2B-G689C (hGluN2B-G689C) cloned in pCl-Neo were obtained from Dr. Garin-Shkolnik T (produced by the Traynelis S. Lab). Human GluN2B-G689S (hGluN2B-G689S; c.G2065A) was generated by us using site-directed mutagenesis (primers: sense- 5’-<named-content content-type="sequence">CCGCTTTGGGACCGTGCCCAACAGCAGCACAGAGAGAAATATTCG</named-content>-3’, antisense 5’-<named-content content-type="sequence">CGAATATTTCTCTCTGTGCTGCTGTTGGGCACGGTCCCAAAGCGG</named-content>-3’) and verified by full DNA sequencing (Faculty of Medicine, Biomedical Core Facility- Technion). For mRNA preparation, DNA plasmids were linearized by restriction enzymes (NotI), followed by in vitro mRNA transcription using mMessage-mMachine T7 kit (Thermo Scientific, Cat.#AM1344), as previously described (<xref ref-type="bibr" rid="bib7">Berlin et al., 2010</xref>). mRNA concentrations were determined using a spectrophotometer. Oocytes were injected with 5–16 ng/oocyte mRNA of each subunit at 1:1 ratio in all of the experiments. For dominant-negative experiments, we co-injected hGluN1a, hGluN2B<italic>wt</italic> and hGluN2B-G689C or −2B-G689S with the following mRNA quantities (ng/oocyte): 5:16.6:1, 5:5:5: and 5:1:16.6 yielding GluN2B-<italic>wt</italic> high (<italic>wt</italic><sub>H</sub>), even (<italic>wt</italic><sub>E</sub>), and low (<italic>wt</italic><sub>L</sub>), respectively.</p></sec><sec id="s4-5"><title>Electrophysiology (TEVC and Patch clamp recordings)</title><p>Two electrode voltage clamp (TEVC) recordings were carried-out 24–72 hr following mRNA injections, as previously described (<xref ref-type="bibr" rid="bib8">Berlin et al., 2011</xref>). Recordings were performed using commercial amplifier (Warner Instruments, USA) and Digitizer (Digidata-1550B; Molecular Devices, USA), controlled by pClamp10 software (Molecular Devices, USA). Electrodes consisted of pulled glass capillaries (by puller- Narishige, Japan) with chlorinated silver wire, filled with 3M KCl. Oocytes were clamped to −60 mV and perfused with nominally Mg<sup>+2</sup>-free barth solution (in mM): 100 NaCl, 0.3 BaCl<sub>2</sub>, 5 HEPES, pH 7.3 (adjusted with NaOH). For glutamate dose-response curves for the hGluN2B<italic>wt</italic>-containing channels glutamate concentrations ranged between 0.2 and 100 μM, including glycine at saturating concentration (100 μM). For the hGluN2B-G689C or G689S variants, glutamate concentrations arranged between 0.2 μM and 100 mM, in the presence of saturating glycine (100 μM). The different barth solutions containing excessively large glutamate concentrations were adjusted for osmolarity. Barth solution with glutamate concentrations ranging between 0.1 and 2 mM contained (in mM): 100 NaCl, 0.3 BaCl<sub>2</sub>, 5 HEPES, 99 NMDG, pH 7.3 (adjusted with HCl). For higher concentrations of glutamate (&gt;5 mM), recording solution contained (in mM): 100 NaCl, 0.3 BaCl<sub>2</sub>, 5 HEPES, 90 NMDG, pH 7.3 (adjusted with HCl) or 100 NaCl, 0.3 BaCl<sub>2</sub>, 5 HEPES, 50 NMDG, pH 7.3 (adjusted with HCl) were used in making 10- and 50 mM glutamate solutions, respectively. For barth containing 100 mM glutamate, we used NMDG-free solution (in mM): 100 NaCl, 0.3 BaCl<sub>2</sub>, 5 HEPES, pH 7.3 (adjusted with NaOH). For glycine dose-response experiments, glycine solutions ranged between 0.05 and 100 μM supplemented with 5 mM glutamate were used. For Mg<sup>+2</sup>-dose-response experiments, receptors were activated by 5 mM glutamate and 100 μM glycine, then gradually blocked by incrementing Mg<sup>+2</sup>-concentrations ranging from 1 μM to 10 mM.</p></sec><sec id="s4-6"><title>HEK293T</title><p>Patch clamp recordings were acquired MultiClamp 700B and Digidata 1440A (Molecular Devices), as previously described (<xref ref-type="bibr" rid="bib11">Berlin and Isacoff, 2018</xref>). Briefly, cells were voltage-clamped at −70 mV. Borosilicate glass capillaries (i.e. pipettes) were pulled to resistances of 4–10 MΩ and were filled with an internal solution containing (in mM): 135 K-gluconate, 10 NaCl, 10 HEPES, 2 MgCl<sub>2</sub>, 2 Mg<sup>2+</sup>-ATP, 1 EGTA, pH = 7.3. Recordings were done in extracellular recording solution containing (in mM): 138 NaCl, 1.5 KCl, 2.5 CaCl<sub>2</sub>, 10 D-glucose, 5 HEPES, 0.05 glycine, pH = 7.4.</p></sec><sec id="s4-7"><title>Neurons</title><p>YFP-positive 10–13 DIV neurons were visually detected by 488 nm LED illumination (X-Cite fluorescence LED illuminator, Excelitas Technologies) and voltage-clamped at −80 mV (Multiclamp 700B amplifier and Digidata 1440A digitizer). Glass capillaries were adjusted to resistances of 8–12 MΩ, and filled with intracellular solution containing (in mM): 135 K-gluconate, 10 NaCl, 10 HEPES, 2 MgCl<sub>2</sub>, 2 Mg-ATP, 1 EGTA, pH = 7.3. For recordings of AMPAR-mediated mEPSCs (mini<sub>AMPAR</sub>), neurons were perfused with an extracellular solution containing (in mM): 138 NaCl, 1.5 KCl, 1.2 MgCl2, 5 CaCl<sub>2</sub>, 10 Glucose, 5 HEPES, pH = 7.4, and 1 μM TTX. For recordings of NMDAR-mediated mEPSCs (mini<sub>NMDAR</sub>), cells were perfused with the extracellular solution enriched with 5 μM Glycine, 1 μM TTX and 20 μM CNQX (selective AMPAR blocker) but without MgCl<sub>2</sub>. Cells were recorded for ~3 min for each perfusion phase.</p></sec><sec id="s4-8"><title>Apparent open probability</title><p>MK-801 (activity-dependent pore blocker of GluNRs) was purchased from Alomone labs (cat.# M-230). One mM stock solutions were made by diluting lyophilized MK-801 in barth solution. Receptors were activated by 3 mM glutamate and 100 μM glycine solution, then blocked by 1 μM MK-801 solution containing both agonists. Deactivation kinetics were fitted from which we extracted t<sub>10-90%</sub> or deactivation constant, τ<sub>off</sub>.</p></sec><sec id="s4-9"><title>Spermine potentiation</title><p>Spermine was purchased from Sigma-Aldrich (Cat. #S3256). A total of 200 mM stock solutions were made by diluting powdered spermine in barth solution at different pHs (6.3 and 7.3). Spermine potentiation was assessed in the presence 5 mM glutamate and 100 μM glycine. Under these conditions, GluN2Bwt-subunits were completely saturated, though both mutants were only at their ~EC<sub>50</sub>. We therefore note that the difference in I<sub>basal</sub> between the three groups is an underestimation of the maximal I<sub>basal</sub>, are therefore behind the lack of statistical significance. Arcaine sulfate was purchased from Alomone labs (Cat. # 14923-17-2). Ten mM solutions were made by diluting lyophilized Arcaine sulfate in barth solution at pH = 6.5. For competition assay, receptors were activated by 5 mM glutamate and 100 μM glycine solution, then blocked by 200 μM arcaine solution containing both agonists, followed by application of incrementing concentrations of spermine.</p></sec><sec id="s4-10"><title>Assessing potentiation by D-serine</title><p>GluNRs variants were expressed in <italic>Xenopus</italic> oocytes and were perfused with barth solution supplemented with 10 μM or 5 mM glutamate and 1-, 10-or 100 μM glycine. D-serine (sigma, Cat. #: 312-84-5) potentiation was examined by perfusing oocytes with barth solution supplemented with both co-agonists onto which we added constant D-serine concentration (100 μM). Amplitude fold change was calculated by normalizing the maximal current before and after exposure to D-serine.</p></sec><sec id="s4-11"><title>pH sensitivity</title><p>pH titration experiment was done by perfusing oocytes with barth solutions of different pHs, ranging from 6 to 8.3 (pH adjusted by NaOH), supplemented with 5 mM glutamate and 100 μM glycine.</p></sec><sec id="s4-12"><title>β-lactamase assay</title><p>HEK293T cells seeded in a 35 mm plates and transiently transfected with cDNA encoding hGluN1 and/or b-lac-GluN2B-wt/G689C/G689S/Kv4.2 using ViaFect (Promega). We used large dishes to obtain sufficient amount of cells for assessing 14 different conditions (amount of DNA used to transfect each group: 1 μg-hGluN2B-<italic>wt</italic>-β-lac, 1 μg hGlun1a + 1 μg hGluN2B-<italic>wt-</italic>β-lac, 1 μg hGlun1a + 1 μg hGlun2B-<italic>wt-</italic>β-lac/G689C-β-lac /G689S- β-lac, 1 μg hGlun1a + 1 μg hGluN2B-<italic>wt-</italic>β-lac + 0.1 μg hGluN2B-G689C/S/Kv 4.2, 1 μg hGlun1a + 1 μg hGluN2B-<italic>wt-</italic>β-lac + 0.5 μg hGluN2B-G689C/S/Kv 4.2, 1 μg hGlun1a + 1 μg hGluN2B-<italic>wt-</italic>β-lac + 1 μg hGluN2B-G689C/S/Kv 4.2). Six hours after transfection 20*10<sup>4</sup> cells were seeded on PDL covered 96-well plates to which we added two different drugs (APV- 2 μM; MK-801–200 μM). Cells transfected with β-lac-GluN2B-<italic>wt</italic> alone were used to determine background absorbance and as a negative control for surface β-lactamase activity. Additionally, cells transfected with Kv4.2 (in different quantities) along with constant amounts of hGlun1a + hGluN2B-<italic>wt-</italic>β-lac were used as control for competition over translation machinery. Four-eight wells were seeded for each condition in each experiment. Twenty-four hrs following transfection, cells were washed with 200 μL Hank’s Balanced Salt Solution (HBSS) supplemented with 10 mM HEPES. For measurements, we added 100 μL of 100 mM nitrocefin (Millipore - CAS 41906-86-9) in HBSS solution with 10 mM HEPES. The absorbance at 486 nm was measured every minute for 30–60 min at 30°C degrees by a plate reader. β-lactamase activity was determined from the slope of linear fit of the data.</p></sec><sec id="s4-13"><title>Structure modeling</title><p>Structural models of GluN2B LBD bearing G689C or G689S mutations generated using Schrodinger’s Maestro 11.2. The glutamate-bound LBD of rat GluN2B (residues 403–539 and 651–802, PDB 4PE5 [<xref ref-type="bibr" rid="bib34">Karakas and Furukawa, 2014</xref>]) was used as a template. All the structures were prepared using the Protein Preparation Wizard (Schrödinger Release 2021–1: Protein Preparation Wizard; Epik, Schrödinger, LLC, New York, NY, 2021) as implemented in Schrodinger's Maestro 11.2. This protocol adds missing hydrogen atoms considering a pH value of 7.2 ± 1.0 and optimizes the hydrogen bond network. Next, energy minimization was performed using MacroModel (Schrödinger Release 2021–2: MacroModel, Schrödinger, LLC, New York, NY, 2021) with the OPLS3e forcefield and Polack-Ribiere Conjugate Gradient (PRCG) algorithm. Minimization was stopped either after 2500 steps of minimization or after reaching a convergence threshold of 0.05 kcal/mol. Graphic representation was done by PyMOL software.</p></sec><sec id="s4-14"><title>Data analysis</title><p>Data were analyzed by Clampfit software (Molecular Devices, USA) and were fitted using Sygmaplot 11 (Systat software, inc) to Hill’s equation (<xref ref-type="disp-formula" rid="equ1">Equation 1</xref>) from which we extracted EC<sub>50</sub> values. In co-expression experiments, results were best fitted by Michaelis-menten-like equations (<xref ref-type="disp-formula" rid="equ2">Equation 2</xref> and <xref ref-type="disp-formula" rid="equ3">Equation 3</xref>), assuming two affinity states, as previously described (<xref ref-type="bibr" rid="bib6">Ben-Chaim et al., 2003</xref>). IC<sub>50</sub> values for Mg<sup>+2</sup> and proton inhibition were extrapolated by fitting the results to Hill’s equation (<xref ref-type="disp-formula" rid="equ4">Equation 4</xref>). τ<sub>off</sub> values for apparent open probability were extrapolated by fitting the result to a mono-exponential function (<xref ref-type="disp-formula" rid="equ5">Equation 5</xref>). t<sub>10-90%</sub> results were obtained by placing cursors at beginning and end of responses, then automatically assessed by the Clampfit software (under statistics, positive going). mEPSCs were detected off-line using pCLAMP 10’s template search. Briefly, 5–10 ‘minis’ were identified and selected by user, followed by an automated search. All automatically identified minis were validated by user. Decay kinetics (τ<sub>off</sub>) were assessed by fitting responses by a mono-exponential function (<xref ref-type="disp-formula" rid="equ5">Equation 5</xref>).<disp-formula id="equ1"><label>(1)</label><mml:math id="m1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">l</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi mathvariant="normal">E</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mn>50</mml:mn><mml:msup><mml:mo stretchy="false">]</mml:mo><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">H</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ2"><label>(2)</label><mml:math id="m2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>X</mml:mi></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>X</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ3"><label>(3)</label><mml:math id="m3"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:msup><mml:mi>X</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>H</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>X</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>B</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:msub><mml:mo>∗</mml:mo><mml:msup><mml:mi>X</mml:mi><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:mi>X</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mfrac></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ4"><label>(4)</label><mml:math id="m4"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">R</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>–</mml:mo><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">M</mml:mi><mml:msup><mml:mi mathvariant="normal">g</mml:mi><mml:mrow><mml:mo>+</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi mathvariant="normal">o</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">p</mml:mi><mml:mi mathvariant="normal">H</mml:mi><mml:mrow><mml:mo>/</mml:mo></mml:mrow><mml:mi mathvariant="normal">I</mml:mi><mml:msub><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mn>50</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mo stretchy="false">]</mml:mo><mml:mrow><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">H</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle></mml:math></disp-formula><disp-formula id="equ5"><label>(5)</label><mml:math id="m5"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi mathvariant="normal">f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="normal">t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munderover><mml:mo movablelimits="false">∑</mml:mo><mml:mrow><mml:mi mathvariant="normal">i</mml:mi><mml:mo>=</mml:mo><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mi mathvariant="normal">A</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mfrac><mml:mrow><mml:mo>−</mml:mo><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:msub><mml:mi>τ</mml:mi><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow></mml:msub></mml:mfrac></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mi mathvariant="normal">c</mml:mi></mml:mrow></mml:mstyle></mml:math></disp-formula></p></sec><sec id="s4-15"><title>Statistical analysis</title><p>All data are presented as mean ± SEM. Number of cells are indicated by n, whereas number of experiments by N. Statistical significance (Sigmaplot 11) was obtained by one-way ANOVA for multiple group comparison with post hoc Tukey test. *, p&lt;0.05; **, p&lt; 0.01 and ***, p&lt;0.001; n.s., non-significant. Kruskal-Wallis ANOVA on ranks was used for assessing neuronal data (specifically, Rm, mini ratios and amplitudes; <xref ref-type="fig" rid="fig8">Figure 8</xref> and <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>). Significance of cumulative distributions was determined by Kolmogorov-Smirnov- (Sigmaplot 11).</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank the GRIN disorder research foundation (GDRF) for providing clinical data on the G689C patient and for the <italic>GRIN</italic> families. The research submitted is in partial fulfillment for a doctoral degree for SK and magister’s degree for AA. <bold>Funding—</bold> Support was provided by the Israel Science Foundation (SB; 1096/17) and by TEVA pharmaceuticals scholarship (SK; PR783187).</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Software, Formal analysis, Visualization, Writing - original draft, Writing - review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis, Investigation, Writing - review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Data curation, Project administration, Writing - review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources</p></fn><fn fn-type="con" id="con6"><p>Resources</p></fn><fn fn-type="con" id="con7"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con8"><p>Formal analysis</p></fn><fn fn-type="con" id="con9"><p>Resources</p></fn><fn fn-type="con" id="con10"><p>Resources</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Resources, Data curation, Software, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing - original draft, Project administration, Writing - review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: All Experiments were approved by the Technion Institutional Animal Care and Use Committee (permit SB, no. IL-129-09-17).</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="scode1"><label>Source code 1.</label><caption><title>Systematic replacement of all residues of the LBD by all other amino acids.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-67555-code1-v2.zip"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Validated <italic>GRIN2B</italic> variants.</title><p>Description of output, functional validation and clinical pictures for reported <italic>GRIN2B</italic> variants. ATD- amino terminal domain; LBD- ligand binding domain; CTD- carboxy terminal domain; GoF and LoF- gain and loss-of-function, respectively.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-67555-supp1-v2.docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Published and unpublished <italic>GRIN2B</italic> variants.</title><p>&gt;500 published and unpublished variants found in <italic>GRIN2B</italic> patients. Search was performed in PubMed, ClinVar and CFERV databases.</p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-67555-supp2-v2.xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>ΔΔG estimation for 5282 substitutions in LBD reveals that glycine and serine are vulnerable residues in GluN2B.</title><p>a. ΔΔG values for 5282 substitutions in the S1/S2 segments (positions 403–539, 651–802) of GluN2B. Stabilizing mutations are represented by ΔΔG&gt;0 (blue box), whereas destabilizing (ΔΔG&lt; −0.5) are marked by red box. b. Most mutations within LBD are destabilizing (~60%; red), with the smallest fraction represented by stabilizing mutations (~16%; blue). Mutations with minor or no effect are noted by white color. c. List of 18 validated LBD mutations in GluN2B and their estimated ΔΔG. Point mutations resulting in stop codons are noted as stop. d. Overlay between mutations shown in c. (dashed arrows) and mean ΔΔG; calculated for each residue by averaging all its possible substitutions for that residue. Red- destabilizing, blue-stabilizing; gray-neutral effect. e. Surface view of the LBD shows that stabilizing residues (blue, taken from d) are located on the outer surface of the LBD. f. Potential effect of all amino acids if these were substituted anywhere in the LBD. This consists of averaging the effect of each substitution across the entire LBD. Analysis highlights glycine (G) and serine (S) as the most destabilizing mutations, whereas methionine (M) as the most stabilizing.</p></caption><media mime-subtype="pdf" mimetype="application" xlink:href="elife-67555-supp3-v2.pdf"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-67555-transrepform-v2.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Raw data is deposited at Dryad (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5061/dryad.1jwstqjv3">https://doi.org/10.5061/dryad.1jwstqjv3</ext-link>).</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Kellner</surname><given-names>S</given-names></name><name><surname>Abbasi</surname><given-names>A</given-names></name><name><surname>Heinrich</surname><given-names>R</given-names></name><name><surname>Garin-Shkolnik</surname><given-names>T</given-names></name><name><surname>Hershkovitz</surname><given-names>T</given-names></name><name><surname>Johannesen</surname><given-names>KM</given-names></name><name><surname>Møller</surname><given-names>RS</given-names></name><name><surname>Berlin</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy</data-title><source>Dryad Digital Repository</source><pub-id assigning-authority="Dryad" pub-id-type="doi">10.5061/dryad.1jwstqjv3</pub-id></element-citation></p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amador</surname> <given-names>A</given-names></name><name><surname>Bostick</surname> <given-names>CD</given-names></name><name><surname>Olson</surname> <given-names>H</given-names></name><name><surname>Peters</surname> <given-names>J</given-names></name><name><surname>Camp</surname> <given-names>CR</given-names></name><name><surname>Krizay</surname> <given-names>D</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Han</surname> <given-names>W</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Kanber</surname> <given-names>A</given-names></name><name><surname>Kim</surname> <given-names>S</given-names></name><name><surname>Teoh</surname> <given-names>J</given-names></name><name><surname>Sah</surname> <given-names>M</given-names></name><name><surname>Petri</surname> <given-names>S</given-names></name><name><surname>Paek</surname> <given-names>H</given-names></name><name><surname>Kim</surname> <given-names>A</given-names></name><name><surname>Lutz</surname> <given-names>CM</given-names></name><name><surname>Yang</surname> <given-names>M</given-names></name><name><surname>Myers</surname> <given-names>SJ</given-names></name><name><surname>Bhattacharya</surname> <given-names>S</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Goldstein</surname> <given-names>DB</given-names></name><name><surname>Poduri</surname> <given-names>A</given-names></name><name><surname>Boland</surname> <given-names>MJ</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Frankel</surname> <given-names>WN</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice</article-title><source>Brain</source><volume>143</volume><fpage>2039</fpage><lpage>2057</lpage><pub-id pub-id-type="doi">10.1093/brain/awaa147</pub-id><pub-id pub-id-type="pmid">32577763</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname> <given-names>JB</given-names></name><name><surname>Leng</surname> <given-names>X</given-names></name><name><surname>Gochman</surname> <given-names>A</given-names></name><name><surname>Zhou</surname> <given-names>HX</given-names></name><name><surname>Wollmuth</surname> <given-names>LP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A conserved glycine harboring disease-associated mutations permits NMDA receptor slow deactivation and high Ca<sup>2+</sup> permeability</article-title><source>Nature communications</source><volume>9</volume><elocation-id>3748</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-06145-w</pub-id><pub-id pub-id-type="pmid">30217972</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araneda</surname> <given-names>RC</given-names></name><name><surname>Lan</surname> <given-names>JY</given-names></name><name><surname>Zheng</surname> <given-names>X</given-names></name><name><surname>Zukin</surname> <given-names>RS</given-names></name><name><surname>Bennett</surname> <given-names>MV</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Spermine and arcaine block and permeate N-methyl-D-aspartate receptor channels</article-title><source>Biophysical journal</source><volume>76</volume><fpage>2899</fpage><lpage>2911</lpage><pub-id pub-id-type="doi">10.1016/S0006-3495(99)77445-X</pub-id><pub-id pub-id-type="pmid">10354418</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banke</surname> <given-names>TG</given-names></name><name><surname>Dravid</surname> <given-names>SM</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Protons trap NR1/NR2B NMDA receptors in a nonconducting state</article-title><source>Journal of Neuroscience</source><volume>25</volume><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3154-04.2005</pub-id><pub-id pub-id-type="pmid">15634765</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname> <given-names>S</given-names></name><name><surname>Maussion</surname> <given-names>G</given-names></name><name><surname>Jefri</surname> <given-names>M</given-names></name><name><surname>Peng</surname> <given-names>H</given-names></name><name><surname>Theroux</surname> <given-names>JF</given-names></name><name><surname>Silveira</surname> <given-names>H</given-names></name><name><surname>Soubannier</surname> <given-names>V</given-names></name><name><surname>Wu</surname> <given-names>H</given-names></name><name><surname>Hu</surname> <given-names>P</given-names></name><name><surname>Galat</surname> <given-names>E</given-names></name><name><surname>Torres-Platas</surname> <given-names>SG</given-names></name><name><surname>Boudreau-Pinsonneault</surname> <given-names>C</given-names></name><name><surname>O'Leary</surname> <given-names>LA</given-names></name><name><surname>Galat</surname> <given-names>V</given-names></name><name><surname>Turecki</surname> <given-names>G</given-names></name><name><surname>Durcan</surname> <given-names>TM</given-names></name><name><surname>Fon</surname> <given-names>EA</given-names></name><name><surname>Mechawar</surname> <given-names>N</given-names></name><name><surname>Ernst</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Disruption of GRIN2B impairs differentiation in human neurons</article-title><source>Stem Cell Reports</source><volume>11</volume><fpage>183</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.stemcr.2018.05.018</pub-id><pub-id pub-id-type="pmid">29937144</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-Chaim</surname> <given-names>Y</given-names></name><name><surname>Tour</surname> <given-names>O</given-names></name><name><surname>Dascal</surname> <given-names>N</given-names></name><name><surname>Parnas</surname> <given-names>I</given-names></name><name><surname>Parnas</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The M2 muscarinic G-protein-coupled receptor is voltage-sensitive</article-title><source>The Journal of biological chemistry</source><volume>278</volume><fpage>22482</fpage><lpage>22491</lpage><pub-id pub-id-type="doi">10.1074/jbc.M301146200</pub-id><pub-id pub-id-type="pmid">12684524</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname> <given-names>S</given-names></name><name><surname>Keren-Raifman</surname> <given-names>T</given-names></name><name><surname>Castel</surname> <given-names>R</given-names></name><name><surname>Rubinstein</surname> <given-names>M</given-names></name><name><surname>Dessauer</surname> <given-names>CW</given-names></name><name><surname>Ivanina</surname> <given-names>T</given-names></name><name><surname>Dascal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>G <sub>alpha(i</sub>) and G betagamma jointly regulate the conformations of a G betagamma effector, the neuronal G protein-activated K+ channel (GIRK)</article-title><source>The Journal of biological chemistry</source><volume>285</volume><fpage>6179</fpage><lpage>6185</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.085944</pub-id><pub-id pub-id-type="pmid">20018875</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname> <given-names>S</given-names></name><name><surname>Tsemakhovich</surname> <given-names>VA</given-names></name><name><surname>Castel</surname> <given-names>R</given-names></name><name><surname>Ivanina</surname> <given-names>T</given-names></name><name><surname>Dessauer</surname> <given-names>CW</given-names></name><name><surname>Keren-Raifman</surname> <given-names>T</given-names></name><name><surname>Dascal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Two distinct aspects of coupling between Gα(i) protein and G protein-activated K+ channel (GIRK) revealed by fluorescently labeled Gα(i3) protein subunits</article-title><source>The Journal of biological chemistry</source><volume>286</volume><fpage>33223</fpage><lpage>33235</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.271056</pub-id><pub-id pub-id-type="pmid">21795707</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname> <given-names>S</given-names></name><name><surname>Szobota</surname> <given-names>S</given-names></name><name><surname>Reiner</surname> <given-names>A</given-names></name><name><surname>Carroll</surname> <given-names>EC</given-names></name><name><surname>Kienzler</surname> <given-names>MA</given-names></name><name><surname>Guyon</surname> <given-names>A</given-names></name><name><surname>Xiao</surname> <given-names>T</given-names></name><name><surname>Trauner</surname> <given-names>D</given-names></name><name><surname>Isacoff</surname> <given-names>EY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>A family of photoswitchable NMDA receptors</article-title><source>eLife</source><volume>5</volume><elocation-id>e12040</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.12040</pub-id><pub-id pub-id-type="pmid">26929991</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname> <given-names>S</given-names></name><name><surname>Artzy</surname> <given-names>E</given-names></name><name><surname>Handklo-Jamal</surname> <given-names>R</given-names></name><name><surname>Kahanovitch</surname> <given-names>U</given-names></name><name><surname>Parnas</surname> <given-names>H</given-names></name><name><surname>Dascal</surname> <given-names>N</given-names></name><name><surname>Yakubovich</surname> <given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A collision coupling model governs the activation of neuronal GIRK1/2 channels by Muscarinic-2 receptors</article-title><source>Frontiers in Pharmacology</source><volume>11</volume><elocation-id>2020.01216</elocation-id><pub-id pub-id-type="doi">10.3389/fphar.2020.01216</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Berlin</surname> <given-names>S</given-names></name><name><surname>Isacoff</surname> <given-names>EY</given-names></name></person-group><year iso-8601-date="2018">2018</year><chapter-title>Optical Control of Glutamate Receptors of the NMDA-Kind in Mammalian Neurons, with the Use of Photoswitchable Ligands</chapter-title><person-group person-group-type="editor"><name><surname>Parrot</surname> <given-names>S</given-names></name><name><surname>Denoroy</surname> <given-names>L</given-names></name></person-group><source>Biochemical Approaches for Glutamatergic Neurotransmission</source><publisher-loc>New York</publisher-loc><publisher-name>Springer</publisher-name><fpage> 293</fpage><lpage> 325</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7228-9</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bosch</surname> <given-names>DG</given-names></name><name><surname>Boonstra</surname> <given-names>FN</given-names></name><name><surname>de Leeuw</surname> <given-names>N</given-names></name><name><surname>Pfundt</surname> <given-names>R</given-names></name><name><surname>Nillesen</surname> <given-names>WM</given-names></name><name><surname>de Ligt</surname> <given-names>J</given-names></name><name><surname>Gilissen</surname> <given-names>C</given-names></name><name><surname>Jhangiani</surname> <given-names>S</given-names></name><name><surname>Lupski</surname> <given-names>JR</given-names></name><name><surname>Cremers</surname> <given-names>FP</given-names></name><name><surname>de Vries</surname> <given-names>BB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Novel genetic causes for cerebral visual impairment</article-title><source>European journal of human genetics : EJHG</source><volume>24</volume><fpage>660</fpage><lpage>665</lpage><pub-id pub-id-type="doi">10.1038/ejhg.2015.186</pub-id><pub-id pub-id-type="pmid">26350515</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burnell</surname> <given-names>ES</given-names></name><name><surname>Irvine</surname> <given-names>M</given-names></name><name><surname>Fang</surname> <given-names>G</given-names></name><name><surname>Sapkota</surname> <given-names>K</given-names></name><name><surname>Jane</surname> <given-names>DE</given-names></name><name><surname>Monaghan</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Positive and negative allosteric modulators of N-Methyl-d-aspartate (NMDA) Receptors: structure-activity relationships and mechanisms of action</article-title><source>Journal of Medicinal Chemistry</source><volume>62</volume><fpage>3</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01640</pub-id><pub-id pub-id-type="pmid">29446949</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname> <given-names>DW</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Ionic dependence of glutamate neurotoxicity</article-title><source>The Journal of Neuroscience</source><volume>7</volume><fpage>369</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.07-02-00369.1987</pub-id><pub-id pub-id-type="pmid">2880938</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname> <given-names>BM</given-names></name><name><surname>Irvine</surname> <given-names>MW</given-names></name><name><surname>Fang</surname> <given-names>G</given-names></name><name><surname>Eaves</surname> <given-names>RJ</given-names></name><name><surname>Mayo-Martin</surname> <given-names>MB</given-names></name><name><surname>Skifter</surname> <given-names>DA</given-names></name><name><surname>Jane</surname> <given-names>DE</given-names></name><name><surname>Monaghan</surname> <given-names>DT</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A novel family of negative and positive allosteric modulators of NMDA receptors</article-title><source>The Journal of pharmacology and experimental therapeutics</source><volume>335</volume><fpage>614</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1124/jpet.110.174144</pub-id><pub-id pub-id-type="pmid">20858708</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="report"><person-group person-group-type="author"><name><surname>de Déu</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>Tolerability and Efficacy of L-Serine in Patients with GRIN-Related Encephalopathy</source><publisher-name>ClinicalTrials.Gov</publisher-name><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04646447?term=L-serine&amp;draw=2&amp;rank=1">https://clinicaltrials.gov/ct2/show/NCT04646447?term=L-serine&amp;draw=2&amp;rank=1</ext-link></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeCoursey</surname> <given-names>TE</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Voltage and pH sensing by the voltage-gated proton channel, HV1</article-title><source>Journal of the Royal Society, Interface</source><volume>15</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.1098/rsif.2018.0108</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Devinsky</surname> <given-names>O</given-names></name><name><surname>Vezzani</surname> <given-names>A</given-names></name><name><surname>O'Brien</surname> <given-names>TJ</given-names></name><name><surname>Jette</surname> <given-names>N</given-names></name><name><surname>Scheffer</surname> <given-names>IE</given-names></name><name><surname>de Curtis</surname> <given-names>M</given-names></name><name><surname>Perucca</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Epilepsy</article-title><source>Nature Reviews Disease Primers</source><volume>4</volume><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/nrdp.2018.24</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diler</surname> <given-names>AS</given-names></name><name><surname>Ziylan</surname> <given-names>YZ</given-names></name><name><surname>Uzum</surname> <given-names>G</given-names></name><name><surname>Lefauconnier</surname> <given-names>JM</given-names></name><name><surname>Seylaz</surname> <given-names>J</given-names></name><name><surname>Pinard</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Passage of spermidine across the blood-brain barrier in short recirculation periods following global cerebral ischemia: effects of mild hyperthermia</article-title><source>Neuroscience research</source><volume>43</volume><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1016/s0168-0102(02)00059-7</pub-id><pub-id pub-id-type="pmid">12135777</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donevan</surname> <given-names>SD</given-names></name><name><surname>Jones</surname> <given-names>SM</given-names></name><name><surname>Rogawski</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Arcaine blocks N-methyl-D-aspartate receptor responses by an open channel mechanism: whole-cell and single-channel recording studies in cultured hippocampal neurons</article-title><source>Molecular Pharmacology</source><volume>41</volume><fpage>727</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">1373801</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endele</surname> <given-names>S</given-names></name><name><surname>Rosenberger</surname> <given-names>G</given-names></name><name><surname>Geider</surname> <given-names>K</given-names></name><name><surname>Popp</surname> <given-names>B</given-names></name><name><surname>Tamer</surname> <given-names>C</given-names></name><name><surname>Stefanova</surname> <given-names>I</given-names></name><name><surname>Milh</surname> <given-names>M</given-names></name><name><surname>Kortüm</surname> <given-names>F</given-names></name><name><surname>Fritsch</surname> <given-names>A</given-names></name><name><surname>Pientka</surname> <given-names>FK</given-names></name><name><surname>Hellenbroich</surname> <given-names>Y</given-names></name><name><surname>Kalscheuer</surname> <given-names>VM</given-names></name><name><surname>Kohlhase</surname> <given-names>J</given-names></name><name><surname>Moog</surname> <given-names>U</given-names></name><name><surname>Rappold</surname> <given-names>G</given-names></name><name><surname>Rauch</surname> <given-names>A</given-names></name><name><surname>Ropers</surname> <given-names>HH</given-names></name><name><surname>von Spiczak</surname> <given-names>S</given-names></name><name><surname>Tönnies</surname> <given-names>H</given-names></name><name><surname>Villeneuve</surname> <given-names>N</given-names></name><name><surname>Villard</surname> <given-names>L</given-names></name><name><surname>Zabel</surname> <given-names>B</given-names></name><name><surname>Zenker</surname> <given-names>M</given-names></name><name><surname>Laube</surname> <given-names>B</given-names></name><name><surname>Reis</surname> <given-names>A</given-names></name><name><surname>Wieczorek</surname> <given-names>D</given-names></name><name><surname>Van Maldergem</surname> <given-names>L</given-names></name><name><surname>Kutsche</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes</article-title><source>Nature genetics</source><volume>42</volume><fpage>1021</fpage><lpage>1026</lpage><pub-id pub-id-type="doi">10.1038/ng.677</pub-id><pub-id pub-id-type="pmid">20890276</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedele</surname> <given-names>L</given-names></name><name><surname>Newcombe</surname> <given-names>J</given-names></name><name><surname>Topf</surname> <given-names>M</given-names></name><name><surname>Gibb</surname> <given-names>A</given-names></name><name><surname>Harvey</surname> <given-names>RJ</given-names></name><name><surname>Smart</surname> <given-names>TG</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties</article-title><source>Nature communications</source><volume>9</volume><elocation-id>957</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-018-02927-4</pub-id><pub-id pub-id-type="pmid">29511171</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Feige</surname> <given-names>MJ</given-names></name><name><surname>Braakman</surname> <given-names>I</given-names></name><name><surname>Hendershot</surname> <given-names>LM</given-names></name></person-group><year iso-8601-date="2018">2018</year><source>Disulfide Bonds in Protein Folding and Stability</source><publisher-name>Royal Society of Chemistry</publisher-name><pub-id pub-id-type="doi">10.1039/9781788013253-00001</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>García-Recio</surname> <given-names>A</given-names></name><name><surname>Santos-Gómez</surname> <given-names>A</given-names></name><name><surname>Soto</surname> <given-names>D</given-names></name><name><surname>Julia-Palacios</surname> <given-names>N</given-names></name><name><surname>García-Cazorla</surname> <given-names>À</given-names></name><name><surname>Altafaj</surname> <given-names>X</given-names></name><name><surname>Olivella</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>GRIN database: A unified and manually curated repertoire of GRIN variants</article-title><source>Human mutation</source><volume>42</volume><fpage>8</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1002/humu.24141</pub-id><pub-id pub-id-type="pmid">33252190</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname> <given-names>GM</given-names></name><name><surname>Dalmolin</surname> <given-names>GD</given-names></name><name><surname>Bär</surname> <given-names>J</given-names></name><name><surname>Karpova</surname> <given-names>A</given-names></name><name><surname>Mello</surname> <given-names>CF</given-names></name><name><surname>Kreutz</surname> <given-names>MR</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Inhibition of the polyamine system counteracts β-amyloid peptide-induced memory impairment in mice: involvement of extrasynaptic NMDA receptors</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e99184</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0099184</pub-id><pub-id pub-id-type="pmid">24921942</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guerra</surname> <given-names>GP</given-names></name><name><surname>Rubin</surname> <given-names>MA</given-names></name><name><surname>Mello</surname> <given-names>CF</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Modulation of learning and memory by natural polyamines</article-title><source>Pharmacological research</source><volume>112</volume><fpage>99</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2016.03.023</pub-id><pub-id pub-id-type="pmid">27015893</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackos</surname> <given-names>DH</given-names></name><name><surname>Lupardus</surname> <given-names>PJ</given-names></name><name><surname>Grand</surname> <given-names>T</given-names></name><name><surname>Chen</surname> <given-names>Y</given-names></name><name><surname>Wang</surname> <given-names>TM</given-names></name><name><surname>Reynen</surname> <given-names>P</given-names></name><name><surname>Gustafson</surname> <given-names>A</given-names></name><name><surname>Wallweber</surname> <given-names>HJ</given-names></name><name><surname>Volgraf</surname> <given-names>M</given-names></name><name><surname>Sellers</surname> <given-names>BD</given-names></name><name><surname>Schwarz</surname> <given-names>JB</given-names></name><name><surname>Paoletti</surname> <given-names>P</given-names></name><name><surname>Sheng</surname> <given-names>M</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name><name><surname>Hanson</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Positive allosteric modulators of GluN2A-Containing NMDARs with distinct modes of action and impacts on circuit function</article-title><source>Neuron</source><volume>89</volume><fpage>983</fpage><lpage>999</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2016.01.016</pub-id><pub-id pub-id-type="pmid">26875626</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname> <given-names>KB</given-names></name><name><surname>Yi</surname> <given-names>F</given-names></name><name><surname>Perszyk</surname> <given-names>RE</given-names></name><name><surname>Furukawa</surname> <given-names>H</given-names></name><name><surname>Wollmuth</surname> <given-names>LP</given-names></name><name><surname>Gibb</surname> <given-names>AJ</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Structure, function, and allosteric modulation of NMDA receptors</article-title><source>The Journal of general physiology</source><volume>150</volume><fpage>1081</fpage><lpage>1105</lpage><pub-id pub-id-type="doi">10.1085/jgp.201812032</pub-id><pub-id pub-id-type="pmid">30037851</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardingham</surname> <given-names>GE</given-names></name><name><surname>Fukunaga</surname> <given-names>Y</given-names></name><name><surname>Bading</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways</article-title><source>Nature neuroscience</source><volume>5</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1038/nn835</pub-id><pub-id pub-id-type="pmid">11953750</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname> <given-names>A</given-names></name><name><surname>Oka</surname> <given-names>T</given-names></name><name><surname>Nishikawa</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Extracellular concentration of endogenous free D-serine in the rat brain as revealed by in vivo microdialysis</article-title><source>Neuroscience</source><volume>66</volume><fpage>635</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(94)00597-x</pub-id><pub-id pub-id-type="pmid">7644027</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horak</surname> <given-names>M</given-names></name><name><surname>Petralia</surname> <given-names>RS</given-names></name><name><surname>Kaniakova</surname> <given-names>M</given-names></name><name><surname>Sans</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>ER to synapse trafficking of NMDA receptors</article-title><source>Frontiers in Cellular Neuroscience</source><volume>8</volume><elocation-id>394</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2014.00394</pub-id><pub-id pub-id-type="pmid">25505872</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname> <given-names>T</given-names></name><name><surname>Sahara</surname> <given-names>Y</given-names></name><name><surname>Takahashi</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>A single packet of transmitter does not saturate postsynaptic glutamate receptors</article-title><source>Neuron</source><volume>34</volume><fpage>613</fpage><lpage>621</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(02)00692-x</pub-id><pub-id pub-id-type="pmid">12062044</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jang</surname> <given-names>MK</given-names></name><name><surname>Mierke</surname> <given-names>DF</given-names></name><name><surname>Russek</surname> <given-names>SJ</given-names></name><name><surname>Farb</surname> <given-names>DH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity</article-title><source>PNAS</source><volume>101</volume><fpage>8198</fpage><lpage>8203</lpage><pub-id pub-id-type="doi">10.1073/pnas.0401838101</pub-id><pub-id pub-id-type="pmid">15150412</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karakas</surname> <given-names>E</given-names></name><name><surname>Furukawa</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Crystal structure of a heterotetrameric NMDA receptor ion channel</article-title><source>Science</source><volume>344</volume><fpage>992</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1126/science.1251915</pub-id><pub-id pub-id-type="pmid">24876489</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katz</surname> <given-names>M</given-names></name><name><surname>Subramaniam</surname> <given-names>S</given-names></name><name><surname>Chomsky-Hecht</surname> <given-names>O</given-names></name><name><surname>Tsemakhovich</surname> <given-names>V</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name><name><surname>Klussmann</surname> <given-names>E</given-names></name><name><surname>Hirsch</surname> <given-names>JA</given-names></name><name><surname>Weiss</surname> <given-names>S</given-names></name><name><surname>Dascal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Reconstitution of β-adrenergic regulation of Ca<sub>V</sub>1.2: rad-dependent and Rad-independent protein kinase A mechanisms</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2100021118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2100021118</pub-id><pub-id pub-id-type="pmid">34001616</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kenny</surname> <given-names>AV</given-names></name><name><surname>Cousins</surname> <given-names>SL</given-names></name><name><surname>Pinho</surname> <given-names>L</given-names></name><name><surname>Stephenson</surname> <given-names>FA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The integrity of the glycine co-agonist binding site of N-methyl-D-aspartate receptors is a functional quality control checkpoint for cell surface delivery</article-title><source>The Journal of biological chemistry</source><volume>284</volume><fpage>324</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1074/jbc.M804023200</pub-id><pub-id pub-id-type="pmid">18990687</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kussius</surname> <given-names>CL</given-names></name><name><surname>Popescu</surname> <given-names>GK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Kinetic basis of partial agonism at NMDA receptors</article-title><source>Nature neuroscience</source><volume>12</volume><fpage>1114</fpage><lpage>1120</lpage><pub-id pub-id-type="doi">10.1038/nn.2361</pub-id><pub-id pub-id-type="pmid">19648915</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lau</surname> <given-names>CG</given-names></name><name><surname>Zukin</surname> <given-names>RS</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders</article-title><source>Nature reviews. Neuroscience</source><volume>8</volume><fpage>413</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nrn2153</pub-id><pub-id pub-id-type="pmid">17514195</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazarewicz</surname> <given-names>JW</given-names></name><name><surname>Salińska</surname> <given-names>E</given-names></name><name><surname>Puka</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Glycine enhances extracellular Ca2+ response to NMDA application investigated with microdialysis of rabbit Hippocampus in vivo</article-title><source>Acta Neurobiologiae Experimentalis</source><volume>52</volume><fpage>83</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">1414510</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemke</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Delineating the GRIN1 phenotypic spectrum</article-title><source>Neurology</source><volume>86</volume><fpage>2171</fpage><lpage>2178</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002740</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname> <given-names>J</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Mizu</surname> <given-names>RK</given-names></name><name><surname>Kusumoto</surname> <given-names>H</given-names></name><name><surname>XiangWei</surname> <given-names>W</given-names></name><name><surname>Xu</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Amin</surname> <given-names>JB</given-names></name><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Kannan</surname> <given-names>V</given-names></name><name><surname>Keller</surname> <given-names>SR</given-names></name><name><surname>Wilcox</surname> <given-names>WR</given-names></name><name><surname>Lemke</surname> <given-names>JR</given-names></name><name><surname>Myers</surname> <given-names>SJ</given-names></name><name><surname>Swanger</surname> <given-names>SA</given-names></name><name><surname>Wollmuth</surname> <given-names>LP</given-names></name><name><surname>Petrovski</surname> <given-names>S</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>De novo <italic>GRIN</italic> variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases</article-title><source>Human mutation</source><volume>40</volume><fpage>2393</fpage><lpage>2413</lpage><pub-id pub-id-type="doi">10.1002/humu.23895</pub-id><pub-id pub-id-type="pmid">31429998</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname> <given-names>SA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond</article-title><source>Nature reviews. Drug discovery</source><volume>5</volume><fpage>160</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1038/nrd1958</pub-id><pub-id pub-id-type="pmid">16424917</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lipton</surname> <given-names>SA</given-names></name><name><surname>Rosenberg</surname> <given-names>PA</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Excitatory amino acids as a final common pathway for neurologic disorders</article-title><source>The New England journal of medicine</source><volume>330</volume><fpage>613</fpage><lpage>622</lpage><pub-id pub-id-type="doi">10.1056/NEJM199403033300907</pub-id><pub-id pub-id-type="pmid">7905600</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lisman</surname> <given-names>JE</given-names></name><name><surname>Raghavachari</surname> <given-names>S</given-names></name><name><surname>Tsien</surname> <given-names>RW</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>The sequence of events that underlie quantal transmission at central glutamatergic synapses</article-title><source>Nature reviews. Neuroscience</source><volume>8</volume><fpage>597</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1038/nrn2191</pub-id><pub-id pub-id-type="pmid">17637801</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname> <given-names>S</given-names></name><name><surname>Zhou</surname> <given-names>L</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Vieira</surname> <given-names>M</given-names></name><name><surname>Sanz-Clemente</surname> <given-names>A</given-names></name><name><surname>Badger</surname> <given-names>JD</given-names></name><name><surname>Lu</surname> <given-names>W</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Roche</surname> <given-names>KW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A rare variant identified within the GluN2B C-Terminus in a patient with autism affects NMDA receptor surface expression and spine density</article-title><source>The Journal of Neuroscience</source><volume>37</volume><fpage>4093</fpage><lpage>4102</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.0827-16.2017</pub-id><pub-id pub-id-type="pmid">28283559</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname> <given-names>CM</given-names></name><name><surname>Lyuboslavsky</surname> <given-names>P</given-names></name><name><surname>French</surname> <given-names>A</given-names></name><name><surname>Le</surname> <given-names>P</given-names></name><name><surname>Wyatte</surname> <given-names>K</given-names></name><name><surname>Thiel</surname> <given-names>WH</given-names></name><name><surname>Marchan</surname> <given-names>EM</given-names></name><name><surname>Igarashi</surname> <given-names>K</given-names></name><name><surname>Kashiwagi</surname> <given-names>K</given-names></name><name><surname>Gernert</surname> <given-names>K</given-names></name><name><surname>Williams</surname> <given-names>K</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Zheng</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Molecular determinants of proton-sensitive <italic>N</italic>-methyl-D-aspartate receptor gating</article-title><source>Molecular pharmacology</source><volume>63</volume><fpage>1212</fpage><lpage>1222</lpage><pub-id pub-id-type="doi">10.1124/mol.63.6.1212</pub-id><pub-id pub-id-type="pmid">12761330</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masuko</surname> <given-names>T</given-names></name><name><surname>Kuno</surname> <given-names>T</given-names></name><name><surname>Kashiwagi</surname> <given-names>K</given-names></name><name><surname>Kusama</surname> <given-names>T</given-names></name><name><surname>Williams</surname> <given-names>K</given-names></name><name><surname>Igarashi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Stimulatory and inhibitory properties of aminoglycoside antibiotics at N-methyl-D-aspartate receptors</article-title><source>The Journal of pharmacology and experimental therapeutics</source><volume>290</volume><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="pmid">10454474</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mony</surname> <given-names>L</given-names></name><name><surname>Kew</surname> <given-names>JN</given-names></name><name><surname>Gunthorpe</surname> <given-names>MJ</given-names></name><name><surname>Paoletti</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential</article-title><source>British journal of pharmacology</source><volume>157</volume><fpage>1301</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2009.00304.x</pub-id><pub-id pub-id-type="pmid">19594762</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mony</surname> <given-names>L</given-names></name><name><surname>Zhu</surname> <given-names>S</given-names></name><name><surname>Carvalho</surname> <given-names>S</given-names></name><name><surname>Paoletti</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Molecular basis of positive allosteric modulation of GluN2B NMDA receptors by polyamines</article-title><source>The EMBO journal</source><volume>30</volume><fpage>3134</fpage><lpage>3146</lpage><pub-id pub-id-type="doi">10.1038/emboj.2011.203</pub-id><pub-id pub-id-type="pmid">21685875</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myers</surname> <given-names>SJ</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Kang</surname> <given-names>J-Q</given-names></name><name><surname>Tan</surname> <given-names>FCK</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Low</surname> <given-names>C-M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Distinct roles of GRIN2A and GRIN2B variants in neurological conditions</article-title><source>F1000Research</source><volume>8</volume><elocation-id>1940</elocation-id><pub-id pub-id-type="doi">10.12688/f1000research.18949.1</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neame</surname> <given-names>S</given-names></name><name><surname>Safory</surname> <given-names>H</given-names></name><name><surname>Radzishevsky</surname> <given-names>I</given-names></name><name><surname>Touitou</surname> <given-names>A</given-names></name><name><surname>Marchesani</surname> <given-names>F</given-names></name><name><surname>Marchetti</surname> <given-names>M</given-names></name><name><surname>Kellner</surname> <given-names>S</given-names></name><name><surname>Berlin</surname> <given-names>S</given-names></name><name><surname>Foltyn</surname> <given-names>VN</given-names></name><name><surname>Engelender</surname> <given-names>S</given-names></name><name><surname>Billard</surname> <given-names>JM</given-names></name><name><surname>Wolosker</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The NMDA receptor activation by d-serine and glycine is controlled by an astrocytic Phgdh-dependent serine shuttle</article-title><source>PNAS</source><volume>116</volume><fpage>20736</fpage><lpage>20742</lpage><pub-id pub-id-type="doi">10.1073/pnas.1909458116</pub-id><pub-id pub-id-type="pmid">31548413</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nimchinsky</surname> <given-names>EA</given-names></name><name><surname>Yasuda</surname> <given-names>R</given-names></name><name><surname>Oertner</surname> <given-names>TG</given-names></name><name><surname>Svoboda</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The number of glutamate receptors opened by synaptic stimulation in single hippocampal spines</article-title><source>Journal of Neuroscience</source><volume>24</volume><fpage>2054</fpage><lpage>2064</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5066-03.2004</pub-id><pub-id pub-id-type="pmid">14985448</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ogden</surname> <given-names>KK</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Swanger</surname> <given-names>SA</given-names></name><name><surname>McDaniel</surname> <given-names>MJ</given-names></name><name><surname>Fan</surname> <given-names>LZ</given-names></name><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Tankovic</surname> <given-names>A</given-names></name><name><surname>Kusumoto</surname> <given-names>H</given-names></name><name><surname>Kosobucki</surname> <given-names>GJ</given-names></name><name><surname>Schulien</surname> <given-names>AJ</given-names></name><name><surname>Su</surname> <given-names>Z</given-names></name><name><surname>Pecha</surname> <given-names>J</given-names></name><name><surname>Bhattacharya</surname> <given-names>S</given-names></name><name><surname>Petrovski</surname> <given-names>S</given-names></name><name><surname>Cohen</surname> <given-names>AE</given-names></name><name><surname>Aizenman</surname> <given-names>E</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Molecular mechanism of Disease-Associated mutations in the Pre-M1 Helix of NMDA receptors and potential rescue pharmacology</article-title><source>PLOS Genetics</source><volume>13</volume><elocation-id>e1006536</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006536</pub-id><pub-id pub-id-type="pmid">28095420</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okumura</surname> <given-names>S</given-names></name><name><surname>Teratani</surname> <given-names>T</given-names></name><name><surname>Fujimoto</surname> <given-names>Y</given-names></name><name><surname>Zhao</surname> <given-names>X</given-names></name><name><surname>Tsuruyama</surname> <given-names>T</given-names></name><name><surname>Masano</surname> <given-names>Y</given-names></name><name><surname>Kasahara</surname> <given-names>N</given-names></name><name><surname>Iida</surname> <given-names>T</given-names></name><name><surname>Yagi</surname> <given-names>S</given-names></name><name><surname>Uemura</surname> <given-names>T</given-names></name><name><surname>Kaido</surname> <given-names>T</given-names></name><name><surname>Uemoto</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Oral administration of polyamines ameliorates liver ischemia/reperfusion injury and promotes liver regeneration in rats</article-title><source>Liver Transplantation</source><volume>22</volume><fpage>1231</fpage><lpage>1244</lpage><pub-id pub-id-type="doi">10.1002/lt.24471</pub-id><pub-id pub-id-type="pmid">27102080</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paoletti</surname> <given-names>P</given-names></name><name><surname>Bellone</surname> <given-names>C</given-names></name><name><surname>Zhou</surname> <given-names>Q</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease</article-title><source>Nature Reviews Neuroscience</source><volume>14</volume><fpage>383</fpage><lpage>400</lpage><pub-id pub-id-type="doi">10.1038/nrn3504</pub-id><pub-id pub-id-type="pmid">23686171</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peleg</surname> <given-names>S</given-names></name><name><surname>Varon</surname> <given-names>D</given-names></name><name><surname>Ivanina</surname> <given-names>T</given-names></name><name><surname>Dessauer</surname> <given-names>CW</given-names></name><name><surname>Dascal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>G(alpha)(i) controls the gating of the G protein-activated K(+) channel, GIRK</article-title><source>Neuron</source><volume>33</volume><fpage>87</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(01)00567-0</pub-id><pub-id pub-id-type="pmid">11779482</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perszyk</surname> <given-names>R</given-names></name><name><surname>Katzman</surname> <given-names>BM</given-names></name><name><surname>Kusumoto</surname> <given-names>H</given-names></name><name><surname>Kell</surname> <given-names>SA</given-names></name><name><surname>Epplin</surname> <given-names>MP</given-names></name><name><surname>Tahirovic</surname> <given-names>YA</given-names></name><name><surname>Moore</surname> <given-names>RL</given-names></name><name><surname>Menaldino</surname> <given-names>D</given-names></name><name><surname>Burger</surname> <given-names>P</given-names></name><name><surname>Liotta</surname> <given-names>DC</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups</article-title><source>eLife</source><volume>7</volume><elocation-id>e34711</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.34711</pub-id><pub-id pub-id-type="pmid">29792594</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pierson</surname> <given-names>TM</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Marsh</surname> <given-names>ED</given-names></name><name><surname>Fuentes-Fajardo</surname> <given-names>K</given-names></name><name><surname>Adams</surname> <given-names>DR</given-names></name><name><surname>Markello</surname> <given-names>T</given-names></name><name><surname>Golas</surname> <given-names>G</given-names></name><name><surname>Simeonov</surname> <given-names>DR</given-names></name><name><surname>Holloman</surname> <given-names>C</given-names></name><name><surname>Tankovic</surname> <given-names>A</given-names></name><name><surname>Karamchandani</surname> <given-names>MM</given-names></name><name><surname>Schreiber</surname> <given-names>JM</given-names></name><name><surname>Mullikin</surname> <given-names>JC</given-names></name><name><surname>Tifft</surname> <given-names>CJ</given-names></name><name><surname>Toro</surname> <given-names>C</given-names></name><name><surname>Boerkoel</surname> <given-names>CF</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Gahl</surname> <given-names>WA</given-names></name><collab>PhD for the NISC Comparative Sequencing Program</collab></person-group><year iso-8601-date="2014">2014</year><article-title><italic>GRIN2A</italic> mutation and early-onset epileptic encephalopathy: personalized therapy with memantine</article-title><source>Annals of clinical and translational neurology</source><volume>1</volume><fpage>190</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1002/acn3.39</pub-id><pub-id pub-id-type="pmid">24839611</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pires</surname> <given-names>DE</given-names></name><name><surname>Ascher</surname> <given-names>DB</given-names></name><name><surname>Blundell</surname> <given-names>TL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>mCSM: predicting the effects of mutations in proteins using graph-based signatures</article-title><source>Bioinformatics</source><volume>30</volume><fpage>335</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btt691</pub-id><pub-id pub-id-type="pmid">24281696</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platzer</surname> <given-names>K</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Schütz</surname> <given-names>H</given-names></name><name><surname>Winschel</surname> <given-names>A</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Kusumoto</surname> <given-names>H</given-names></name><name><surname>Heyne</surname> <given-names>HO</given-names></name><name><surname>Helbig</surname> <given-names>KL</given-names></name><name><surname>Tang</surname> <given-names>S</given-names></name><name><surname>Willing</surname> <given-names>MC</given-names></name><name><surname>Tinkle</surname> <given-names>BT</given-names></name><name><surname>Adams</surname> <given-names>DJ</given-names></name><name><surname>Depienne</surname> <given-names>C</given-names></name><name><surname>Keren</surname> <given-names>B</given-names></name><name><surname>Mignot</surname> <given-names>C</given-names></name><name><surname>Frengen</surname> <given-names>E</given-names></name><name><surname>Strømme</surname> <given-names>P</given-names></name><name><surname>Biskup</surname> <given-names>S</given-names></name><name><surname>Döcker</surname> <given-names>D</given-names></name><name><surname>Strom</surname> <given-names>TM</given-names></name><name><surname>Mefford</surname> <given-names>HC</given-names></name><name><surname>Myers</surname> <given-names>CT</given-names></name><name><surname>Muir</surname> <given-names>AM</given-names></name><name><surname>LaCroix</surname> <given-names>A</given-names></name><name><surname>Sadleir</surname> <given-names>L</given-names></name><name><surname>Scheffer</surname> <given-names>IE</given-names></name><name><surname>Brilstra</surname> <given-names>E</given-names></name><name><surname>van Haelst</surname> <given-names>MM</given-names></name><name><surname>van der Smagt</surname> <given-names>JJ</given-names></name><name><surname>Bok</surname> <given-names>LA</given-names></name><name><surname>Møller</surname> <given-names>RS</given-names></name><name><surname>Jensen</surname> <given-names>UB</given-names></name><name><surname>Millichap</surname> <given-names>JJ</given-names></name><name><surname>Berg</surname> <given-names>AT</given-names></name><name><surname>Goldberg</surname> <given-names>EM</given-names></name><name><surname>De Bie</surname> <given-names>I</given-names></name><name><surname>Fox</surname> <given-names>S</given-names></name><name><surname>Major</surname> <given-names>P</given-names></name><name><surname>Jones</surname> <given-names>JR</given-names></name><name><surname>Zackai</surname> <given-names>EH</given-names></name><name><surname>Abou Jamra</surname> <given-names>R</given-names></name><name><surname>Rolfs</surname> <given-names>A</given-names></name><name><surname>Leventer</surname> <given-names>RJ</given-names></name><name><surname>Lawson</surname> <given-names>JA</given-names></name><name><surname>Roscioli</surname> <given-names>T</given-names></name><name><surname>Jansen</surname> <given-names>FE</given-names></name><name><surname>Ranza</surname> <given-names>E</given-names></name><name><surname>Korff</surname> <given-names>CM</given-names></name><name><surname>Lehesjoki</surname> <given-names>AE</given-names></name><name><surname>Courage</surname> <given-names>C</given-names></name><name><surname>Linnankivi</surname> <given-names>T</given-names></name><name><surname>Smith</surname> <given-names>DR</given-names></name><name><surname>Stanley</surname> <given-names>C</given-names></name><name><surname>Mintz</surname> <given-names>M</given-names></name><name><surname>McKnight</surname> <given-names>D</given-names></name><name><surname>Decker</surname> <given-names>A</given-names></name><name><surname>Tan</surname> <given-names>WH</given-names></name><name><surname>Tarnopolsky</surname> <given-names>MA</given-names></name><name><surname>Brady</surname> <given-names>LI</given-names></name><name><surname>Wolff</surname> <given-names>M</given-names></name><name><surname>Dondit</surname> <given-names>L</given-names></name><name><surname>Pedro</surname> <given-names>HF</given-names></name><name><surname>Parisotto</surname> <given-names>SE</given-names></name><name><surname>Jones</surname> <given-names>KL</given-names></name><name><surname>Patel</surname> <given-names>AD</given-names></name><name><surname>Franz</surname> <given-names>DN</given-names></name><name><surname>Vanzo</surname> <given-names>R</given-names></name><name><surname>Marco</surname> <given-names>E</given-names></name><name><surname>Ranells</surname> <given-names>JD</given-names></name><name><surname>Di Donato</surname> <given-names>N</given-names></name><name><surname>Dobyns</surname> <given-names>WB</given-names></name><name><surname>Laube</surname> <given-names>B</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Lemke</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title><italic>GRIN2B</italic> encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects</article-title><source>Journal of Medical Genetics</source><volume>54</volume><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1136/jmedgenet-2016-104509</pub-id><pub-id pub-id-type="pmid">28377535</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Platzer</surname> <given-names>K</given-names></name><name><surname>Lemke</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="1993">1993</year><chapter-title>GRIN2B-Related Neurodevelopmental Disorder</chapter-title><person-group person-group-type="editor"><name><surname>Adam</surname> <given-names>M. P</given-names></name></person-group><source>GeneReviews</source><publisher-loc>Seattle</publisher-loc><publisher-name>University of Washington Press</publisher-name><fpage>1</fpage><lpage>17</lpage></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname> <given-names>IJ</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Arcaine is a competitive antagonist of the polyamine site on the NMDA receptor</article-title><source>European journal of pharmacology</source><volume>177</volume><fpage>215</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1016/0014-2999(90)90274-a</pub-id><pub-id pub-id-type="pmid">2155812</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos-Gómez</surname> <given-names>A</given-names></name><name><surname>Miguez-Cabello</surname> <given-names>F</given-names></name><name><surname>García-Recio</surname> <given-names>A</given-names></name><name><surname>Locubiche-Serra</surname> <given-names>S</given-names></name><name><surname>García-Díaz</surname> <given-names>R</given-names></name><name><surname>Soto-Insuga</surname> <given-names>V</given-names></name><name><surname>Guerrero-López</surname> <given-names>R</given-names></name><name><surname>Juliá-Palacios</surname> <given-names>N</given-names></name><name><surname>Ciruela</surname> <given-names>F</given-names></name><name><surname>García-Cazorla</surname> <given-names>À</given-names></name><name><surname>Soto</surname> <given-names>D</given-names></name><name><surname>Olivella</surname> <given-names>M</given-names></name><name><surname>Altafaj</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function</article-title><source>Human molecular genetics</source><volume>29</volume><fpage>3859</fpage><lpage>3871</lpage><pub-id pub-id-type="doi">10.1093/hmg/ddaa220</pub-id><pub-id pub-id-type="pmid">33043365</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>She</surname> <given-names>K</given-names></name><name><surname>Ferreira</surname> <given-names>JS</given-names></name><name><surname>Carvalho</surname> <given-names>AL</given-names></name><name><surname>Craig</surname> <given-names>AM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Glutamate binding to the GluN2B subunit controls surface trafficking of N-methyl-D-aspartate (NMDA) receptors</article-title><source>The Journal of biological chemistry</source><volume>287</volume><fpage>27432</fpage><lpage>27445</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.345108</pub-id><pub-id pub-id-type="pmid">22740692</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname> <given-names>WW</given-names></name><name><surname>Fong</surname> <given-names>WF</given-names></name><name><surname>Pang</surname> <given-names>SF</given-names></name><name><surname>Wong</surname> <given-names>PC</given-names></name></person-group><year iso-8601-date="1985">1985</year><article-title>Limited blood-brain barrier transport of polyamines</article-title><source>Journal of neurochemistry</source><volume>44</volume><fpage>1056</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.1985.tb08724.x</pub-id><pub-id pub-id-type="pmid">3973604</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shin</surname> <given-names>W</given-names></name><name><surname>Kim</surname> <given-names>K</given-names></name><name><surname>Serraz</surname> <given-names>B</given-names></name><name><surname>Cho</surname> <given-names>YS</given-names></name><name><surname>Kim</surname> <given-names>D</given-names></name><name><surname>Kang</surname> <given-names>M</given-names></name><name><surname>Lee</surname> <given-names>EJ</given-names></name><name><surname>Lee</surname> <given-names>H</given-names></name><name><surname>Bae</surname> <given-names>YC</given-names></name><name><surname>Paoletti</surname> <given-names>P</given-names></name><name><surname>Kim</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Early correction of synaptic long-term depression improves abnormal anxiety-like behavior in adult GluN2B-C456Y-mutant mice</article-title><source>PLOS Biology</source><volume>18</volume><elocation-id>e3000717</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3000717</pub-id><pub-id pub-id-type="pmid">32353004</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname> <given-names>GM</given-names></name><name><surname>Barcelos</surname> <given-names>MP</given-names></name><name><surname>Poiani</surname> <given-names>JGC</given-names></name><name><surname>Hage-Melim</surname> <given-names>L</given-names></name><name><surname>da Silva</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Allosteric modulators of potential targets related to Alzheimer's Disease: a Review</article-title><source>ChemMedChem</source><volume>14</volume><fpage>1467</fpage><lpage>1483</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201900299</pub-id><pub-id pub-id-type="pmid">31310701</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname> <given-names>D</given-names></name><name><surname>Olivella</surname> <given-names>M</given-names></name><name><surname>Grau</surname> <given-names>C</given-names></name><name><surname>Armstrong</surname> <given-names>J</given-names></name><name><surname>Alcon</surname> <given-names>C</given-names></name><name><surname>Gasull</surname> <given-names>X</given-names></name><name><surname>Santos-Gómez</surname> <given-names>A</given-names></name><name><surname>Locubiche</surname> <given-names>S</given-names></name><name><surname>Gómez de Salazar</surname> <given-names>M</given-names></name><name><surname>García-Díaz</surname> <given-names>R</given-names></name><name><surname>Gratacòs-Batlle</surname> <given-names>E</given-names></name><name><surname>Ramos-Vicente</surname> <given-names>D</given-names></name><name><surname>Chu-Van</surname> <given-names>E</given-names></name><name><surname>Colsch</surname> <given-names>B</given-names></name><name><surname>Fernández-Dueñas</surname> <given-names>V</given-names></name><name><surname>Ciruela</surname> <given-names>F</given-names></name><name><surname>Bayés</surname> <given-names>À</given-names></name><name><surname>Sindreu</surname> <given-names>C</given-names></name><name><surname>López-Sala</surname> <given-names>A</given-names></name><name><surname>García-Cazorla</surname> <given-names>À</given-names></name><name><surname>Altafaj</surname> <given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>L-Serine dietary supplementation is associated with clinical improvement of loss-of-function <italic>GRIN2B</italic>-related pediatric encephalopathy</article-title><source>Science Signaling</source><volume>12</volume><elocation-id>eaaw0936</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.aaw0936</pub-id><pub-id pub-id-type="pmid">31213567</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname> <given-names>L</given-names></name><name><surname>Hall</surname> <given-names>J</given-names></name><name><surname>Van Buren</surname> <given-names>N</given-names></name><name><surname>Hall</surname> <given-names>A</given-names></name><name><surname>Knight</surname> <given-names>L</given-names></name><name><surname>Morgan</surname> <given-names>A</given-names></name><name><surname>Zuger</surname> <given-names>S</given-names></name><name><surname>Van Deusen</surname> <given-names>H</given-names></name><name><surname>Gentile</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Differential regulation of ionotropic glutamate receptors</article-title><source>Biophysical Journal</source><volume>92</volume><fpage>1343</fpage><lpage>1349</lpage><pub-id pub-id-type="doi">10.1529/biophysj.106.089896</pub-id><pub-id pub-id-type="pmid">17114218</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strehlow</surname> <given-names>V</given-names></name><name><surname>Heyne</surname> <given-names>HO</given-names></name><name><surname>Vlaskamp</surname> <given-names>DRM</given-names></name><name><surname>Marwick</surname> <given-names>KFM</given-names></name><name><surname>Rudolf</surname> <given-names>G</given-names></name><name><surname>de Bellescize</surname> <given-names>J</given-names></name><name><surname>Biskup</surname> <given-names>S</given-names></name><name><surname>Brilstra</surname> <given-names>EH</given-names></name><name><surname>Brouwer</surname> <given-names>OF</given-names></name><name><surname>Callenbach</surname> <given-names>PMC</given-names></name><name><surname>Hentschel</surname> <given-names>J</given-names></name><name><surname>Hirsch</surname> <given-names>E</given-names></name><name><surname>Kind</surname> <given-names>PC</given-names></name><name><surname>Mignot</surname> <given-names>C</given-names></name><name><surname>Platzer</surname> <given-names>K</given-names></name><name><surname>Rump</surname> <given-names>P</given-names></name><name><surname>Skehel</surname> <given-names>PA</given-names></name><name><surname>Wyllie</surname> <given-names>DJA</given-names></name><name><surname>Hardingham</surname> <given-names>GE</given-names></name><name><surname>van Ravenswaaij-Arts</surname> <given-names>CMA</given-names></name><name><surname>Lesca</surname> <given-names>G</given-names></name><name><surname>Lemke</surname> <given-names>JR</given-names></name><collab>GRIN2A study group</collab></person-group><year iso-8601-date="2019">2019</year><article-title><italic>GRIN2A</italic>-related disorders: genotype and functional consequence predict phenotype</article-title><source>Brain : a journal of neurology</source><volume>142</volume><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/brain/awy304</pub-id><pub-id pub-id-type="pmid">30544257</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sutton</surname> <given-names>MA</given-names></name><name><surname>Ito</surname> <given-names>HT</given-names></name><name><surname>Cressy</surname> <given-names>P</given-names></name><name><surname>Kempf</surname> <given-names>C</given-names></name><name><surname>Woo</surname> <given-names>JC</given-names></name><name><surname>Schuman</surname> <given-names>EM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Miniature neurotransmission stabilizes synaptic function via tonic suppression of local dendritic protein synthesis</article-title><source>Cell</source><volume>125</volume><fpage>785</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.03.040</pub-id><pub-id pub-id-type="pmid">16713568</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swanger</surname> <given-names>SA</given-names></name><name><surname>Chen</surname> <given-names>W</given-names></name><name><surname>Wells</surname> <given-names>G</given-names></name><name><surname>Burger</surname> <given-names>PB</given-names></name><name><surname>Tankovic</surname> <given-names>A</given-names></name><name><surname>Bhattacharya</surname> <given-names>S</given-names></name><name><surname>Strong</surname> <given-names>KL</given-names></name><name><surname>Hu</surname> <given-names>C</given-names></name><name><surname>Kusumoto</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>J</given-names></name><name><surname>Adams</surname> <given-names>DR</given-names></name><name><surname>Millichap</surname> <given-names>JJ</given-names></name><name><surname>Petrovski</surname> <given-names>S</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Mechanistic insight into NMDA receptor dysregulation by rare variants in the GluN2A and GluN2B agonist binding domains</article-title><source>The American Journal of Human Genetics</source><volume>99</volume><fpage>1261</fpage><lpage>1280</lpage><pub-id pub-id-type="doi">10.1016/j.ajhg.2016.10.002</pub-id><pub-id pub-id-type="pmid">27839871</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname> <given-names>W</given-names></name><name><surname>Liu</surname> <given-names>D</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders</article-title><source>Neuropharmacology</source><volume>177</volume><elocation-id>108247</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuropharm.2020.108247</pub-id><pub-id pub-id-type="pmid">32712275</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Hartley</surname> <given-names>M</given-names></name><name><surname>Heinemann</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines</article-title><source>Science</source><volume>268</volume><fpage>873</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1126/science.7754371</pub-id><pub-id pub-id-type="pmid">7754371</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traynelis</surname> <given-names>SF</given-names></name><name><surname>Wollmuth</surname> <given-names>LP</given-names></name><name><surname>McBain</surname> <given-names>CJ</given-names></name><name><surname>Menniti</surname> <given-names>FS</given-names></name><name><surname>Vance</surname> <given-names>KM</given-names></name><name><surname>Ogden</surname> <given-names>KK</given-names></name><name><surname>Hansen</surname> <given-names>KB</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Myers</surname> <given-names>SJ</given-names></name><name><surname>Dingledine</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Glutamate receptor ion channels: structure, regulation, and function</article-title><source>Pharmacological reviews</source><volume>62</volume><fpage>405</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1124/pr.109.002451</pub-id><pub-id pub-id-type="pmid">20716669</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verkhratsky</surname> <given-names>A</given-names></name><name><surname>Kirchhoff</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>NMDA receptors in glia</article-title><source>The Neuroscientist</source><volume>13</volume><fpage>28</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1177/1073858406294270</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vyklicky</surname> <given-names>V</given-names></name><name><surname>Krausova</surname> <given-names>B</given-names></name><name><surname>Cerny</surname> <given-names>J</given-names></name><name><surname>Ladislav</surname> <given-names>M</given-names></name><name><surname>Smejkalova</surname> <given-names>T</given-names></name><name><surname>Kysilov</surname> <given-names>B</given-names></name><name><surname>Korinek</surname> <given-names>M</given-names></name><name><surname>Danacikova</surname> <given-names>S</given-names></name><name><surname>Horak</surname> <given-names>M</given-names></name><name><surname>Chodounska</surname> <given-names>H</given-names></name><name><surname>Kudova</surname> <given-names>E</given-names></name><name><surname>Vyklicky</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Surface expression, function, and pharmacology of Disease-Associated mutations in the membrane domain of the human GluN2B subunit</article-title><source>Frontiers in Molecular Neuroscience</source><volume>11</volume><elocation-id>110</elocation-id><pub-id pub-id-type="doi">10.3389/fnmol.2018.00110</pub-id><pub-id pub-id-type="pmid">29681796</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>P</given-names></name><name><surname>Eshaq</surname> <given-names>RS</given-names></name><name><surname>Meshul</surname> <given-names>CK</given-names></name><name><surname>Moore</surname> <given-names>C</given-names></name><name><surname>Hood</surname> <given-names>RL</given-names></name><name><surname>Leidenheimer</surname> <given-names>NJ</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Neuronal gamma-aminobutyric acid (GABA) type A receptors undergo cognate ligand chaperoning in the endoplasmic reticulum by endogenous GABA</article-title><source>Frontiers in Cellular Neuroscience</source><volume>9</volume><elocation-id>188</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2015.00188</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warikoo</surname> <given-names>N</given-names></name><name><surname>Brunwasser</surname> <given-names>SJ</given-names></name><name><surname>Benz</surname> <given-names>A</given-names></name><name><surname>Shu</surname> <given-names>HJ</given-names></name><name><surname>Paul</surname> <given-names>SM</given-names></name><name><surname>Lewis</surname> <given-names>M</given-names></name><name><surname>Doherty</surname> <given-names>J</given-names></name><name><surname>Quirk</surname> <given-names>M</given-names></name><name><surname>Piccio</surname> <given-names>L</given-names></name><name><surname>Zorumski</surname> <given-names>CF</given-names></name><name><surname>Day</surname> <given-names>GS</given-names></name><name><surname>Mennerick</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Positive allosteric modulation as a potential therapeutic strategy in Anti-NMDA receptor encephalitis</article-title><source>The Journal of Neuroscience</source><volume>38</volume><fpage>3218</fpage><lpage>3229</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3377-17.2018</pub-id><pub-id pub-id-type="pmid">29476014</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wells</surname> <given-names>G</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>McDaniel</surname> <given-names>MJ</given-names></name><name><surname>Kusumoto</surname> <given-names>H</given-names></name><name><surname>Snyder</surname> <given-names>JP</given-names></name><name><surname>Liotta</surname> <given-names>DC</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The GluN2B‐Glu413Gly NMDA receptor variant arising from a <italic>de novo GRIN2B</italic> mutation promotes ligand‐unbinding and domain opening</article-title><source>Proteins: Structure, Function, and Bioinformatics</source><volume>86</volume><fpage>1265</fpage><lpage>1276</lpage><pub-id pub-id-type="doi">10.1002/prot.25595</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilding</surname> <given-names>TJ</given-names></name><name><surname>Lopez</surname> <given-names>MN</given-names></name><name><surname>Huettner</surname> <given-names>JE</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Radial symmetry in a chimeric glutamate receptor pore</article-title><source>Nature communications</source><volume>5</volume><elocation-id>3349</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms4349</pub-id><pub-id pub-id-type="pmid">24561802</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkinson</surname> <given-names>ST</given-names></name><name><surname>Sanacora</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems</article-title><source>Drug discovery today</source><volume>24</volume><fpage>606</fpage><lpage>615</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2018.11.007</pub-id><pub-id pub-id-type="pmid">30447328</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Williams</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2009">2009</year><chapter-title>Extracellular Modulation of NMDA Receptors</chapter-title><person-group person-group-type="editor"><name><surname>Van Dongen</surname> <given-names>A. M</given-names></name></person-group><source>Biology of the NMDA Receptor</source><publisher-name>Taylor &amp; Francis CRC Press</publisher-name><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>XiangWei</surname> <given-names>W</given-names></name><name><surname>Jiang</surname> <given-names>Y</given-names></name><name><surname>Yuan</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title><italic>De novo</italic> Mutations and Rare Variants Occurring in NMDA Receptors</article-title><source>Current Opinion in Physiology</source><volume>2</volume><fpage>27</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.cophys.2017.12.013</pub-id><pub-id pub-id-type="pmid">29756080</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname> <given-names>XX</given-names></name><name><surname>Luo</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutations of N-Methyl-D-Aspartate receptor subunits in epilepsy</article-title><source>Neuroscience Bulletin</source><volume>34</volume><fpage>549</fpage><lpage>565</lpage><pub-id pub-id-type="doi">10.1007/s12264-017-0191-5</pub-id><pub-id pub-id-type="pmid">29124671</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yakubovich</surname> <given-names>D</given-names></name><name><surname>Berlin</surname> <given-names>S</given-names></name><name><surname>Kahanovitch</surname> <given-names>U</given-names></name><name><surname>Rubinstein</surname> <given-names>M</given-names></name><name><surname>Farhy-Tselnicker</surname> <given-names>I</given-names></name><name><surname>Styr</surname> <given-names>B</given-names></name><name><surname>Keren-Raifman</surname> <given-names>T</given-names></name><name><surname>Dessauer</surname> <given-names>CW</given-names></name><name><surname>Dascal</surname> <given-names>N</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A quantitative model of the GIRK1/2 channel reveals that its basal and evoked activities are controlled by unequal stoichiometry of gα and Gβγ</article-title><source>PLOS Computational Biology</source><volume>11</volume><elocation-id>e1004598</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1004598</pub-id><pub-id pub-id-type="pmid">26544551</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname> <given-names>J</given-names></name><name><surname>Bengtson</surname> <given-names>CP</given-names></name><name><surname>Buchthal</surname> <given-names>B</given-names></name><name><surname>Hagenston</surname> <given-names>AM</given-names></name><name><surname>Bading</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Coupling of NMDA receptors and TRPM4 guides discovery of unconventional neuroprotectants</article-title><source>Science</source><volume>370</volume><elocation-id>eaay3302</elocation-id><pub-id pub-id-type="doi">10.1126/science.aay3302</pub-id><pub-id pub-id-type="pmid">33033186</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname> <given-names>H</given-names></name><name><surname>Low</surname> <given-names>CM</given-names></name><name><surname>Moody</surname> <given-names>OA</given-names></name><name><surname>Jenkins</surname> <given-names>A</given-names></name><name><surname>Traynelis</surname> <given-names>SF</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ionotropic GABA and glutamate receptor mutations and human neurologic diseases</article-title><source>Molecular Pharmacology</source><volume>88</volume><fpage>203</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1124/mol.115.097998</pub-id><pub-id pub-id-type="pmid">25904555</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zehavi</surname> <given-names>Y</given-names></name><name><surname>Mandel</surname> <given-names>H</given-names></name><name><surname>Zehavi</surname> <given-names>A</given-names></name><name><surname>Rashid</surname> <given-names>MA</given-names></name><name><surname>Straussberg</surname> <given-names>R</given-names></name><name><surname>Jabur</surname> <given-names>B</given-names></name><name><surname>Shaag</surname> <given-names>A</given-names></name><name><surname>Elpeleg</surname> <given-names>O</given-names></name><name><surname>Spiegel</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>De novo GRIN1 mutations: An emerging cause of severe early infantile encephalopathy</article-title><source>European journal of medical genetics</source><volume>60</volume><fpage>317</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.ejmg.2017.04.001</pub-id><pub-id pub-id-type="pmid">28389307</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname> <given-names>WH</given-names></name><name><surname>Herde</surname> <given-names>MK</given-names></name><name><surname>Mitchell</surname> <given-names>JA</given-names></name><name><surname>Whitfield</surname> <given-names>JH</given-names></name><name><surname>Wulff</surname> <given-names>AB</given-names></name><name><surname>Vongsouthi</surname> <given-names>V</given-names></name><name><surname>Sanchez-Romero</surname> <given-names>I</given-names></name><name><surname>Gulakova</surname> <given-names>PE</given-names></name><name><surname>Minge</surname> <given-names>D</given-names></name><name><surname>Breithausen</surname> <given-names>B</given-names></name><name><surname>Schoch</surname> <given-names>S</given-names></name><name><surname>Janovjak</surname> <given-names>H</given-names></name><name><surname>Jackson</surname> <given-names>CJ</given-names></name><name><surname>Henneberger</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Monitoring hippocampal glycine with the computationally designed optical sensor GlyFS</article-title><source>Nature chemical biology</source><volume>14</volume><fpage>861</fpage><lpage>869</lpage><pub-id pub-id-type="doi">10.1038/s41589-018-0108-2</pub-id><pub-id pub-id-type="pmid">30061718</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname> <given-names>S</given-names></name><name><surname>Paoletti</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Allosteric modulators of NMDA receptors: multiple sites and mechanisms</article-title><source>Current opinion in pharmacology</source><volume>20</volume><fpage>14</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.coph.2014.10.009</pub-id><pub-id pub-id-type="pmid">25462287</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67555.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Chao</surname><given-names>Moses V</given-names></name><role>Reviewing Editor</role><aff><institution>New York University Langone Medical Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>This interesting study characterizes NMDA receptor mutants in regard to ion channel physiology and to functional consequences from clinical impairments of two pediatric cases. A strength of the study is that missense mutations are analyzed with respect to ion channel receptor function. The mechanism of a dominant negative effect on NMDA receptor function is proposed. A combination of modeling and electrophysiological methods is used to support the key conclusions of the paper.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Two de novo GluN2B mutations affect multiple NMDAR-functions and instigate severe pediatric encephalopathy&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Huda Zoghbi as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this letter to help you prepare a revised submission. Detailed comments are below.</p><p>Essential revisions:</p><p>The study was considered to be well done and to be of interest. Positive comments were also raised about the nature and details of the findings. Several major reservations were raised. There have been many characterizations of NMDAR variants that have been published. Given the two missense mutations in the agonist binding site of GluN2B, the conclusions should be strengthened by additional pharmacological or translational insights to delineate the novelty and impact of the results.</p><p>1) Either a novel insight into the function of NMDARs or a new clinical insight would greatly enhance the impact of the manuscript. There are many papers being generated on this topic that draw correlations between functional characterizations and clinical phenotypes. We are not certain that they provide new insights into the etiology of the disease phenotype or potential treatment options.</p><p>2) One point to address is the nature of the dominant negative mechanism. A discussion of significance should make clear the novelty of the dominant negative mechanism of suppression of receptor currents by the mutations studied here. How is this mechanism distinguished from other disability-causing mutations that have been reported elsewhere. The NMDA receptor does not open unless all four LBDs are occupied. Therefore, the incorporation of one mutant NR2B into the hetero-tetramer can block function. So mutant NR2B Is dominant over wild type NR2B, in the same tetramer. Is this novel or are most NMDA receptor mutations like this?</p><p><italic>Reviewer #1:</italic></p><p>NMDA receptors are glutamate-gated ion channels that make significant contributions to a variety of brain functions. Recently, de novo missense mutations have been identified in genes encoding NMDA receptor subunits and are often associated with severe clinical phenotypes. How these missense mutations lead to clinical phenotypes is unknown and one way to address this is to characterize their effect on receptor function. In the present manuscript, the authors characterize the effect of two missense mutations at a glycine in the agonist binding pocket of the GluN2B subunit. The authors find that the mutations have different effects on receptor function and propose that these differences may contribute to variations in their associated clinical phenotypes.</p><p>The manuscript is a positive characterization of two missense mutations at a site in the agonist binding pocket of the GluN2B subunit. The data are quite reasonable and are displayed appropriately. The general conclusions are appropriate.</p><p>Potential impact of the manuscript. While a nice characterization, many of these have been done and it is not clear that the results in the present manuscript provide a high impact insight. Perhaps it is there but the authors need to do a better job of demonstrating that they have made a significant new discovery about NMDA receptors, either in terms of structure-function or clinical aspects. Many characterizations of missense mutations in NMDA receptors have been done and have provided new insights into how receptors carry out their biological function (e.g., Odgen et al., 2017, PLoS Genetics, Amin et al., 2018, Nat Comm; Fedele et al., 2018, Nat Comms) or how they might function at synapse (e.g., Liu et al., 2017 J. Neurosci.). Other pathways are available to provide impact, e.g., providing some new therapeutic insight or potentially how they affect signaling in vivo but these are absent in the present version.</p><p>Again, perhaps there is buried in the manuscript some new insight but at present it feels like a number of observations (e.g., that has a very strong effect on glutamate potency or have effects on pH sensing) with no clear advance in terms of mechanism. Also in terms of relating the observed effects of the missense mutations on receptor function to clinical phenotypes is always challenging and is really just speculation unless a large number are done.</p><p><italic>Reviewer #2:</italic></p><p>This is a well-written manuscript in which the authors have identified two patients with missense mutations in the GRIN2B gene, substituting a highly conserved glycine residue. They find the mutations produce marked reductions in glutamate potency, one showing the largest reduction in EC50 reported for GRIN2B-mutations (~2000-fold reduction). Variants readily multimerize with the GluN2Bwt- subunits, promote their surface expression and exert a dominant- negative effect on receptor function. Interestingly, one variant entirely fails to respond to spermine, a specific GluN2B-potentiator, at physiological pH. The manuscript provides important contribution to the understanding of functional consequences of two specific mutations of the GRIN2B gene. As such the manuscript is a great example of how to integrate knowledge on basic receptor function and personalized medicine. This is indeed achieved by combining sophisticated modeling and electrophysiological techniques that have permitted addressing of important aspects of receptor function which has been investigated in depth by a large variety of experiments that were well executed. Because of the clinical relevance of the study, the research and clinical community should learn from this manuscript and be interested in it. This reviewer could not identify any weakness in the manuscript.</p><p><italic>Reviewer #3:</italic></p><p>Kelner et al. have studied the effects of naturally occurring mutations in the ligand binding domain of the GluN2B subunit of the NMDA receptor. Two mutations at the same residue, G689S and G698C, were identified in two pediatric patients with severe intellectual disability and delayed neural development. The authors describe the clinical manifestations of these mutations and investigate the molecular and physiological consequences through expression in oocytes and mammalian cells.</p><p>The GluN2B crystal structure suggested that the mutations would occlude glutamate binding, and indeed, while the EC50 (glutamate concentration for half maximal current) of the wt was in the μM range, the EC50 was 1000 x higher for 2B-G689S and 2000 x higher for 2B-G698C, with both in the millimolar range. This indicates reduced affinity of glutamate for the mutant receptors leading to loss of function, although at saturating glutamate concentrations (10mM), Imax for the mutants and wt were similar.</p><p>Experiments in 293 cells showed that surface expression of GluN2B-G689S was similar to wt, and GluN2B2B-G689C was 45% of this value. Both variants increased the surface expression of wt subunits, indicating that both mutants could multimerize with wt and GluN1a to form surface-expressed heterotetramers. Expression of increasing levels of mutant with an excess of wt progressively depressed currents and increased KD values, supporting co-assembly of mutant and wt into heterotetramers resulting in loss of function through a strong dominant negative effect on glutamate affinity, but a much lower effect on co-assembly and surface expression.</p><p>Analysis of dose-response curves indicated that co-expression of wt and mutant led to the formation of two receptor populations, one wt and the other incorporating a mutant receptor.</p><p>In an attempt to find a pharmacologic treatment that overcame the diminished currents of the mutants, the authors treated oocytes expressing hetero-tetramers with spermine, a GluN2B-specific potentiator. However under conditions for which spermine potentiates wt receptors, spermine poorly potentiated the mutants. Furthermore, decreasing the pH, which greatly increased spermine potentiation of wt, only modestly increased mutant receptor currents in oocytes. Experiments with a competitive antagonist of spermine indicated that the spermine binding site was intact in the mutants. Further, the mutants were more resistant to proton inhibition, which suggested that residue 689 is part of the proton sensing domain.</p><p>Other experiments showed that while D-serine, another possible potentiator, increased currents of wt and of the mutants, this increase was eliminated in the presence of the co-agonist, glycine, indicating D-serine simply augments filling the glycine site in GluN1a, rather than acting as a true potentiator.</p><p>Finally, the current reduction by GluN2B-G689C seen in oocytes was reproduced in the mammalian 293 cell line, confirming the relevance of the oocyte studies.</p><p>The paper presents a comprehensive analysis of the changes in physiological and cell biological properties of two GluN2B subunits with LBD mutations that are associated with intellectual disability and delayed development, and in one case, epileptic seizures. The data support a mechanism of dominant negative inhibition of NMDA receptor function, in which the mutant subunit assembles with wt GluN1a and wt GluN2B to form tri-heterotetrametric receptors that traffic to the plasma membrane but fail to conduct because they have very low affinity for glutamate.</p><p>In addition to the graphic presentation of the data in Figures, the data is also presented numerically in Tables in a comprehensive form. Also summarized in Tables are the clinical assessments of the two proband patients from whom the mutants were isolated.</p><p>The patient with the G689S mutation also had mutations in SLC6A8 gene (sodium- and chloride-dependent creatine transporter 1) and CACNA1A gene (Calcium Voltage-Gated Channel Subunit Alpha1A). It is not known whether these mutations contributed to the clinical phenotype. Similar data are not available for the G689C mutation patient.</p><p>The paper provides considerable insight into the mechanism by which GluN2B mutations exert a strong, dominant negative effect on NMDA receptor function. The paper does not address how these mutations affect function in neurons, either in vivo or in vitro.</p><p>This article presents a set of well-chosen and well executed experiments that supports a dominant-negative mode of action of mutant NMDA receptor GluN2B subunits that cause severe intellectual disability.</p><p>Although not necessary for this submission or for drawing the main conclusions of the article, experiments in neurons, either in vivo in genetically modified mice, or in cultured neurons, would enhance this report. Experiments in oocytes and heterologous cells, although providing valuable information about receptor assembly, trafficking and electrophysiological function, cannot take into account factors that arise only in vivo in a neuronal context. These include the developmental patterns of expression of the various NMDA receptor subunits and binding proteins, and neuron-specific interactions including ones at synapses. Also, the effects of the mutations on synaptic plasticity, such as LTP/LTD, cannot be assessed.</p><p>The conclusions of a number of the experiments depend on expressing wt and mutant receptors at comparable or other predetermined levels, and this can be affected by the quality of oocyte-injected mRNA, differences in expression efficiency and protein stability etc. Indeed, the mutant receptors are not expressed at the surface with the same efficiency and have differences in expression and/or stability. The authors should discuss more fully how these parameters were addressed.</p><p>The authors discuss the effects of the mutations on the stereochemistry of the ligand binding site occupied by glutamate. But because the mutations occlude binding glutamate, it would be interesting to consider the LBD structure of the mutants in the unliganded state, if the appropriate crystal structure were available. This might suggest a pharmacologic (small molecule) means for closing the clamshell and opening the pore of the mutant, even in the absence of bound glutamate.</p><p>The speculation about the effects of water access on deactivation kinetics (p 5), which turned out to be incorrect, interrupts the flow of the Results section and might be considered better in the Discussion.</p><p>The manuscript has a significant number of typographical errors and a large number of grammatical errors or non-colloquial phrasings. It should be revised carefully by a native English speaker.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.67555.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The study was considered to be well done and to be of interest. Positive comments were also raised about the nature and details of the findings. Several major reservations were raised. There have been many characterizations of NMDAR variants that have been published. Given the two missense mutations in the agonist binding site of GluN2B, the conclusions should be strengthened by additional pharmacological or translational insights to delineate the novelty and impact of the results.</p><p>1) Either a novel insight into the function of NMDARs or a new clinical insight would greatly enhance the impact of the manuscript. There are many papers being generated on this topic that draw correlations between functional characterizations and clinical phenotypes. We are not certain that they provide new insights into the etiology of the disease phenotype or potential treatment options.</p></disp-quote><p>We thank the reviewers for highlighting the issue of novelty. We now realize to have clearly downplayed the importance of our findings. We would therefore like emphasize that our study not only provides description and characterization of two novel GRIN2B variants, it also provides several new insights into NMDAR function, dominant effect of variants over tri-heteromeric channels and effect in neurons. These are now specifically highlighted throughout the text.</p><p>Briefly, the novelties we report are:</p><p>1. We describe two mutations that lead to the most extreme cases of reduction in glutamate potency of the GluN2B subunit (and only second to a <italic>GRIN2A</italic> mutation). We therefore expected these mutations to mirror effects of mutations that completely abolish expression of the subunit (e.g., truncation mutations<sup>1</sup>). This would suggest that the disease could be associated with cases of haploinsufficiency (as commonly suggested in literature<sup>2–4</sup>). Instead, we observe the opposite. First G689S expresses as well as the native subunit and, although G689C expresses less, both variants significantly reduce glutamate potency of mixed channels (Figures 2 and 3). Additionally, both variants promote the expression of 2Bwt subunits (Figure 3). In neurons, the variants affect synaptic currents (significantly alter frequency and amplitude of miniature EPSCs; Figure 8 and Figure 8—figure supplement 2). These are best explained by a very strong dominant-negative effect (<italic>and</italic> see next reply specifically addressing the novelty of the dominant negative effect).</p><p>2. We provide new insights pertaining to glutamate-affinity and expression levels. Briefly, high affinity is not essential for proper membrane trafficking. This is very different than most LoF mutations in the LBD and argues against classification of the latter as haploinsufficiency (now explicitly noted in page 11). In fact, we deem this as a major issue as the medical community often confuses between these terms (For an explicit example see our reply for query #2).</p><p>3. We discover that the G689 residue is involved in proton sensing of the GluN2B-subunit.</p><p>4. We present new simulations showing that residues that protrude towards the glutamate and shift its position are likely behind the significant decrease in glutamate-affinity (Figure 1 and Figure 1—figure supplement 1).</p><p>5. Moreover, we present ∆∆G predictions for ALL possible mutations in the LBD (consisting of 5282 mutations; we provide the scripts and graphical analysis in Suppl. File 3). These suggest that most substitutions (~60%) within the LBD destabilize its structure; providing plausible explanation why most LBD mutation lead to reduced affinity to glutamate (i.e, LoF). The data also show that substitutions to glycines or serines are the most destabilizing. Interestingly, the same may apply inversely, namely removal of glycine and its substitution by other (larger) residues should be highly disfavorable for receptor function. In support, glycine residues are suggested to serve as essential hinges in GRIN2B and their mutagenesis causes severe channel dysfunction<sup>5</sup>, including the two cases shown here (pages 18-19)</p><p>Per the second part of the question (potential treatment), we would first like reiterate that this was our primary goal and the reason behind the scrutiny of specific and non-specific channel potentiators (spermine and D-serine, respectively). These failed to enhance receptor function (but provided valuable insights into proton sensitivity). Notably, whereas most therapeutics target GoF mutations, and therefore employ channel blockers (most commonly FDA-approved pan-NMDAR blocker memantine, e.g., <sup>3,6–10</sup>, pages 3-4)., there are very few openers (e.g., <sup>11–13</sup>) and even fewer GluN2B-selective.</p><p>Nevertheless, to try and develop a potential treatment, we wanted to explore gene editing techniques, specifically base editing<sup>14</sup> (see details below). We examined all possible substitutions that can be made:</p><p>WT – p.689 – GGC,</p><p>G689C – p.689 – TGC</p><p>G689S – p.689 – (AGC)</p><p>C•G to T•A base editors (CBEs)-</p><p>G689C – p.689 – TGT = maintains Cysteine mutation</p><p>G689S – p.689 – AGT = maintains Serine mutation</p><p>A•T to G•C base editors (ABEs)</p><p>G689C – p.689 – TGC – none-modifiable</p><p>G689S – p.689 – GGC – Glycine **restores to normal**</p><p>C•G to G•C base editors<sup>15</sup></p><p>G689C – p.689 – TGG – modifies to Tryptophan (W)</p><p>G689S – p.689 – AGG – modifies to Arginine (R)</p><p>Whereas only G689S can be restored to normal (i.e., glycine) by using A•T to G•C base editors (ABEs), G689C cannot. G689C can only be modified to tryptophan using C•G to G•C base editors<sup>15</sup> (which would produce an arginine if applied onto G689S). We produced both of these variants and tested in oocytes and find that both yield very low expression levels/complete loss of function. We would be happy to include these results, even if negative should the reviewers deem it interesting.</p><p>Lastly, we address the comment about genotype-phenotype correlations by several ways. First, we provide an extensive analysis of the literature, collating <italic>all r</italic>eported GRIN2B mutations (using PubMed, ClinVar and CFERV databases; described in text- page 17 and shown in Suppl. File 2), as well as focus on LBD mutations (Suppl. Table 1). Unfortunately, there are too few LBD mutations with reported characterizations (&lt;20), and not all mutations show a clear binary effect (e.g., I655F mutation acts both as LoF mutation – instigating ~3-fold reduction in glutamate EC<sub>50</sub>, as well as a GoF mutation –by reducing Mg<sup>2+</sup>-sensitivity) from which we can draw any firm conclusions (Suppl. File 3). We also examined several correlations with the various clinical phenotypes though fail to find any clear associations. These observations are not completely unexpected (and the reason why we have initially left them out of the manuscript), as similar analyses have been previously performed and they all provide a very limited genotype-phenotype associations (e.g., <sup>2,7,16</sup>; see below for specific details). Resultantly, there is lack of formal diagnostic criteria based on clinical phenotype for GRIN2B-related disorders (<sup>17</sup>). We now note all these in discussion (pages 16-17), in particular the current consensus regarding the strong evidence that mutations in GRIN2B are more associated with developmental delays and autism spectrum disorder, whereas GRIN2A more associated with epilepsy (<sup>2</sup> and “Clinical and genetic spectrum of GRIN2A and GRIN2B variants.” Dr. Johannes Lemke. University of Leipzig. Presented at 2019 CFERV Conference on GRIN Variants. Atlanta. 2019).</p><p>Details:</p><p>A recent analysis of the largest GRIN2B patient cohort (86 patients) found no clear association between: (1) effect of mutation (GoF or LoF), (2) extent of effect (how much gain or loss compared to wt), (3) localization of the mutations and clinical phenotype (<sup>6</sup> and Clinical and genetic spectrum of GRIN2A and GRIN2B variants.” Dr. Johannes Lemke. University of Leipzig. Presented at 2019 CFERV Conference on GRIN Variants. Atlanta. 2019). The only significant correlation obtained was between variant class (i.e., missense or truncation) and intellectual outcome (mild to moderate moderate vs severe ID) (Fisher’s exact test, p=0.0079) with truncation carriers tending to present mild/moderate intellectual disability. This is not completely unexpected as this appears to be the only recurring theme for GRIN2B mutations (as we have mentioned in the text) owing to its embryonic expression. With regard to GRIN2A, analysis of a larger cohort (248 patients) found only two distinct phenotype groups that could be explained by the location and effect (gain or loss – but not size of effect) of the mutations<sup>7</sup>. More precisely, the authors show that most mutations in the TMDs (and there are 4 TMDs) or linkers are associated with broad developmental and epileptic encephalopathy phenotypes and these mutations are also typically associated with GoF of the receptors (though to very different extents), whereas mutations in the two large extracellular domains (amino terminal domain and ligand binding domain) are associated with speech abnormalities and/or seizures with mild to no ID only; and these typically instigate LoF<sup>7</sup> (these are now mentioned in page 17).</p><disp-quote content-type="editor-comment"><p>2) One point to address is the nature of the dominant negative mechanism. A discussion of significance should make clear the novelty of the dominant negative mechanism of suppression of receptor currents by the mutations studied here. How is this mechanism distinguished from other disability-causing mutations that have been reported elsewhere. The NMDA receptor does not open unless all four LBDs are occupied. Therefore, the incorporation of one mutant NR2B into the hetero-tetramer can block function. So mutant NR2B Is dominant over wild type NR2B, in the same tetramer. Is this novel or are most NMDA receptor mutations like this?</p></disp-quote><p>We agree with the reviewers that the dominant-negative effect should be further discussed, as it is unique as it diverges from the effect of other reported mutations. We now provide these details in pages 10-11 and in the discussion. We highlight the fact that a dominant-negative effect in <italic>GRINs</italic> is not commonly reported. In support, only a handful of reports (three) explicitly describe or note a dominant-negative effect for three <italic>GRIN</italic> variants (GRIN1<sup>18</sup>, GRIN2A<sup>19</sup> and GRIN2B<sup>20</sup>). In two reports (<sup>18,19</sup>) the authors interpret reduced current amplitudes (~50%) as an indication for dominant negative effect, whereas the third shows that a single copy of GluN2B‐N616K produces a dominant reduction in Mg<sup>2+</sup>-block similar to channels including two copies of the variant<sup>20</sup>. However, most reports examining other <italic>GRIN</italic> mutations do not describe dominance, even though we expect the least functional subunit to be the limiting factor in mixed channels. For instance, a recent report examining eight different <italic>GRIN</italic> variants (M2-pore mutations) shows that mixed-channels exhibit very mild reduction in Mg<sup>2+</sup> IC<sub>50</sub>, with values corresponding to values of the wt channels<sup>20</sup>. Another report examining mixed-channels containing GluN2Awt and 2A-P552R<sup>21</sup> shows that, whereas 2A-P552R significantly alters stability of the pore when it is found in two copies per channel, it fails to do so when mixed with GluN2Awt. Very similar observations are reported for mixed channels bearing 2Bwt and the GluN2B-E413G variant in which the EC<sub>50</sub> is not dominated by the low affinity subunit <sup>16</sup>. Thus, while a dominant negative effect is somewhat intuitive – as all LBDs of NMDARs need to be liganded for full channel opening<sup>22–24</sup> – it is not commonly observed in <italic>GRINs</italic>, especially not LBD mutations of <italic>GRIN2B</italic>.</p><p>Notably, following an extensive re-review of the literature, we found two additional reviews (specifically<sup>25,26</sup>) that cite the reports mentioned above, and notice that they also cite additional ones. The reviews interpret the findings of the added reports as proof for dominant negative. However, close scrutiny of the added citations shows that the original reports do not show a dominant negative effect, nor suggest it in their original manuscripts Chen et al. <sup>26</sup> refers readers to references #5,6-11, 13,16 and 18; Poot M<sup>25</sup>, refers to Lemke 2016 and Platzer 2017. Thus, we still maintain that we show a unique dominant negative effect.</p><p>Significance of dominant negative findings – Our findings diverge from reports that examined the effect of variants on mixed channels (i.e., channel made of one copy of a <italic>wt</italic>-subunit mixed with another copy of the variant). First, previous reports reach this conclusion by relying on a single observation whereby mixed channels exhibit reduced (~50%) current amplitudes. However, as reduced currents can result from multiple reasons, such as expression. This motivated us to address this by multiple means. Indeed, we do not rely on a single DNA-mixture and current amplitude, rather explore different channel stoichiometries (by employing a highly established method of mRNA titrations, e.g., <sup>27–29</sup>) and assess current amplitudes, expression levels and, importantly, glutamate potency. These ultimately lead to the likely interpretation that mixed channels that exhibit normal current amplitudes (supported by expression assays, Figure 3) contain the <italic>wt</italic> subunits, but the very reduced EC<sub>50</sub> results from the limiting effect of the variants. We go on to confirm that our results do not reflect two distinct populations of channels (Figure 4). Notably, this is different than previous reports (see <sup>16</sup>). Thus, we do not simply suggest a dominant negative, we explore it by numerous means and provide strong evidence to support it. Finally, though severe LoF are commonly equated to cases of haploinsufficiency (e.g., by null mutations and early stop codons), we show that this is not the case for these two variants. We now provide these details in the discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>NMDA receptors are glutamate-gated ion channels that make significant contributions to a variety of brain functions. Recently, de novo missense mutations have been identified in genes encoding NMDA receptor subunits and are often associated with severe clinical phenotypes. How these missense mutations lead to clinical phenotypes is unknown and one way to address this is to characterize their effect on receptor function. In the present manuscript, the authors characterize the effect of two missense mutations at a glycine in the agonist binding pocket of the GluN2B subunit. The authors find that the mutations have different effects on receptor function and propose that these differences may contribute to variations in their associated clinical phenotypes.</p><p>The manuscript is a positive characterization of two missense mutations at a site in the agonist binding pocket of the GluN2B subunit. The data are quite reasonable and are displayed appropriately. The general conclusions are appropriate.</p><p>Potential impact of the manuscript. While a nice characterization, many of these have been done and it is not clear that the results in the present manuscript provide a high impact insight. Perhaps it is there but the authors need to do a better job of demonstrating that they have made a significant new discovery about NMDA receptors, either in terms of structure-function or clinical aspects. Many characterizations of missense mutations in NMDA receptors have been done and have provided new insights into how receptors carry out their biological function (e.g., Odgen et al., 2017, PLoS Genetics, Amin et al., 2018, Nat Comm; Fedele et al., 2018, Nat Comms) or how they might function at synapse (e.g., Liu et al., 2017 J. Neurosci.). Other pathways are available to provide impact, e.g., providing some new therapeutic insight or potentially how they affect signaling in vivo but these are absent in the present version.</p><p>Again, perhaps there is buried in the manuscript some new insight but at present it feels like a number of observations (e.g., that has a very strong effect on glutamate potency or have effects on pH sensing) with no clear advance in terms of mechanism. Also in terms of relating the observed effects of the missense mutations on receptor function to clinical phenotypes is always challenging and is really just speculation unless a large number are done.</p></disp-quote><p>We thank the review for the positive comments on our manuscript and understand his/her comment about list of observations. We would like to emphasize that we have not simply tested random features, rather the results of one observation led us to test the next. More specifically, our hypothesis regarding lower glutamate potency (based on location of mutation, simulations and literature<sup>3</sup>) led to the assessment of glutamate affinity (but not other features related to other domains, such as amino terminal domain). The smaller currents motivated evaluation of expression. Lastly, our aspirations to find a potential treatment led us to explore channel potentiators, which in turn led us to uncover the variants’ diminished proton-sensitivity and to elaborate on the <italic>agonistic</italic> actions of D-serine, rather than <italic>potentiator</italic>.</p><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>[…] Although not necessary for this submission or for drawing the main conclusions of the article, experiments in neurons, either in vivo in genetically modified mice, or in cultured neurons, would enhance this report. Experiments in oocytes and heterologous cells, although providing valuable information about receptor assembly, trafficking and electrophysiological function, cannot take into account factors that arise only in vivo in a neuronal context. These include the developmental patterns of expression of the various NMDA receptor subunits and binding proteins, and neuron-specific interactions including ones at synapses. Also, the effects of the mutations on synaptic plasticity, such as LTP/LTD, cannot be assessed.</p></disp-quote><p>We now provide results from cultured rat hippocampal neurons in which we have overexpressed 2B, G689C or G689S (Figure 8 and Figure 8—figure supplement 2, page 15). Briefly, overexpression of the variants causes a strong reduction in synaptic GluNR-events: neurons overexpressing the variants showed a strong reduction in the frequency of mini<sub>NMDAR</sub>, without any effect on the frequencies of mini<sub>AMPAR.</sub> Moreover, overexpression of G689S (but not G689C) reduces amplitudes of mini<sub>NMDAR</sub>, with a concomitant increase in the amplitude of mini<sub>AMPAR</sub>. Lastly, mini<sub>NMDARs</sub> from neurons overexpressing the variants display faster deactivation kinetics than control. Together, these results demonstrate that expression of the variants in hippocampal neurons prompts a pronounced effect on synaptic GluNRs. The reduction in the frequency of mini<sub>NMDAR</sub> – in combination with the unaffected frequency of mini<sub>AMPAR</sub> – rules-out loss of excitatory synapses (as may be instigated by other variants, e.g., GluN2B-S1413L<sup>31</sup>). Moreover, G689S dual effect on amplitudes of both mini-types suggests that the ‘silencing’ of GluNRs (by the dominant negative effect) induces compensatory mechanism that drive increases in synaptic GluARs<sup>32</sup>. Lastly, acceleration of τ<sub>off</sub> due to overexpression of the variants reveals that the remaining minis are more associated with the faster deactivating GluN2A subunits<sup>33</sup>. Notably, all of these effects are highly consistent with our dominant negative observations (see Figure 4) and with results obtained from animal model bearing a GluN2B LoF mutation<sup>34</sup>.</p><disp-quote content-type="editor-comment"><p>The conclusions of a number of the experiments depend on expressing wt and mutant receptors at comparable or other predetermined levels, and this can be affected by the quality of oocyte-injected mRNA, differences in expression efficiency and protein stability etc. Indeed, the mutant receptors are not expressed at the surface with the same efficiency and have differences in expression and/or stability. The authors should discuss more fully how these parameters were addressed.</p></disp-quote><p>We now elaborate on these in methods. Briefly, mRNA quality is systematically assessed by electrophoresis and diluted mRNA is aliquoted, and stored at -80 degrees (as previously reported<sup>28,35</sup>). Thus, the same batch of mRNA serves in multiple experiments. Moreover, we also note that we do not record from dying/unhealthy oocytes (assessed by appearance, resting potentials and leak currents). All experiments are repeated multiple times. In the particular case of the mixed groups experiments (Figure 4), the experiments themselves serve as control for mRNA quality. All groups are injected with the same GluN1a mRNA. Moreover, every experiment consists of multiple groups, including control groups that express the variants or <italic>wt</italic> subunits on their own, not to mention the groups in which one mRNA is excessively expressed over the other. (e.g., G689C mRNA &gt;&gt; wt mRNA; 16:1). In cases these failed to provide any current, we did not analyze the experiment. However, as the reviewer rightly notes, when the variants are mixed with the 2Bwt-subunit, expression levels may vary – but only in the case of the G689C subunit (G689S expresses as well as 2Bwt). In mixed groups, we obtain large currents in all groups despite the differing mRNA stoichiometries. In the case of G689C, this is indicative of the expression of the wt subunits, but not in the case of G689S. The dramatic drop in EC<sub>50</sub> (and complete lack of two populations assessed by various fitting modes), demonstrates that there are no purely-2B<italic>wt</italic> channels, rather most are mixed channels. Of note, this is one particular strength in our work over previous reports, namely employing mRNA titration for controlling protein levels is a (e.g., <sup>28,29,35</sup>) as we could determine a bona-fide dominant negative effect that does not solely rely on current amplitudes (i.e., <sup>18,19</sup>), which is prone to yield errors owing to the limitations mentioned by the reviewer.</p><disp-quote content-type="editor-comment"><p>The authors discuss the effects of the mutations on the stereochemistry of the ligand binding site occupied by glutamate. But because the mutations occlude binding glutamate, it would be interesting to consider the LBD structure of the mutants in the unliganded state, if the appropriate crystal structure were available. This might suggest a pharmacologic (small molecule) means for closing the clamshell and opening the pore of the mutant, even in the absence of bound glutamate.</p></disp-quote><p>We agree with the reviewer, but there are no crystal structures of this LBD (or other subunits) without a ligand. However, we now provide better simulations (along PDBs) of the LBD with the mutations (Figure 1).</p><disp-quote content-type="editor-comment"><p>The speculation about the effects of water access on deactivation kinetics (p 5), which turned out to be incorrect, interrupts the flow of the Results section and might be considered better in the Discussion.</p></disp-quote><p>We have re-written this part. We describe the general outcomes of the simulations, without going into detail about the holes, to lessen interruption.</p><disp-quote content-type="editor-comment"><p>The manuscript has a significant number of typographical errors and a large number of grammatical errors or non-colloquial phrasings. It should be revised carefully by a native English speaker.</p></disp-quote><p>The text has been substantially revised, edited and corrected by a native English speaker, as suggested. We hope this version reads better.</p><p>References:</p><p>1. Hu, C., Chen, W., Myers, S. J., Yuan, H. and Traynelis, S. F. Human GRIN2B variants in neurodevelopmental disorders. J. Pharmacol. Sci. 132, 115–121 (2016).</p><p>2. Myers, S. J. et al. Distinct roles of GRIN2A and GRIN2B variants in neurological conditions. F1000Research 8, (2019).</p><p>3. XiangWei, W., Jiang, Y. and Yuan, H. de novo mutations and rare variants occurring in NMDA receptors. Curr. Opin. Physiol. 2, 27–35 (2018).</p><p>4. Santos-Gómez, A. et al. Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function. Hum. Mol. Genet. 29, 3859–3871 (2020).</p><p>5. Amin, J. B., Leng, X., Gochman, A., Zhou, H.-X. and Wollmuth, L. P. A conserved glycine harboring disease-associated mutations permits NMDA receptor slow deactivation and high Ca 2+ permeability. Nat. Commun. 9, 3748 (2018).</p><p>6. Platzer, K. et al. GRIN2B encephalopathy: novel findings on phenotype, variant clustering, functional consequences and treatment aspects. J. Med. Genet. 54, 460–470 (2017).</p><p>7. Strehlow, V. et al. GRIN2A -related disorders: genotype and functional consequence predict phenotype. Brain 142, 80–92 (2019).</p><p>8. Gheța, I. et al. GRIN2A Variant in A 3-Year-Old – An Expanding Spectrum? Neurol. Int. 13, 184–189 (2021).</p><p>9. Amador, A. et al. Modelling and treating GRIN2A developmental and epileptic encephalopathy in mice. Brain (2020) doi:10.1093/brain/awaa147.</p><p>10. Fedele, L. et al. Disease-associated missense mutations in GluN2B subunit alter NMDA receptor ligand binding and ion channel properties. Nat. Commun. 9, 957 (2018).</p><p>11. Burnell, E. S. et al. Positive and Negative Allosteric Modulators of N-Methyl-D-Aspartate (NMDA) Receptors; Structure-Activity Relationships and Mechanisms of Action. J. Med. Chem. 62, 3–23 (2019).</p><p>12. Hackos, D. H. et al. Positive Allosteric Modulators of GluN2A-Containing NMDARs with Distinct Modes of Action and Impacts on Circuit Function. Neuron 89, 983–999 (2016).</p><p>13. Addis, L. et al. Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency – molecular profiling and functional rescue. Sci. Rep. 7, 66 (2017).</p><p>14. Porto, E. M., Komor, A. C., Slaymaker, I. M. and Yeo, G. W. Base editing: advances and therapeutic opportunities. Nat. Rev. Drug Discov. 19, 839–859 (2020).</p><p>15. Kurt, I. C. et al. CRISPR C-to-G base editors for inducing targeted DNA transversions in human cells. Nat. Biotechnol. 39, 41–46 (2021).</p><p>16. Swanger, S. A. et al. Mechanistic Insight into NMDA Receptor Dysregulation by Rare Variants in the GluN2A and GluN2B Agonist Binding Domains. Am. J. Hum. Genet. 99, 1261–1280 (2016).</p><p>17. Platzer, K. and Lemke, J. R. GRIN2B-Related Neurodevelopmental Disorder. in GeneReviews (eds. Adam, M. P. et al.) (University of Washington, Seattle, 1993).</p><p>18. Lemke, J. R. et al. Delineating the GRIN1 phenotypic spectrum. Neurology 86, 2171–2178 (2016).</p><p>19. Endele, S. et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat. Genet. 42, 1021–1026 (2010).</p><p>20. Li, J. et al. de novo GRIN variants in NMDA receptor M2 channel pore‐forming loop are associated with neurological diseases. Hum. Mutat. 40, 2393–2413 (2019).</p><p>21. Ogden, K. K. et al. Molecular Mechanism of Disease-Associated Mutations in the Pre-M1 Helix of NMDA Receptors and Potential Rescue Pharmacology. PLoS Genet. 13, (2017).</p><p>22. Berlin, S. et al. A family of photoswitchable NMDA receptors. <italic>eLife</italic> 5, e12040 (2016).</p><p>23. Wilding, T. J., Lopez, M. N. and Huettner, J. E. Radial symmetry in a chimeric glutamate receptor pore. Nat. Commun. 5, 3349 (2014).</p><p>24. Kussius, C. L. and Popescu, G. K. Kinetic basis of partial agonism at NMDA receptors. Nat. Neurosci. 12, 1114–1120 (2009).</p><p>25. Poot, M. Phenotypic Spectrum and Severity of Disease Depending on the Mutated Protein Domain of NMDA Receptor-Encoding Genes. Mol. Syndromol. 10, 127–129 (2019).</p><p>26. Chen, W. et al. GRIN1 mutation associated with intellectual disability alters NMDA receptor trafficking and function. J. Hum. Genet. 62, 589–597 (2017).</p><p>27. Peleg, S., Varon, D., Ivanina, T., Dessauer, C. W. and Dascal, N. Gαi Controls the Gating of the G Protein-Activated K<sup>+</sup> Channel, GIRK. Neuron 33, 87–99 (2002).</p><p>28. Berlin, S. et al. A Collision Coupling Model Governs the Activation of Neuronal GIRK1/2 Channels by Muscarinic-2 Receptors. Front. Pharmacol. 11, (2020).</p><p>29. Katz, M. et al. Reconstitution of β-adrenergic regulation of CaV1.2: Rad-dependent and Rad-independent protein kinase A mechanisms. Proc. Natl. Acad. Sci. 118, (2021).</p><p>30. Pires, D. E. V., Ascher, D. B. and Blundell, T. L. mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics 30, 335–342 (2014).</p><p>31. Liu, S. et al. A Rare Variant Identified Within the GluN2B C-Terminus in a Patient with Autism Affects NMDA Receptor Surface Expression and Spine Density. J. Neurosci. 37, 4093–4102 (2017).</p><p>32. Sutton, M. A. et al. Miniature Neurotransmission Stabilizes Synaptic Function via Tonic Suppression of Local Dendritic Protein Synthesis. Cell 125, 785–799 (2006).</p><p>33. Paoletti, P., Bellone, C. and Zhou, Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14, 383–400 (2013).</p><p>34. W, S. et al. Early correction of synaptic long-term depression improves abnormal anxiety-like behavior in adult GluN2B-C456Y-mutant mice. PLoS Biol. 18, (2020).</p><p>35. Berlin, S. et al. Gαi and Gβγ Jointly Regulate the Conformations of a Gβγ Effector, the Neuronal G Protein-activated K<sup>+</sup> Channel (GIRK). J. Biol. Chem. 285, 6179–6185 (2010).</p></body></sub-article></article>